,sentence,label,score
0,"(ab)  iS Ee  oO  SOcie J Environmental  & Governance Re  AG  82 Introduction  A Letter from our Chairman & CEO  A Letter from Our Lead Independent Director  2022 Progress and Highlights  Our Approach to ESG  Priority ESG Issues  Impact Stories  Tackling the Health Equity Gap Together  Keeping Patients at the Center of Everything We Do  Environment  Climate Change  Sustainable Medicines  Social  Innovation and Global Health  Human Capital  Governance  Ethics, Transparency, and Quality  Accountability  Performance  Environment  Social  Governance  Appendix  GRI Index  SASB Index  TCFD  About This Report  Independent Accountants’ Report What this report covers  This report shares an overview of our Environmental, Social, and Governance  (ESG) vision, achievements, and progress in the year from January 1, 2022 to  December 31, 2022, including data on 32 key performance indicators (KPIs), as  well as our path toward a sustainable life sciences future.",Governance - Business_Ethics,0.2567907273769378
1,"For more information, please see About this Report on page 81.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3997860848903656
2,"Where to find more information  14} 2022 Annual Documents — 2022 Annual Review — 2022 Annual Report on Form 10-K — 2023 Proxy Statement  =] Pfizer  This report provides a comprehensive overview of Pfizer's  commitment to our priority ESG goals toward contributing  to long term value creation and a sustainable, responsible,  and patient centric business model.",Governance - Business_Model_Resilience,0.7600102424621582
3,"Our focus is rooted in our  purpose to deliver Breakthroughs that change patients’ lives  through ethical decision-making and our core values—Courage,  Excellence, Equity, and Joy.",Social - Human_Rights_And_Community_Relations,0.3002519607543945
4,"Stepping Up to Meet the Demands of a  Changing World  At Pfizer, our purpose—Breakthroughs that change patients’  lives—drives us to be a force for good in the world.",Social - Access_And_Affordability,0.1961608976125717
5,"We  believe that scientific innovation can help people live  longer, healthier lives, and we are proud to continue to  advance our scientific pipeline and strengthen our research  and development in support of this goal.",Social - Access_And_Affordability,0.3112299144268036
6,"Specifically, to  help ensure science will win against ongoing and future  health threats, we invested approximately $11.4 billion in  internal research and development programs in 2022.",Social - Employee_Health_And_Safety,0.7517264485359192
7,"While many people know about what Pfizer does, fewer  know how we go about this work in a way that fulfills our  purpose, builds trust, and takes accountability for the impact we make on society.",Social - Human_Rights_And_Community_Relations,0.2395252734422683
8,"We take  our work seriously, as the impact is felt by not only the more than 1.3 billion patients treated  with our medicines and vaccines in 2022', but also the communities in which we, and our  stakeholders, live and work.",Social - Access_And_Affordability,0.6096282601356506
9,"2022—like the two years preceding it—was punctuated by a growing number of daunting  global challenges—from COVID-19, which remains a threat to global health, to political and  economic instability, to the armed conflict in Ukraine, to increased attacks on marginalized  groups that have made it harder for people to live safe, healthy, and productive lives.",Social - Human_Rights_And_Community_Relations,0.8588701486587524
10,"At the  same time, continued climate change has led to observable effects—from floods and heat  waves to droughts and dwindling ice caps—and may be linked to not-so-obvious effects, such  as potential increased health risks from air pollution, extreme weather events, and pressures  on mental health.",Environmental - Physical_Impacts_Of_Climate_Change,0.9421326518058776
11,"Global action and collaboration are needed to address these issues, and as a private-sector  leader, Pfizer is committed to responding.",Social - Human_Rights_And_Community_Relations,0.2080508321523666
12,"At Pfizer, our commitment is anchored to our six ESG priorities: product innovation; equitable  access and pricing; product quality and safety; diversity, equity, and inclusion; climate  change; and business ethics.",Social - Employee_Engagement_Inclusion_And_Diversity,0.8861851096153259
13,"Our progress in these areas is detailed in this report, and we  look forward to continuing to engage with colleagues and other stakeholders to hear how  we can continue to enhance our impact, both within and outside of Pfizer.",Governance - Business_Model_Resilience,0.370166927576065
14,We also continue  1 Patient counts are estimates based on multiple data sources.,Social - Access_And_Affordability,0.3172387182712555
15,See footnotes within the Performance section for more details.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3791691362857818
16,"4 Pfizer 2022 ESG Report Introduction to refine the metrics we use to measure our performance as the voluntary and emerging  regulatory frameworks governing ESG reporting evolve at the local, national, regional, and  global level.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.952678680419922
17,Acting Ethically  Our approach to helping address the issues facing our planet and its people is rooted in our  purpose.,Social - Human_Rights_And_Community_Relations,0.9136964678764344
18,"And while our breakthroughs can take the form of new medicines and vaccines,  they can also shape new ways of working, new ways of helping ensure equitable access to  our innovations, and new ways of leveraging our voice.",Social - Access_And_Affordability,0.2994832098484039
19,"We're a company that is guided by our values—courage, excellence, equity, and joy.",Social - Employee_Engagement_Inclusion_And_Diversity,0.2890636622905731
20,"To that  end, we deploy an ethical decision-making framework that seeks to guide how we discuss,  consider and act to help address global challenges.",Governance - Business_Ethics,0.4652834832668304
21,"Values-and ethics-based decision-making  promotes accountability and helps ensure that integrity, quality, safety, and ethics are  foundational to all we do.",Governance - Business_Ethics,0.9653782248497008
22,Actions > Words  These decisions have led to action.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3906211256980896
23,"For example, we remain committed to working towards  equitable and affordable access to the Pfizer-BioNTech COVID-19 Vaccine and Pfizer's oral  therapy for people around the world.",Social - Access_And_Affordability,0.7930968999862671
24,Why?,Governance - Competitive_Behavior,0.1697306185960769
25,Because our vaccines and medicines cannot  positively impact patients if those patients do not have access to them.,Social - Access_And_Affordability,0.832774817943573
26,This commitment to equitable access extends beyond COVID-19.,Social - Access_And_Affordability,0.8386074304580688
27,We live in a time when  science can increasingly take on the world’s most devastating diseases.,Social - Critical_Incident_Risk_Management,0.1858006864786148
28,"But there is a gap  determining who can access these innovations, and who cannot.",Governance - Product_Design_And_Lifecycle_Management,0.2783754765987396
29,"To help bridge this gap,  we announced in May 2022 that we will provide on a not-for-profit basis all our innovative  medicines and vaccines available in the U.S.",Social - Selling_Practices_And_Product_Labeling,0.3304786682128906
30,"or the European Union to 1.2 billion people  in 45 lower-income countries and will work closely with global health leaders to make  improvements in diagnosis, education, infrastructure, storage, and more.",Social - Access_And_Affordability,0.8627052903175354
31,"The Accord for a  Healthier World—which we expanded in January 2023 to include the full portfolio of products  for which we have global rights, bringing the total offering from 23 patented medicines and  vaccines to around 500 patented and off-patent products-aims to greatly reduce the health  inequities that exist between many lower-income countries and the rest of the world.",Governance - Product_Design_And_Lifecycle_Management,0.3312470018863678
32,=] Pfizer  — Continued  Action also requires stepping up during times of international crisis.,Social - Critical_Incident_Risk_Management,0.5701625943183899
33,"We remain deeply  concerned by the human suffering we have witnessed during the ongoing armed conflict in  Ukraine, and we are committed to contributing to ongoing humanitarian efforts that support  the safety, health, and wellbeing of people affected by this tragic event.",Social - Employee_Health_And_Safety,0.8132677674293518
34,"We are determined  to ensure the safety of our colleagues and their families, and we are equally determined to  facilitate continued access to our medicines and vaccines for patients.",Social - Product_Quality_And_Safety,0.5041047930717468
35,But we recognize that  we are in a position to do even more.,Governance - Competitive_Behavior,0.1777465343475341
36,"That is why, effective March 14, 2022, Pfizer began  donating profits of our Russian subsidiary to the Pfizer Foundation?",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3924013674259186
37,"for direct humanitarian  support to the people of Ukraine, in addition to our ongoing humanitarian response efforts  in the region.",Social - Critical_Incident_Risk_Management,0.8809517025947571
38,"Pfizer, through The Pfizer Foundation, has committed over $30 million to  support these efforts.",Social - Access_And_Affordability,0.2604831159114837
39,We believe that product donations play an important role in relief and humanitarian  emergencies.,Social - Critical_Incident_Risk_Management,0.9418968558311462
40,We are proud to work through established non-governmental organizations  with expertise in managing product donations in connection with humanitarian emergencies.,Social - Critical_Incident_Risk_Management,0.9695047736167908
41,"In 2022, this included Hurricane Fiona, Hurricane Ian, the Afghanistan earthquake, and the  flooding in Pakistan.",Environmental - Physical_Impacts_Of_Climate_Change,0.844237744808197
42,"We recognize that planetary health has a profound impact on human health, which is why  we are building on more than 20 years of climate action to reduce our company and value  chain Greenhouse Gas (GHG) emissions.",Environmental - GHG_Emissions,0.967635452747345
43,"In June 2022, we announced our aim to achieve  the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in  the standard.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6335588693618774
44,"As part of this commitment, we aim to reduce our company GHG emissions  by 95 percent and our value chain GHG emissions by 90 percent from 2019 levels through  accelerating the transition away from fossil fuels and engaging suppliers to catalyze  equivalent action.",Environmental - GHG_Emissions,0.9685041904449464
45,2.,Governance - Competitive_Behavior,0.1579564213752746
46,The Pfizer Foundation is a separate legal entity from Pfizer Inc.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3442288935184479
47,with distinct legal restrictions.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7182366847991943
48,"5 Pfizer 2022 ESG Report Introduction Force for Good  As we look ahead, as remarkable as 2022 has been for Pfizer, I believe we have only scratched  the surface of the transformative impact we can have on human health.",Social - Employee_Health_And_Safety,0.8641510605812073
49,"Our third ESG Report, which shares our vision and approach, showcases progress on key  strategies and reaffirms our commitment to keeping patients at the center of all we do and  to furthering the positive impact that we have on the world.",Social - Access_And_Affordability,0.4359344840049743
50,"Nobody can predict with certainty how the world will change in 2023, and what challenges  humankind will have to overcome.",Governance - Business_Model_Resilience,0.273301899433136
51,But I do know this: all of us at Pfizer consider it a  privilege to be allowed by society to help address these issues.,Social - Human_Rights_And_Community_Relations,0.5146202445030212
52,"Against this backdrop, we  remain committed to keeping patients as our North Star, applying ethical decision-making  frameworks to our work, embedding ESG into our corporate strategies, and continuing to be  a force for good in the world.",Governance - Business_Ethics,0.7554414868354797
53,Mert Bou La  Dr.,,0.0949032753705978
54,"Albert Bourla  Pfizer Chairman & Chief Executive Officer  =] Pfizer  Dear Stakeholders, Strive to maintain a Board with a diverse set of experiences, qualifications, and attributes,  ; ; as well as gender and ethnic diversity.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9742767810821532
55,"Accordingly, when seeking new Directors, the Board On behalf of the Board of Directors, I would like to thank  you for your interest in Pfizer’s environmental, social, and  governance progress.",Governance - Director_Removal,0.4406338930130005
56,We believe that Pfizer's commitment  to our Purpose—Breakthroughs that change patients’ lives—  is essential to the company’s long-term success.,Governance - Business_Model_Resilience,0.2408463805913925
57,We are  proud to share Pfizer’s progress on our ESG efforts in our  third formal report.,Governance - Business_Model_Resilience,0.5495862364768982
58,"considers a diverse pool of qualified candidates across several dimensions, including skills,  gender, age, race, ethnicity, background, professional experience, and perspectives.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9682186841964722
59,"The  Board is committed to ongoing refreshment, as evidenced by the addition of five new  independent Directors since 2018.",Governance - Director_Removal,0.7506328225135803
60,"We are proud to share Pfizer’s progress on these efforts in this report and appreciate your  interest,  Recognizing the importance of ESG to Pfizer and our  stakeholders, the Board remains highly engaged in  overseeing Pfizer's ESG strategy, with the Governance  & Sustainability Committee (the G&S Committee) of the  Board assuming oversight responsibility of Pfizer's overall ESG strategy, reporting, policies Sincerely,  and practices.",Governance - Business_Model_Resilience,0.6900951266288757
61,The Board’s other Committees are also actively engaged and oversee specific  elements of ESG associated with their respective areas of responsibility.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.292847990989685
62,"During 2022, the G&S Committee received updates from management concerning Pfizer's  ESG priorities and the company’s progress measured against related metrics and goals at  nearly every meeting and shared this information with the full Board.",Governance - Business_Model_Resilience,0.7313698530197144
63,The Committee also  was informed of potential changes to the external regulatory and reporting environment  that may impact our future ESG disclosures and internal changes to our ESG governance  structure to enhance our risk management and oversight.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9529181718826294
64,"In addition, the Board was Shantanu Narayen  informed of Pfizer's progress in achieving our diversity, equity, and inclusion goals and our Lead Independent Director  environmental priorities and milestones, including our aim to achieve the voluntary Net-Zero  Standard for greenhouse gas emissions by 2040.",Environmental - GHG_Emissions,0.9606181979179382
65,"In terms of diversity, the Board recognizes the critical importance and value of Pfizer's  colleagues and the need to continuously work to maintain a culture where colleagues of  diverse backgrounds, abilities and experiences contribute their unique viewpoints and  perspectives to all aspects of our business.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9733611941337584
66,"Pfizer’s leaders establish and reinforce the  company’s culture, which the Board and its Committees oversee.",Governance - Director_Removal,0.5842048525810242
67,"At the Board level, we  6 Pfizer 2022 ESG Report Introduction Pfizer  of)  | See footnotes within the Performance section for more details.",Governance - Systemic_Risk_Management,0.4240854978561401
68,"Net-Zero  Standard  Aiming to achieve by 2040,  which is 10 years earlier than  expectations of the standard  # |  Ranking among the largest  Pharma companies in the most  recent Global PatientView  Survey (#2 overall)  4 out of 12  members of the Board of  Directors are women  3 out of 12  members of the Board of  Directors are ethnically diverse.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9685488343238832
69,7 Pfizer 2022 ESG Report Recognized at the  Leadership  Level  for our CDP Climate Change  Disclosure  43.1%  Representation for  women at VP+ levels globally  28.1%  Representation for U.S.,Environmental - Physical_Impacts_Of_Climate_Change,0.9187270402908324
70,"minorities at VP+ level  Pfizer leaders have ESG  KPIs factored into their  compensation  Introduction vi,  = oe  & ~  @)/WORLD’S MOST™  Si|ETH | COMPANIES*  ETHISPHERE  “World's Most Ethicat  Companies” and “Ethisphere”  names and marks are  registered trademarks of  Ethisphere LLC.",Governance - Competitive_Behavior,0.2833696007728576
71,"11%  Reduction in Scope 1 &  2 greenhouse gas (GHG)  emissions from 2019 baseline  44%  Pfizer New Molecular Entity  and novel biologic applications  approved by the FDA between  2018-2022 designated as  Breakthrough Therapies  Named one of the World’s  Most Ethical Companies by  Ethisphere for the second  year ina row  =] Pfizer  Underpinned by our core values, our ESG approach helps Pfizer deliver on our strategy and our purpose.",Environmental - GHG_Emissions,0.9685072302818298
72,"Guided by our values and our commitment to long term sustainability, our ESG approach informs how we can advance our purpose—  Breakthroughs that change patients’ lives—in a responsible and sustainable way that takes accountability for the impact we make on society.",Social - Human_Rights_And_Community_Relations,0.4423186182975769
73,"By taking proactive, collaborative steps to advance ESG at Pfizer, we can help improve health outcomes, build trust, create shared value,  and make a positive impact on society for years to come.",Social - Employee_Health_And_Safety,0.445568323135376
74,"Pfizer's 6 ESG Priorities  ¢ Product innovation: Reducing cycle times, increasing success rates, and getting more breakthroughs into the hands of patients sooner  ¢ Equitable access and pricing: Expanding affordable access to our breakthrough medicines and vaccines, and protecting people from the burden of infectious and  other diseases  ¢ Product quality and safety: Maintaining a quality culture to ensure the highest priority is placed on the safety, efficacy and reliability of our products, the safety  of our patients and consumers, the quality of data supporting regulatory submissions, and interactions with our stakeholders  ¢ Business ethics: Exercising strong corporate governance and risk management practices to promote the long term interests of our stakeholders  ¢ Diversity, equity, and inclusion: Creating opportunities to advance diversity, equity, and inclusion across our workforce, those with whom we do business, and  society at large  * Climate change: Taking action to reduce our greenhouse gas emissions and mitigate risks associated with a changing climate  Governance  * Business ethics  * Product quality and safety Environment Social  ey * Climate change * Product innovation  * Equitable access and pricing  * Diversity, equity, and inclusion  8 Pfizer 2022 ESG Report Introduction Pfizer  Advancing our ESG performance is an interconnected effort requiring cross-company alignment and collaboration.",Social - Product_Quality_And_Safety,0.4457893073558807
75,"ESG best practice is often recognized as aligning  and embedding robust ESG management into our strategy—so that the company and its priority ESG workstreams move together, leading to opportunities of  mutual reinforcement and impact.",Governance - Business_Model_Resilience,0.6821420788764954
76,We have continuously refined our ESG strategy in alignment with our purpose and corporate strategy.,Governance - Business_Model_Resilience,0.8526973724365234
77,"Building on our efforts—which include our acquisition of Global  Blood Therapeutics, Inc.",,0.2432352304458618
78,"to help underserved patient communities, such as those with sickle cell disease, as well as expanded access programming through An Accord  for a Healthier World—we more purposefully integrated ESG into our ways of working in 2022, including strategic decisions, business operations, and governance, to  create greater ownership of impact at all levels.",Social - Access_And_Affordability,0.9474559426307678
79,"In 2023, we aim to further integrate ESG into our corporate strategy, reinforcing our commitment to being a purpose-  driven organization.",Governance - Business_Model_Resilience,0.8135772347450256
80,"By embedding ESG into our strategy, we can make it the common denominator that underpins how we fulfill our commitments to our stakeholders.",Governance - Business_Model_Resilience,0.700101375579834
81,"For example, in  our financing strategy, we were the first U.S.",Governance - Systemic_Risk_Management,0.424568623304367
82,"biopharmaceutical company to include ESG Key Performance Indicator (KPI)-linked metrics in our $7 billion, five-year  revolving credit facility.",Governance - Systemic_Risk_Management,0.7106596827507019
83,"We apply science and our global resources to bring therapies to people that  extend and significantly improve their lives through the discovery, development,  and manufacture of medicines and vaccines.",Social - Access_And_Affordability,0.2494909167289734
84,"ESG  ESG priority areas Core values - priority  areas  * Product innovation * Courage  * Equitable access and pricing * Excellence  * Product quality and safety * Equity  * Business ethics * Joy  * Diversity, equity, and inclusion  * Climate change Purpose  Breakthroughs that change patients’ lives  9 Pfizer 2022 ESG Report Introduction Pfizer  In 2020, we led an in-depth priority assessment that helped map ESG issues and their relative impact on our business and expectations of our stakeholders.",Social - Product_Quality_And_Safety,0.2563507258892059
85,"We  identified 30 priority topics and mapped these to our six ESG priority areas, which in turn closely align to our corporate strategy, as well as the risks and opportunities  identified with our Enterprise Risk Management (ERM) approach.",Governance - Systemic_Risk_Management,0.714175283908844
86,These six priority issues are consistent with our values and our patient-centric approach.,Social - Human_Rights_And_Community_Relations,0.763708770275116
87,"In 2022, we continued to engage a variety of stakeholders—including patients, caregivers, investors, colleagues, and partners—to better understand their changing  needs, interests and expectations of Pfizer.",Social - Access_And_Affordability,0.6987133026123047
88,"These insights further sharpened the focus of our ESG strategy on the issues important to our stakeholders, while also  monitoring and managing the other issues in our ESG priority assessment.",Governance - Business_Model_Resilience,0.3741339445114136
89,"We recognize that our priority issues may evolve over time, and remain committed to adjusting our  approach, as appropriate, to ensure our ESG efforts prioritize issues that could have a significant impact  on our business and matter most to our stakeholders.",Governance - Business_Model_Resilience,0.5692577958106995
90,"Pfizer’s ESG Priority Areas:  The ESG function within Pfizer and its cross-functional governing committees (at the senior management  * Product innovation and the executive level) have responsibility for considering and adopting potential goals and targets,  with escalation to the Governance & Sustainability Committee (G&SC) of the Board, based on input from  « Equitable access and pricing experienced subject matter experts and advisors.",Governance - Business_Model_Resilience,0.3136207163333893
91,Our efforts are directed towards making an impact that  furthers our purpose to improve patients’ lives and support the global communities we aim to serve.,Social - Human_Rights_And_Community_Relations,0.8123811483383179
92,"¢ Product quality and safety  ¢ Business ethics  ¢ Diversity, equity, and inclusion  « Climate change  10 Pfizer 2022 ESG Report Introduction Pfizer  — Continu ed Governance > Performance > Appendix >  VERY  HIGH  Importance to stakeholders s) Health care infrastructure  s Health, safety, well-being  Partnerships Clinical trials  Board diversity Patient-cenetered design  Water scarcity and discharge Supply chain transparency  Waste management Human rights  Lobbying Environment and health  Product end-of-life  Disease prevention Retention and attraction  Employee development Reliable supply  Global community investment Pharmaceuticals in the environment  Laws and regulation compliance  Right incentives Product innovation  Equitable access and pricing  Product quality and safety  Colleague diversity, equity, and inclusion ]  ®  ®  © Business ethics  ®  = Climate change  ce Transparency  Cy IP protection  © Data privacy  LOWER Significance of impact to Pfizer’s business  11 Pfizer 2022 ESG Report Introduction VERY  HIGH Prioritize Topics that we give the oT most prominence to  Manage Topics that we actively  manage as a business  Monitor Topics that we  monitor for a change in  relative importance  E Environment  S Social  G Governance  eS Pfizer  — Continued  Esl  Goal Setting  12 Pfizer 2022 ESG Report Based on our six ESG priority areas, we have identified, set and communicated public ESG goals  so that our stakeholders understand how we are measuring success.",Social - Product_Quality_And_Safety,0.7950239181518555
93,"We believe that setting  and publicizing our goals energizes our colleagues, showcases our priorities, and demonstrates  transparency to external stakeholders.",Governance - Business_Ethics,0.8762493133544922
94,"By tracking our work, we can better understand what works,  what doesn’t, and whether we are living up to the goals we are setting for ourselves.",Governance - Business_Model_Resilience,0.2329966425895691
95,"For example, with regards to our climate change goal, we aim to achieve the voluntary Net-Zero  Standard by 2040, ten years earlier than the expectations of the Standard.",Environmental - Physical_Impacts_Of_Climate_Change,0.9443093538284302
96,This goal informs our aim  to reduce our company emissions by 95 percent and our value chain emissions by 90 percent from  2019 levels by 2040.,Environmental - GHG_Emissions,0.6571693420410156
97,"With regards to our Diversity, Equity and Inclusion goal, by 2025 we aim to achieve global workforce  parity of 47 percent for women at the Vice President+ level, and 32 percent for U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9752668738365172
98,minority  representation at the Vice President+ level.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9636733531951904
99,We look forward to continuing to advance and report on our ESG priority areas and related goals.,Governance - Business_Model_Resilience,0.3662151098251343
100,Introduction =] Pfizer  Our stakeholders’ opinions matter to us.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3308039009571075
101,"Each one brings a unique perspective to the table, and we collaborate with them at various levels to inform our ESG strategy  and make a positive impact internally and externally.",Governance - Business_Model_Resilience,0.6967756152153015
102,"Governments,  Policymakers  & Regulators  Patients &  Caregivers  Partners  Shareholders  & Investors  Colleagues  Patients and Caregivers  Patients are our North Star.",Social - Access_And_Affordability,0.6812889575958252
103,We work with patients and their caregivers to  understand their needs and help ensure that our medicines and vaccines work to  address them.,Social - Access_And_Affordability,0.8669453859329224
104,"13 Pfizer 2022 ESG Report Introduction As part of this, we engage with patients and patient advocacy groups to listen,  learn, collaborate, and address areas of unmet patient need and to incorporate  their perspectives before we launch our medicines and vaccines.",Social - Access_And_Affordability,0.6446766257286072
105,"In 2022, Pfizer's Global Patient Advocacy Team engaged more than 1,800 global  patient advocacy organizations across North America, Europe, Latin America, and  Asia through trainings, workshops, and webinars focused on health policy issues,  capacity building, patient centricity, and patient education and information.",Social - Access_And_Affordability,0.4248108565807342
106,"In 2022, we also hosted our second annual event, Patients in Focus, which  recognizes the influence that patients have on every facet of our work.",Social - Access_And_Affordability,0.3044075071811676
107,"Pfizer  CEO and Chairman, Albert Bourla, as well as other leadership met directly with  patients and advocates to learn about their experiences and discuss how Pfizer  can continue to embed the patient perspective into our work to discover, develop,  and bring to market medicines and vaccines.",,0.2061945647001266
108,"Shareholders and Investors  Our shareholders, investors, and analysts have a vested interest in Pfizer's  operations and the short, medium, and long term success of Pfizer.",Governance - Business_Model_Resilience,0.6188017129898071
109,"We work to  engage investors on ESG issues through ongoing one-on-one conversations,  surveys and questionnaires, and targeted communications, for example ESG-  related content on our Investor Insights website.",Governance - Business_Model_Resilience,0.486849695444107
110,"We also host investor-aimed  fireside chats to review priority ESG initiatives and topics, including on priority  areas such as equitable access and climate action.",Environmental - Physical_Impacts_Of_Climate_Change,0.7404101490974426
111,These fireside chats were  broadcast publicly and aimed to provide investors the opportunity to learn more  about Pfizer’s ESG priorities and activities.,Governance - Business_Model_Resilience,0.8235535025596619
112,"=] Pfizer  — Continued  Colleagues  We want all our colleagues to develop, grow, and succeed and believe everyone  deserves to be seen, heard, and respected for who they are.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3766131997108459
113,"We hold regular  meetings and Town Hall events focused on employees and their needs, conduct  regular surveys to understand colleague satisfaction and other aspects of  corporate culture, and invest in programs to help colleagues manage their mental  and physical well-being.",Social - Employee_Health_And_Safety,0.8899042010307312
114,"Partners  The scale of our ambition requires us to work in coordination and collaboration  with external partners, so that we advance new breakthroughs, improve access to  our medicines and vaccines, and nurture the growth of our business.",Social - Access_And_Affordability,0.3156793117523193
115,"We engage  with foundations, multilaterals, non-governmental organizations, and coalitions,  including groups like the World Health Organization, Save the Children, Access  to Medicine Foundation, and Science Based Targets Initiative (SBTi)—among  others—on issues including access to medicines and vaccines, environmental  concerns, transparency, and business ethics.",Governance - Business_Ethics,0.9634410738945008
116,We also engage suppliers to  understand their needs and support their efforts to reduce their environmental  footprints.,Social - Supply_Chain_Management,0.8920417428016663
117,"We work alongside global health and public health organizations to  expand access to our medicines and vaccines, including on-the-ground support  for health and education initiatives, and partner with academic and industry  research alliances to help increase the number of future breakthroughs for  patients.",Social - Access_And_Affordability,0.7635679841041565
118,"We also educate medical organizations about the latest research on our  medicines and vaccines, our pipelines, and ways to access our products.",Social - Selling_Practices_And_Product_Labeling,0.4818311929702759
119,"14 Pfizer 2022 ESG Report Introduction Governments, policymakers, and regulators  We engage policymakers and regulators to understand shifting external and  regulatory landscapes to help ensure that issues facing our company and our  commitment to breakthroughs that change patients’ lives are communicated.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9578863978385924
120,"We  have consistent, two-way dialogue with policymakers through targeted one-on-  one engagement and through trade association and industry bodies alongside  biopharmaceutical peers to help guide our medicines from the laboratory to  patients.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6491051316261292
121,We also provide policymakers with updates on our medicines and  vaccines to facilitate decision-making and improved patient outcomes.,Social - Access_And_Affordability,0.5182213187217712
122,"=] Pfizer  The stories that follow highlight our extensive efforts in our  priority areas, leading with our global work to help tackle the  challenge of health inequity through the launch of An Accord  for a Healthier World.",Social - Employee_Health_And_Safety,0.7658220529556274
123,"We also cover the work we do directly  with patients, advocates, and caregivers to carry out our core  purpose: Breakthroughs that change patients’ lives.",Social - Access_And_Affordability,0.5764465928077698
124,> Governance > Performance > Appendix >  Breaking down barriers with a new collective and holistic approach  Ue  Health inequity is one of the greatest and most urgent challenges we face today.,Governance - Systemic_Risk_Management,0.5358818769454956
125,Half of the  world’s population cannot access the healthcare they need.,Social - Access_And_Affordability,0.7891799211502075
126,"Significant improvements in local  health systems are still needed in many lower-income countries to ensure broader and better  access to care.""  Consistent with Pfizer's responsibility to respect the right to health, we are always looking for  new ways to tackle this challenge—not only by working to assure consistent supply and access  to medicines and vaccines, but also by addressing other system barriers that impede progress.",Social - Access_And_Affordability,0.8856600522994995
127,That's why Pfizer launched An Accord for a Healthier World in 2022 to apply what we learned and  catalyze a collective effort to help address the health equity gap.,Social - Access_And_Affordability,0.3564963936805725
128,"The Accord is a first-of-its kind,  comprehensive initiative focused on helping increase access to medicines and vaccines for 1.2  billion people living in 45 lower-income countries that have historically been most vulnerable to  healthcare inequalities.",Social - Access_And_Affordability,0.7814303040504456
129,"Alongside governments and global health organizations, Pfizer aims to  co-create scalable and sustainable solutions to help address systemic barriers to better health.",Governance - Systemic_Risk_Management,0.9575021266937256
130,"The Accord is focused on working to find faster, more efficient pathways for supply of medicines and vaccines as well as strengthening the resources, capabilities, and platforms  that will help enable sustainable access to those medicines.",Social - Access_And_Affordability,0.4323794841766357
131,"This includes technical expertise,  training, diagnostic capacity, innovative financing, and more within the public health system.",Social - Access_And_Affordability,0.4928075671195984
132,We aim for the Accord to be a catalyst bringing together governments and multi-sector  organizations to effectively identify and apply solutions across the entire healthcare ecosystem.,Governance - Systemic_Risk_Management,0.2359222769737243
133,"No one government, organization, or company can close the health equity gap alone.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5543408989906311
134,"USSelsairiines com  a Ie reeeaes, SVIAeeeee  Vaccine delivery in Rwanda  At the launch of the Accord in May 2022, Pfizer initially committed to provide on a not-for-profit  basis all our innovative medicines and vaccines available in the U.S.",Social - Selling_Practices_And_Product_Labeling,0.3010347783565521
135,or the European Union  to 1.2 billion people in 45 lower-income countries.,Social - Employee_Engagement_Inclusion_And_Diversity,0.3245889842510223
136,"However, in the early months following  the launch as Accord outreach began, the resounding feedback from governments was that  access to a broader and more immediate scope of consistent, high-quality products is needed  for meaningful and sustainable transformation.",Governance - Product_Design_And_Lifecycle_Management,0.9644633531570436
137,"Based on this feedback and to better align  with unmet patient needs, Pfizer made the decision to significantly expand the offering from  the initial patented medicines and vaccines to the full portfolio of medicines for which Pfizer  ' https://www.who.int/news/item/13-12-2017-world-bank-and-who-half-the-world-lacks-access-to-essential-health-services-100-million-still-pushed-into-extreme-poverty-because-of-health-expenses#:~:text=At%20least%20half%200f%20  the,out%200f%20their%200wn%20pockets  16 Pfizer 2022 ESG Report Impact Stories eS Pfizer  — Continued  has global rights.",Social - Access_And_Affordability,0.6076124310493469
138,The portfolio offered by Pfizer on a not-for-profit basis through the Accord  expanded from 23 to hundreds of patented and off-patent products that help treat or prevent  many of the greatest infectious and non-communicable disease threats faced today in lower-  income countries.,Social - Access_And_Affordability,0.1082601100206375
139,Nearly 40 percent of the medicines and vaccines now offered are part of  the World Health Organization's (WHO) list of essential medicines.,Social - Selling_Practices_And_Product_Labeling,0.5456799268722534
140,"As Pfizer introduces new  medicines and vaccines, those products will also be included in the Accord portfolio.",Social - Selling_Practices_And_Product_Labeling,0.3765939772129059
141,The supply of these medicines and vaccines is only one step in getting them to people in need.,Social - Access_And_Affordability,0.6844057440757751
142,"Each country and community faces unique circumstances, so Pfizer will be working with the  governments in each location to identify specific barriers and mobilize resources to address  them.",Social - Human_Rights_And_Community_Relations,0.8404160737991333
143,"Geographic Scope  Initiative includes ALL low-income countries and 18 lower-middle-income countries that transitioned from low-income  classification in the last 10 years, as defined by the World Bank.",Governance - Systemic_Risk_Management,0.1568924933671951
144,"Afghanistan” Guinea-Bissau | Senegal  Bangladesh Haiti Sierra Leone  Benin Kenya Solomon  Burkina Faso | Kyrgyzstan Island  Burundi Laos Somalia  Cambodia Liberia South Sudan  Central African | Madagascar | Sudan”  Republic Malawi Syria”  Chad Mali Tajikistan  Comoros Mauritania Tanzania  Congo DR Mozambique | Togo  Eritrea Myanmar* Uganda  Ethiopia* Nepal Yemen  Gambia Niger Zambia  Ghana North Korea’ | Zimbabwe”  Guinea Rwanda  Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord and solutions  identified will then be leveraged for faster enrollment and access in all 45 countries.",Social - Access_And_Affordability,0.3478877246379852
145,*Supply contingent upon compliance with applicable laws including any required sanctions and export control licenses or other authorizations.,Social - Supply_Chain_Management,0.5267626643180847
146,"Since the launch of An Accord for a Healthier World, Pfizer has engaged with the majority of the  45 Accord-eligible lower-income countries and is in advanced conversations with a number  of them to explore opportunities to address health equity.",Social - Access_And_Affordability,0.5818430185317993
147,Rwanda has already received its  first deliveries of Pfizer medicines and vaccines under the Accord.,Social - Access_And_Affordability,0.2035616934299469
148,"In collaboration with the  Rwandan Ministry of Health, Pfizer also provided professional healthcare education and  17 Pfizer 2022 ESG Report Impact Stories Governance > Performance > Appendix >  training to support the use of these medicines and vaccines, and we have deployed the first  Global Health Team to the country to help identify opportunities for long term supply chain  optimization.",Social - Supply_Chain_Management,0.94935405254364
149,"Active collaboration is underway with the Ministries of Health in Malawi, Ghana, and Senegal  as well as a number of other Accord-eligible lower-income countries to better understand the  critical healthcare needs and opportunities for health system strengthening.",Social - Access_And_Affordability,0.8451331257820129
150,"Pfizer remains committed to helping support the needs of ail patients, everywhere.",Social - Access_And_Affordability,0.5539254546165466
151,"eS Pfizer  Keeping Patients at the Center of Everything We Do  Working directly with patients, advocates, and caregivers to deliver breakthroughs that change patients’ lives.",Social - Access_And_Affordability,0.6893529891967773
152,Patient Centricity is our North Star at Pfizer.,Governance - Competitive_Behavior,0.2082047760486602
153,"In keeping this steadfast focus, we know  we're best positioned to deliver on our purpose: developing breakthroughs that change  patients’ lives.",Social - Access_And_Affordability,0.2347341030836105
154,WHAT IS PATIENT CENTRICITY?,Governance - Competitive_Behavior,0.5596836805343628
155,"Pfizer set out to define “patient centricity” in 2022, working collaboratively with patient  advocates to ensure our definition was inclusive of a diversity of experiences.",Social - Access_And_Affordability,0.3266065120697021
156,We surveyed  colleagues as well as a group of global pan-therapeutic patient centricity advisors.,Governance - Competitive_Behavior,0.253715842962265
157,"We ulti-  mately launched the definition as follows: “Patient Centricity exists at Pfizer when we listen  and learn from the patient perspective, acting as partners with accountability and integrity  to deliver outcomes that matter most to patients and those involved in their care.”  That's what inspired us to host our first-ever Global Patient Advocacy Forum in 2022,  bringing together senior advocacy leaders from around the world at our New York  headquarters to discuss how to continue to best partner with and serve patients.",Social - Access_And_Affordability,0.4681604206562042
158,@Pfizer Pfizer's first-ever Global  fi-: Patient Advocacy Forum was  held in 2022 bringing  together patient advocacy  leaders from around the  world working across a  wide variety of patient  populations.,Social - Access_And_Affordability,0.5238862633705139
159,"The forum also set the stage for Pfizer's upcoming Global Pan-Therapeutic Patient  Centricity Advisors council, which will include advocates from Latin America, Europe,  Asia, Canada, and the United States.",Social - Access_And_Affordability,0.2239855676889419
160,"The Global Pan-Therapeutic Patient Centricity  Advisors council has been assembled to educate Pfizer colleagues on trends and  issues patient groups face, provide candid input on key patient-focused programs and  resources, and collaborate with Pfizer colleagues and senior leadership to co-develop  meaningful approaches to measure progress on behalf of patients.",Social - Access_And_Affordability,0.5093076825141907
161,"18 Pfizer 2022 ESG Report Pfizer was recognized as the most patient-centric organization among the world’s largest pharma-  ceutical companies, according to the 2021 PatientView Corporate Reputation of Pharma Survey.",Governance - Competitive_Behavior,0.3343250751495361
162,"The survey, collecting insights from more than 2,150 patient groups across 90 countries, measures  their perceptions of pharma companies across nine indicators, including transparency, patient  safety, quality information, integrity, support for patients, and more.",Governance - Business_Ethics,0.837460994720459
163,"Working in Partnership with Patient Advocacy Groups  Day in and day out, colleagues across Pfizer collaborate with hundreds of Patient Advocacy  Groups around the world to advance shared goals and better support the needs of patients  everywhere.",Social - Access_And_Affordability,0.6540247797966003
164,"Advocacy leaders and patient groups understand the needs and perspectives  of patients and, for this reason, are essential partners to leaders across the industry.",Social - Access_And_Affordability,0.6430421471595764
165,"By  speaking directly with patients and advocates, Pfizer colleagues glean insights on patients’  experiences with their conditions and treatments, inform patients about clinical trials,  discuss possible side effects, and educate the wider healthcare community about tools that  might be helpful to patients.",,0.1803718358278274
166,Our Global Patient Advocacy team contributes to Pfizer’s advocacy and engagement strategy  by supporting teams to drive deep therapeutic and regional relationship models with patient  advocacy groups.,Social - Access_And_Affordability,0.4568516314029693
167,"With a patient engagement lead based in every region, the team works  with patients and advocates regardless of geography, disease focus, or economic status.",Social - Access_And_Affordability,0.6999357342720032
168,"These partnerships can help improve patient outcomes by increasing patient engagement  in research and development, elevating priority policy and social impact issues, creating  meaningful resources and programs that provide value to patients, and more.",Social - Access_And_Affordability,0.3926829695701599
169,"For example, in 2022, Pfizer Spain’s Global Patient Advocacy colleagues joined forces with  Global Patient Advocacy colleagues across Latin American Pfizer sites to organize the first joint  webinar for Spanish-speaking advocates and patient groups titled Entre GENte y GENte, a play  on words connoting ‘between people and gene therapies.’ The webinar educated the audience  about gene therapy and other new, advanced therapies available for rare disease patients  and brought together experts, industry leaders, and over 100 patient advocacy groups for  the first time.",Social - Access_And_Affordability,0.3730238080024719
170,"Patient representatives from Latin America and Spain participated, intending to  work together between both continents through the exchange of information and concerns,  and Pfizer leaders had the opportunity to reinforce the commitment to patient centricity and  highlight the value of science.",Social - Access_And_Affordability,0.3835645020008087
171,"Events like these are multi-purpose: we are able to share knowledge and promote dialogue,  increase literacy around advanced therapies for patient advocacy groups, and reinforce our  longstanding commitment to listening to patients’ needs and challenges.",Social - Access_And_Affordability,0.7805235981941223
172,"Impact Stories eS Pfizer  Keeping Patients at the Center of Everything We Do  — Continued  Our Patient Centric Design  Patient perspectives are embedded into all of our work  end-to-end, from the earliest stages of research to the final  approval and use of our medicines and vaccines.",,0.2726972103118896
173,We're not  only considering their needs but also including them in the  process.,Social - Human_Rights_And_Community_Relations,0.2211728394031524
174,"By working for and with patients, caregivers, and  advocates directly, we are able to better understand and  serve the evolving needs of patients everywhere.",Social - Access_And_Affordability,0.8471958637237549
175,"PATIENT SPOTLIGHT: KEVIN'S STORY  Diagnosed with sickle cell disease (SCD) at a young age, Kevin  was determined to not let his diagnosis define his life.",Social - Employee_Health_And_Safety,0.4645120501518249
176,"He now  serves as a patient advocate, using his voice to help provide  hope and reinforce that the future is brighter for those  impacted by sickle cell disease.",Social - Access_And_Affordability,0.7709813117980957
177,"Because of their unique experience and insights into the  realities patients face each day, patient advocates like Kevin  are crucial partners in understanding and serving patient  needs.",Social - Access_And_Affordability,0.3545855283737182
178,"After all, nobody understands a health condition  better than the person experiencing it.",Social - Employee_Health_And_Safety,0.8495750427246094
179,Collaborations like  these are a priority across every therapeutic area and Pfizer  could not deliver our purpose without advocates and patient  groups.,Social - Access_And_Affordability,0.2580110132694244
180,Learn more about Kevin's determination to combat the  stigma of this rare disease and his passion for patient  advocacy here.,Social - Employee_Health_And_Safety,0.2768657803535461
181,"19 Pfizer 2022 ESG Report For example, in early 2022, patient advocacy leaders working  across Pfizer’s Rare Disease team designed a survey with  Qualtrics to collect insights from respondents with sickle cell  disease and their caregivers to better understand the effects  of sickle cell disease that matter most to the patient and  preferences for treatment options.",Social - Employee_Health_And_Safety,0.3529695272445678
182,"By bringing the patient  voice in early, decision-makers at Pfizer develop a deep  reservoir of insights about patients’ concerns and priorities,  and in time, these can help inform therapeutic development,  clinical trial design, as well as our support programs and  services.",Social - Human_Rights_And_Community_Relations,0.2492450028657913
183,"As another demonstration of this approach, the Pfizer  Germany Patient Dialog has gathered more than 100 patient  organizations and leaders across the industry to discuss  patients’ most pressing needs.",Social - Access_And_Affordability,0.4454858899116516
184,"Launched in 2002, the  Dialog has transformed from a small networking event and  workshop into a pivotal healthcare convention in Germany,  uniting experts from the pharmaceutical industry, healthcare,  politics, and patient advocacy organizations.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3385650515556335
185,"The program  includes a discussion about the future of the healthcare  system, a debate about the opportunities presented by  different therapies, and a best practices presentation on  patient information.",Social - Access_And_Affordability,0.6418811678886414
186,The Pfizer Germany Patient Dialog gathers more than 100  patient organizations and leaders across the industry to discuss  patients’ most pressing needs.,Social - Access_And_Affordability,0.3747020065784454
187,Impact Stories Governance > Performance > Appendix >  These in-person gatherings offer important opportunities  for co-creation.,Governance - Business_Model_Resilience,0.255490630865097
188,"For example, the 2017 dialog led to the  development of a Pfizer Germany website and information  platform, the “Support for Me” Patient Navigator.",Social - Access_And_Affordability,0.3190809190273285
189,"Developed  by advocates, healthcare professionals and other experts  across the industry to cater to patients’ most pressing  needs, the website now features insights from more than 70  external experts with advice on topics such as disease basics,  insights on living with a particular condition, recommended  examinations, and treatment, as well as support and  guidance for caregivers and family members.",Social - Access_And_Affordability,0.7259860038757324
190,"eS Pfizer  Keeping Patients at the Center of Everything We Do  — Continued  Improving Health Literacy for All Patients  Even the best programs, resources or health information  can't help patients if they don’t know how to act on it.",Social - Access_And_Affordability,0.8069667816162109
191,"Health  literacy is the measure of how patients get health information  and services, understand them, and use them.",Social - Access_And_Affordability,0.6477357745170593
192,"Many people  find health information difficult or confusing, which can  contribute to poor health decisions.",Social - Employee_Health_And_Safety,0.8854312896728516
193,That’s why Pfizer is  working with advocates to make health information easier  to understand and to provide patients with resources to  promote conversations that result in better outcomes.,Social - Access_And_Affordability,0.3700861036777496
194,"From ensuring that clinical trial data is accessible and useful  to developing easy-to-understand product information  and labels, Pfizer colleagues aim to ensure that all patient  information is shared in plain language, without any technical  jargon and in a timely manner.",Social - Selling_Practices_And_Product_Labeling,0.5930569171905518
195,"Pfizer's Health Literacy  Position Paper outlines various initiatives to improve health  literacy, including our work with advocacy groups and non-  profit partners.",Social - Access_And_Affordability,0.5663291811943054
196,"For example, in recent years, we worked  with a number of organizations—including multicultural  20 Pfizer 2022 ESG Report groups and community centers—to evaluate the language  around health topics, such as COVID-19, and to suggest  phrasing that is easy to understand.",Social - Access_And_Affordability,0.3787601888179779
197,"In addition, Pfizer has  sponsored organizations, such as the National Academies  of Science Engineering and Medicine (NASEM) Roundtable  on Health Literacy and Pharma Collaborative, to support the  development of workshops around topics like communicating  with vulnerable populations and developing health literacy  skills to improve equity.",Social - Access_And_Affordability,0.5373373031616211
198,We've also created two resources to support patients and  caregivers this year.,Social - Access_And_Affordability,0.8610297441482544
199,"A new e-book, Making the Most of  Patient Centricity: How to Be an Empowered, Engaged Patient Governance >  helps empower them to make smart healthcare choices,  improve their communication with healthcare providers, and  make sure they have the information needed to advocate for  themselves in a medical setting.",Social - Access_And_Affordability,0.492718368768692
200,"Similarly, our new guide, A.",Governance - Competitive_Behavior,0.132252961397171
201,"Lifetime of Health Literacy, helps parents and providers learn  how to promote health literacy in children.",Social - Access_And_Affordability,0.8216215372085571
202,The guide features  expert-backed tips on how to foster a greater sense of shared  health decision-making with kids.,Social - Employee_Health_And_Safety,0.5392228364944458
203,"From crystalizing health information for patients to ensuring  we are always learning, listening, and acting as partners  with accountability and integrity with advocates and patient  groups, we continue to ensure that patients remain at the  center of all the work that we do.",Governance - Business_Ethics,0.245606780052185
204,Impact Stories Performance > Appendix >  eS Pfizer  The health of our global environment impacts everyone.,Environmental - Physical_Impacts_Of_Climate_Change,0.2648994028568268
205,"At Pfizer, we are committed to reducing our environmental footprint.",Governance - Product_Design_And_Lifecycle_Management,0.2490816563367843
206,"Our company  purpose—Breokthroughs that change patients’ lives—gquides our environmental priorities, with a focus on impact reduction, conservation of  resources, and the minimization of waste arising from our operations.",Environmental - Waste_And_Hazardous_Materials_Management,0.3925458490848541
207,"Climate Change 22 How our approach “xt} Industry, Innovation, and Infrastructure  Reducing Emissions From Our Operations to environmental Rs We promote resilient and sustainable  .",Environmental - Physical_Impacts_Of_Climate_Change,0.910508930683136
208,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
209,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
210,"infrastructure, scientific research and Accelerating Action Across Our Supply Chain sustainability innovation.",Social - Supply_Chain_Management,0.9471034407615662
211,Proactive External Engagement supports the  Understanding How Climate Change Could Impact Our Business Sustainable ia Responsible Consumption and Production QO We aim to achieve environmentally  Development sound life cycle management and adopt  Sustainable Medicines 24 Goals (SDGs) sustainable practices  Pharmaceuticals In The Environment A= Climate Action  Waste G Through our goals we are taking urgent  Water Stress action to help combat climate change  and its impacts.,Environmental - Physical_Impacts_Of_Climate_Change,0.9304748773574828
212,14} More information on the SDGs here.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2792305052280426
213,Climate Change  We recognize global climate change as one of the defining  issues of our time requiring collective action to mitigate  the risks it poses such as increased adverse impacts on  human health and decreased access to critical medicines  and vaccines due to disruptions in value chains caused by  the greater frequency of severe weather.,Environmental - Physical_Impacts_Of_Climate_Change,0.9564708471298218
214,Pfizer is continuing its near-term commitment to reduce  company Greenhouse Gas (GHG) emissions aligned witha  1.5°C trajectory and to engage suppliers so that they also  set science-based GHG emissions reduction goals.,Environmental - GHG_Emissions,0.9705121517181396
215,"In June 2022, Pfizer announced a broader commitment to  further reduce GHG emissions by working to achieve the  voluntary Net-Zero Standard by 2040, ten years earlier  than the timeline described in the standard.",Environmental - GHG_Emissions,0.9691091775894164
216,By 2040 Pfizer  aims to decrease its company GHG emissions by 95% and  its value chain emissions by 90% from 2019 levels through  accelerating the transition away from fossil fuels and  engaging suppliers to catalyze equivalent action.,Environmental - GHG_Emissions,0.9653056263923644
217,"In June 2022, Pfizer became one of the initial signatories  to the U.S.",Governance - Business_Model_Resilience,0.3435454070568084
218,Department of Health and Human Services  (HHS) climate pledge that calls on stakeholders in the U.S.,Environmental - Physical_Impacts_Of_Climate_Change,0.9143790006637572
219,"healthcare system—including hospitals, health systems,  payers, suppliers, and pharmaceutical companies—to  reduce GHG emissions and build a more climate resilient  healthcare infrastructure.",Environmental - GHG_Emissions,0.9351477026939392
220,"By doing so, we committed to  reducing GHG emissions and to publicly report on progress  as well as develop climate resiliency plans, among other  actions.",Environmental - GHG_Emissions,0.9354839324951172
221,"In recognition of these ambitions and other efforts, Pfizer  was also included in Corporate Knights’ 2023 100 Most  Sustainable Corporations in the World list.",Governance - Business_Model_Resilience,0.2874048352241516
222,' Pfizer is pursuing SBTi validation of our Net-Zero target in 2023.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.1986635774374008
223,Pfizer aims to achieve a 95% reduction in company (Scope 1 & 2) greenhouse gas (GHG) emissions and a 90% reduction in value chain  (Scope 3) emissions by 2040’.,Environmental - GHG_Emissions,0.9684107303619384
224,"Our near term targets, approved by the Science Based Targets Initiative (SBTi), are outlined below:  Target  Reducing scope 1 and 2 GHG emissions  by 46% from a 2019 baseline by 2030  Sourcing 80% of electricity from renew-  ables by 2025, and 100% by 2030  Reducing emissions from upstream  transportation and distribution by 10%  and from business travel by 25% by  2025 from a 2019 baseline  Working to accelerate change across  our supply chain, driving 64% of our  suppliers of goods and services by  spend to also set science-based GHG  emission reduction goals by 2025 Progress  Scope 1 & 2 GHG emissions in 2022 were 1.5% lower than 2021 in spite of production  increases, including the production of PAXLOVID® (nirmatrelvir tablets and ritonavir  tablets)*.",Environmental - GHG_Emissions,0.9620817303657532
225,Emissions for 2022 were 11.2% lower than the 2019 baseline.,Environmental - GHG_Emissions,0.8341391682624817
226,Pfizer sourced 7.8% renewable electricity in 2022.,Environmental - Energy_Management,0.966058075428009
227,"Although emissions associated with the transportation and distribution of PAXLOVID and  the COVID-19 vaccine, transported predominantly by air using cold-chain technologies,  continued to increase, we eliminated approximately 50,000 mt of GHG emissions by tran-  sitioning other product shipments from air to ocean in 2022.",Environmental - GHG_Emissions,0.6917643547058105
228,Travel-related GHG emissions were 78% lower than the 2019 baseline.,Environmental - GHG_Emissions,0.9637994766235352
229,Going forward we  will continue to utilize digital tools as appropriate to limit travel.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.256504625082016
230,Currently 29% of our suppliers by spend have or have committed to develop GHG emis-  sions reduction targets approved by the SBTi.,Environmental - GHG_Emissions,0.9643606543540956
231,Our environmental data included in this ESG Report may include certain estimates and assumptions given data avail-  ability at the time of publication.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3340045511722564
232,Our finalized 2022 data with additional details will be published on Pfizer's Environ-  mental Sustainability Page.,Governance - Business_Model_Resilience,0.3534981608390808
233,2 Please refer to About this Report for the Emergency Use Authorization (EUA) statement for COMIRNATY® and PAXLOVID®.,Social - Critical_Incident_Risk_Management,0.9721633791923524
234,"22 Pfizer 2022 ESG Report Environment =] Pfizer  — Continued > Performance > Appendix >  Reducing Emissions From Our Operations  As part of our efforts to reduce our overall environmental  footprint globally, our manufacturing and R&D sites  have environmental sustainability plans to reduce  impact.",Environmental - GHG_Emissions,0.3352453112602234
235,"We seek opportunities to design new facilities  or renovation projects with reduced environmental  impact (such as energy consumption, water usage,  and waste management) So we can reduce resource  demand.",Environmental - Energy_Management,0.9386733174324036
236,"For example, we aim to replace equipment  at end-of-life with energy-efficient alternatives.",Environmental - Energy_Management,0.9741986989974976
237,We  invest in no- / low-carbon technologies at our sites and  through power purchase agreements (PPAs) that enable  sourcing of energy from renewable sources.,Environmental - Energy_Management,0.9719703793525696
238,We also  undertake process enhancements within our product  manufacturing to increase efficiency and reduce the  number of process steps and resources required.,Governance - Product_Design_And_Lifecycle_Management,0.962622344493866
239,"In 2021, Pfizer entered into a virtual PPA with Vesper  Energy (Vesper).",Environmental - Energy_Management,0.9253485202789308
240,"Certain market and supply chain issues  have been resolved and we now expect the project  to begin generating power on or before December  31, 2024.",Social - Supply_Chain_Management,0.9515461325645448
241,"Under this 15-year agreement, Vesper will  deliver at least 310 megawatts (MW) of renewable  energy to the grid from the Hornet Solar project in  west Texas.",Environmental - Energy_Management,0.9736538529396056
242,"Once operational, we expect Pfizer’s North  American purchased electricity needs, which comprise  approximately 50% of our electricity use globally, will  be addressed by the renewable energy certificates  generated by this solar energy project.",Environmental - Energy_Management,0.9736817479133606
243,"In 2022, we also continued our efforts to establish a  virtual PPA in Europe and aim to secure renewable  energy certificates and / or additional PPAs to meet our  goal of 80% renewable energy by 2025.",Environmental - Energy_Management,0.9690167903900146
244,"As outlined by our  goals and demonstrated by our commitment to RE100,  we are working to transition electricity generated by our  operations and any remaining purchased electricity to  renewable sources by 2030.",Environmental - Energy_Management,0.973491668701172
245,Accelerating Action Across Our Supply Chain  Pfizer’s scope 3 (value chain) GHG footprint is four times  that associated with the company’s direct operations.,Environmental - GHG_Emissions,0.9591674208641052
246,"Based on this, we recognize action is needed throughout  our value chain to help address the complex threat of  climate change.",Environmental - Physical_Impacts_Of_Climate_Change,0.95598566532135
247,"Procurement of goods and services,  which is essential to producing medicines and vaccines,  is the most significant contributor to our scope 3  emissions.",Governance - Product_Design_And_Lifecycle_Management,0.7306373715400696
248,"Therefore, we urge all our suppliers to commit  to ambitious, science-based GHG reduction targets and  have integrated environmental criteria in our supplier  sourcing, contracting, and performance management  processes.",Environmental - GHG_Emissions,0.9040547013282776
249,"From 2018 to 2021 Pfizer was recognized as a  CDP Supplier Engagement Leader for our work to reduce  environmental risks in our supply chain.'  In November 2022, Pfizer also announced our intention  to join a collective action initiative, Activate, to support  the decarbonization of a major source of GHG emissions  in the pharmaceutical value chain.",Environmental - GHG_Emissions,0.8253365755081177
250,"Through Activate,  Pfizer will work in partnership with peer pharma  companies to accelerate decarbonization in active  pharmaceutical ingredient (API) supply chains.",Social - Supply_Chain_Management,0.8962073922157288
251,Activate  targets sustainability / GHG emission improvements  at API suppliers including Contract Manufacturing  Organizations.,Environmental - GHG_Emissions,0.9384658932685852
252,"Proactive External Engagement  Tackling climate change requires action from all parties  across all sectors, and Pfizer urges governments both  in the U.S.",Environmental - Physical_Impacts_Of_Climate_Change,0.9559369683265686
253,and abroad to establish ambitious climate  policies to stabilize global temperature rise at 1.5  degrees.,Environmental - Physical_Impacts_Of_Climate_Change,0.84836745262146
254,"For additional information on Pfizer's climate action  program, please see our:  * Climate Change Position Statement  * 2022 CDP Climate Change Response  1 CDP Supplier Engagement Leaderboard results for calendar year 2022 were not yet available at the time of publication.",Environmental - Physical_Impacts_Of_Climate_Change,0.928883731365204
255,23 Pfizer 2022 ESG Report Environment Understanding How Climate Change Could  Impact Our Business  We are committed to transparency in evaluating the risks  and opportunities that climate change may present to  our business.,Environmental - Physical_Impacts_Of_Climate_Change,0.9562467932701112
256,"To meet this commitment, we incorporate  the Task Force on Climate-Related Financial Disclosures  (TCFD) framework into our enterprise risk management  governance process and voluntarily report aligned with  TCFD recommendations.",Environmental - Physical_Impacts_Of_Climate_Change,0.8846558928489685
257,See our TCFD Response on  page 74.,Environmental - GHG_Emissions,0.3773538470268249
258,"Wind turbines at Puurs, Belgium Pfizer site.",Environmental - Energy_Management,0.6706673502922058
259,eS Pfizer  — Continued Governance > Performance > Appendix >  Sustainable Medicines  Pfizer has a long history of using the concepts of green chemistry and promoting them  across the industry.,Governance - Product_Design_And_Lifecycle_Management,0.4827035069465637
260,Through scientific innovation we strive to design more efficient  processes that can reduce the environmental impact of our medicines throughout the  product life cycle.,Governance - Product_Design_And_Lifecycle_Management,0.9637916088104248
261,"To expand on this, we are developing sustainable product design principles to transform  the way we work across all modalities in both research and development.",Governance - Product_Design_And_Lifecycle_Management,0.966439425945282
262,"Our intent is to  positively impact our environmental performance by systematically conserving energy,  reducing water and raw materials usage, driving out waste, and embracing circular  solutions where possible.",Environmental - Waste_And_Hazardous_Materials_Management,0.941517174243927
263,"The principles also serve to educate and inform our colleagues,  define key metrics and performance targets, and encourage innovation through  collaboration and partnerships.",Governance - Business_Model_Resilience,0.4230955839157104
264,"Pfizer is conducting representative life cycle assessments (LCAs) for small molecules,  large molecules, vaccines, and devices.",Governance - Product_Design_And_Lifecycle_Management,0.1985905766487121
265,"The output of these assessments is used to  identify areas of focus in development and manufacturing processes, which can help  enable preventative actions where we can have the most impact, with particular  emphasis on GHG emissions reductions.",Environmental - GHG_Emissions,0.9679861068725586
266,24 Pfizer 2022 ESG Report Environment Pharmaceuticals in the Environment  Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be  critically important environmental issues for our industry.,Environmental - Ecological_Impacts,0.3457706272602081
267,"Pfizer is committed to limiting  discharge of active pharmaceutical ingredients to wastewater from our manufacturing  processes, using environmental risk assessment methodologies and emission control  practices and technologies.",Environmental - Water_And_Wastewater_Management,0.8530523777008057
268,"As an active member, Pfizer follows the best practices in  the AMR Industry Alliance’s (AMRIA) Antibiotic Manufacturing Standard, published  in June 2022.",,0.3658688962459564
269,"We are on track to meet our goal of achieving the industry published  targets (Predicted No Effect Concentrations) for antibiotics by 2025 and are piloting  innovative wastewater management and treatment practices at several sites, including  manufacturing and supplier sites, to advance our management of wastewater discharges.",Environmental - Water_And_Wastewater_Management,0.9667383432388306
270,In 2022 Pfizer participated in an effort led by AMRIA and BSI Standards Limited to develop  an antibiotic certification scheme that is designed to demonstrate implementation  of AMRIA’s Antibiotic Manufacturing Standard through an independent third-party  certification body.,Social - Product_Quality_And_Safety,0.6934806108474731
271,Pfizer is one of the first companies to participate in the 2023  certification assessment pilot.,Social - Product_Quality_And_Safety,0.3207577764987945
272,Waste  Central to our sustainable medicines program is the minimization of waste across  our sites globally.,Environmental - Waste_And_Hazardous_Materials_Management,0.98423832654953
273,"We pursue process improvements in our research, development  and manufacturing operations through next-generation design projects and the  implementation of green chemistry and other sustainability practices.",Governance - Product_Design_And_Lifecycle_Management,0.7830016016960144
274,"Pfizer sites  consistently seek opportunities to reduce, reuse, repurpose, and recycle materials such  as packaging and plastics.",Governance - Product_Design_And_Lifecycle_Management,0.9406748414039612
275,"For the past four years, we've tracked an internal performance  metric to evaluate our sites’ waste management practices as they relate to the hierarchy  of control of handling waste: avoid, reduce, reuse, recycle, dispose.",Environmental - Waste_And_Hazardous_Materials_Management,0.9846771955490112
276,The metric is used to  drive waste handling decisions to improve the circularity of our sites’ waste streams and  promote minimization.,Environmental - Waste_And_Hazardous_Materials_Management,0.9849112033843994
277,We are also able to use this metric to benchmark our performance  against others in our industry and identify opportunities for improvement.,Governance - Systemic_Risk_Management,0.4587213397026062
278,"Since 2019, we  have reduced the quantity of waste sent to landfill by over 5.4 million kilograms.",Environmental - Waste_And_Hazardous_Materials_Management,0.9843097925186156
279,Pfizer participates in the Pharmaceutical Product Stewardship Work Group (PPSWG) in  the United States and MEDSdisposal in Europe to help enable proper disposal of unused  medicines.,Governance - Product_Design_And_Lifecycle_Management,0.3568972945213318
280,"eS Pfizer  — Continued Governance > Performance > Appendix >  Creating Sustainable Solutions in Memphis  At Pfizer's logistics center in Memphis, Tennessee, we took steps to reduce the environmental  impact of cold chain shipping operations.",Governance - Product_Design_And_Lifecycle_Management,0.8419679999351501
281,"Only about 3% of the single-use Styrofoam containers  being used for cold chain shipments were being returned by our customers for recycling, with  the majority being sent to landfill for disposal.",Environmental - Waste_And_Hazardous_Materials_Management,0.7745459675788879
282,"We replaced the Styrofoam shippers with reus-  able shipping containers that are easily returned and can be re-used over 70 times, reducing  the amount of packaging waste sent to landfill by customers by 90%.",Environmental - Waste_And_Hazardous_Materials_Management,0.9834663271903992
283,Water Stress  The availability of and access to clean water is a basic human need globally and must  be addressed locally.,Environmental - Water_And_Wastewater_Management,0.9779378175735474
284,"In 2022, Pfizer published a Water Stewardship position statement,  which describes our commitment to being good stewards of the water we use to make  medicines, particularly in water-stressed areas.",Environmental - Water_And_Wastewater_Management,0.9753869771957396
285,"To this end, we completed water risk  assessments at all Pfizer sites in 2022 to better evaluate and understand water quality  and scarcity issues across our network.",Environmental - Water_And_Wastewater_Management,0.9766269326210022
286,"As a result of these risk assessments, in 2023 we plan to develop action plans at sites with  elevated risk scores, which include elements such as quantifying water use, implementing  mitigation plans and establishing water conservation targets, protecting water quality,  improving wastewater treatment where necessary, evaluating recycling practices, and  engaging with surrounding communities.",Environmental - Water_And_Wastewater_Management,0.9755717515945436
287,"We will measure progress at our internal sites,  while engaging with our key suppliers in water-stressed areas to encourage them to  develop and implement similar action plans.",Environmental - Water_And_Wastewater_Management,0.9730307459831238
288,"25 Pfizer 2022 ESG Report Pfizer teammates completed a biodiversity related project involving the inventory and planting of  native trees at its Itapevi, Brazil site.",Environmental - Ecological_Impacts,0.977305829524994
289,"CASE STUDY: ITAPEVI NATURE BASED SOLUTIONS PROJECT  As Pfizer sets out on its Net-Zero journey, we recognize the interconnectedness of climate  change, natural systems and biodiversity.",Environmental - Physical_Impacts_Of_Climate_Change,0.634563148021698
290,"Several of our sites around the globe have undertaken  projects focused on protecting and promoting local, natural systems.",Environmental - Ecological_Impacts,0.978690505027771
291,"In recent years, Pfizer  Global Supply colleagues in Itapevi have been working to increase biodiversity by doubling the  number of native trees onsite.",Environmental - Ecological_Impacts,0.9592657089233398
292,"In 2022, an inventory was completed of the more than 2,000 trees  on the property confirming their health.",Social - Employee_Health_And_Safety,0.406683474779129
293,"These trees not only provide additional habitat and  shade, but also help clean the air and act as a carbon sink.",Environmental - Ecological_Impacts,0.9577178955078124
294,"eS Pfizer  At Pfizer, our purpose—Breakthroughs that change patients’ lives—is rooted in achieving social good.",Social - Human_Rights_And_Community_Relations,0.8729234337806702
295,"We know that when we succeed, our  breakthroughs can potentially have life-changing effects.",Governance - Business_Model_Resilience,0.530723512172699
296,We aim to be the solution for illnesses from widespread infectious diseases to conditions  with historically unmet need.,Social - Critical_Incident_Risk_Management,0.2450624108314514
297,"Pfizer is mindful of the urgency of our mission, as the world fights against the spread of deadly new diseases and struggles with inequities in  health outcomes among populations.",Social - Employee_Health_And_Safety,0.2979146838188171
298,Our goal is to leverage partnerships and programs to allow quick and widespread access to our  breakthrough medicines and vaccines across all corners of the world.,Social - Access_And_Affordability,0.3597978353500366
299,"Innovation and Global Health 27  Product Innovation  Equitable Access and Pricing How our approach Sc =6Good Health and Well-Being  wore Ny is We aspire to ensure health and well-being  to social issues , for all at all ages through equitable access to  supports the SDGs medicines and vaccines.",Social - Access_And_Affordability,0.6925873756408691
300,"Healthcare Infrastructure  Gender Equality  We aim to end discrimination against women,  ensure equal opportunities for leadership and  access to reproductive health.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9388712644577026
301,Patient Centric Design  14} More information on  the SDGs here.,Social - Access_And_Affordability,0.4156060218811035
302,"Human Capital 33  Colleague Engagement fi Decent Work and Economic Growth ECONOMIC GROWTH i Growth and Development We promote inclusive and sustainable  economic growth, employment, and decent  and safe working environments.",Social - Labor_Practices,0.7330864667892456
303,"Colleague Diversity, Equity, and Inclusion  Health, Safety, and Well-being  10 2, Reduced Inequalities  ‘=> We empower and promote the social and  v economic inclusion of all, irrespective of age,  sex, disability, race, ethnicity, origin, religion  or economic or other status.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9746153354644777
304,17 rammessrs Partnerships for the Goals & We are working to create new partnerships  to help attain relevant sustainable  development goals.,Social - Human_Rights_And_Community_Relations,0.7095845937728882
305,"Innovation and Global Health  As the global health landscape continues to evolve, so do we, making innovation our greatest tool as we uncover new combinations, designs, and  advances to address an array of challenges.",Governance - Product_Design_And_Lifecycle_Management,0.4808824062347412
306,"But medicinal solutions are only part of the equation: getting vaccines and therapies to patients who need  them, regardless of location, requires innovation in delivery systems.",Social - Access_And_Affordability,0.4352050125598907
307,Pfizer focuses on both aspects of innovation by investing in the right people and partnerships.,Governance - Product_Design_And_Lifecycle_Management,0.4226734936237335
308,Pfizer colleagues continue to break barriers in the  discovery and delivery of treatments and solutions with a relentless focus on providing for underserved and vulnerable communities around the world.,Social - Access_And_Affordability,0.9382177591323853
309,Our strategic public and private partnerships allow for reach and scale when key players are brought together.,Governance - Business_Model_Resilience,0.2678599059581756
310,"Product Innovation  At Pfizer, we measure ourselves by our  relentless pursuit of breakthroughs  that change patients’ lives.",Governance - Product_Design_And_Lifecycle_Management,0.763875424861908
311,This means  prioritizing innovation and accelerating  our efforts to bring solutions to those  who need them at “lightspeed.” We have  been consistently investing in innovation  with a research and development budget  that has grown by more than 70 percent  in less than five years.,Governance - Product_Design_And_Lifecycle_Management,0.294391006231308
312,"As of January 31,  2023, our current pipeline of 110 programs  in development, from Phase 1 through  registration, reflects our empowerment of  scientists, culture of excellence, and deep-  seated drive to deliver on our purpose for  patients.",Social - Access_And_Affordability,0.3502615988254547
313,A greater success rate means the potential  to affect more patients’ lives.,Social - Access_And_Affordability,0.6583841443061829
314,"By the end  of 2022, Pfizer achieved an end-to-end  success rate of 18 percent—from first-in-  human (FIH) to approval at a new molecular  entity (NME) level — which is nearly 10  times our 2010 performance.",,0.2034977078437805
315,This improved  success rate can be largely attributed to a  27 Pfizer 2022 ESG Report years-long narrowing of our therapeutic  focus areas to where we believe we are  equipped to make the biggest impact on  patients’ lives.,Social - Access_And_Affordability,0.3258772790431976
316,"Reduced cycle times, while continuing  our focus on safety and quality, can help  get our breakthroughs to patients faster,  potentially addressing more unmet needs.",Social - Product_Quality_And_Safety,0.8085280060768127
317,Pfizer reduced our median FIH to approval  cycle time for new medicines and vaccines  from nine years in 2019 to approximately  five years in 2022.,Social - Selling_Practices_And_Product_Labeling,0.3042446076869964
318,"Based on an evolving  mix of approvals, including accelerated  development for COVID-19 products, Pfizer  now develops medicines and vaccines  45 percent faster from FIH to approval  compared to 2019.",,0.2718622386455536
319,We work every day to upend the standard  approach to clinical development in areas  with a high unmet need in order to pursue  breakthroughs in vaccines and treatments.,Social - Access_And_Affordability,0.3306497931480407
320,Pfizer’s NME and Biologics License  Application (BLA) approvals reflect a greater  Social proportion of Breakthrough Therapy and  Expedited Regulatory Designations relative  to the industry.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8132367730140686
321,"* Between 2018 and 2022, 44 percent  of Pfizer NME and novel BLA  applications approved by the U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4491232335567474
322,"FDA  were designated as Breakthrough  Therapies compared to 30 percent of  industry Center for Drug Evaluation  and Research (CDER) and Center for  Biologics Evaluation and Research  (CBER) vaccine applications approved  over the same period  * Including other FDA designations  involving expedited review between  2018 and 2022, 100 percent of Pfizer  NME and novel BLA applications  approved by the FDA achieved one  (or more) expedited designations  compared to 67 percent of industry  CDER and CBER vaccine applications Digital Innovation  Greater social impact is the result of our re-  lentless focus on productivity, as we get more  life-changing medicines into the hands of pa-  tients and at a faster rate.",Governance - Product_Design_And_Lifecycle_Management,0.2036418914794922
323,"Pfizer is leveraging  digital, data, artificial intelligence (AI), and  machine learning to accelerate innovation in  the interests of patients at every step—from  discovery to clinical development, manufac-  turing, distribution, and commercialization.",Governance - Competitive_Behavior,0.3183256387710571
324,"Technology enhancements like computation-  al modeling and simulation, and quantum  computing capabilities, are making our crit-  ical work faster and more relevant to actual  patient experiences.",Environmental - Energy_Management,0.2647791504859924
325,"In 2022, our digital innovation included  partnering with major retail pharmacy chains  to introduce digital health products that  support patients on their treatment journey,  and applying advanced analytics and AI ca-  pabilities that accelerate access to PAXLOVID,  Pfizer's COVID-19 oral treatment.",,0.4441030323505401
326,Pfizer also  launched an Al-driven program to monitor  and identify counterfeit versions of Pfizer  medicines in real-time to help ensure patient  access to safe and effective medications.,Social - Selling_Practices_And_Product_Labeling,0.2191397845745086
327,"To  deliver these and other innovations at speed  and scale, we accelerated the migration of  our global IT footprint to the cloud from 25  percent in 2019 to 80 percent in 2022.",Governance - Business_Model_Resilience,0.2081611156463623
328,"eS Pfizer  — Continued  Our Innovations Are Guided by Patient Needs  28 ~ RSV vaccine candidate  In 2022, Pfizer received Breakthrough Therapy Designation for our respiratory syncytial virus (RSV) vaccine candidate, RSVpreF, for prevention of RSV-associated lower respiratory tract illness  in both infants, through maternal immunization, and older adults aged 60+.",Social - Employee_Health_And_Safety,0.8488098978996277
329,"With RSV's potentially serious and in some cases life-threatening impacts, RSVpreF has the potential to be the  first maternal vaccine candidate to help protect infants from birth through six months of age, if approved.",Social - Access_And_Affordability,0.4435632526874542
330,"© Pneumococcal conjugate vaccine  or)  ™~ Pfizer received approval from the European Medicines Agency in 2022 for APEXXNAR® [pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)], our _ “ 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in people ages 18 and up.",Social - Product_Quality_And_Safety,0.1636644005775451
331,"— TT \ Following positive results in studies of the pediatric population, the FDA accepted the application for the vaccine for priority review to expand use to prevent infection in  infants in the U.S.",Social - Employee_Health_And_Safety,0.2901757955551147
332,"\ \  -~—@©@ \ \ , , , \ ® Next generation COVID-19 vaccine candidate  \ © \ In the ongoing response to COVID-19, Pfizer and BioNTech have established a long term and multi-pronged scientific strategy with the aim of developing  \ \ \ next generation COVID-19 vaccines to generate more robust, longer-lasting, and broader immune responses against COVID-19.",,0.2200408577919006
333,"+ | |  / / , Ulcerative colitis  Pfizer announced positive Phase 3 results for etrasimod, an investigational, oral, once-a-day (S1P) receptor modulator for the treatment of moderate-to-  / / severe ulcerative colitis—a chronic and debilitating disease with high rates of progression to colectomy.",Social - Employee_Health_And_Safety,0.8450130820274353
334,"In the trial, etrasimod showed an encouraging  we y / balance of efficacy and safety, and could have a meaningful impact for patients, if approved.",Social - Product_Quality_And_Safety,0.5874255895614624
335,"ae __ _—  we -  _  _@ / © Type 2 diabetes  2 = Rising rates of obesity and diabetes carry significant health consequences, as these diseases have increased comorbidity risk.",Social - Employee_Health_And_Safety,0.2153079807758331
336,Pfizer's investigational oral GLP-1receptor _ agonists are designed to address what we understand to be key drivers of these diseases and are showing best-in-class potential.,Governance - Competitive_Behavior,0.340361088514328
337,"While ensuring the compliance with — oO a our high-quality standards and keeping patient safety at the forefront, we are working to accelerate clinical development timelines for these treatment candidates  and, subject to clinical success and approval of regulatory authorities, we hope to be able to provide a convenient oral option for patients alongside currently approved  injectable medicines.",Social - Product_Quality_And_Safety,0.8731899261474609
338,® Oncology  Oncology continues to be another therapeutic area where Pfizer has deep scientific and biologic understanding.,,0.225269615650177
339,"* In 2022, Pfizer's investigational cancer immunotherapy, elranatamab, received FDA Breakthrough Therapy Designation for the treatment of people with relapsed or refractory multiple  myeloma, representing our twelfth breakthrough designation in oncology  * To help patients with advanced prostate cancer—the second most common type of cancer in men—Pfizer is conducting the Phase 3 TALAPRO-2 study, examining a combination  treatment with TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase inhibitor, and XTANDI® (enzalutamide)—an existing standard of care.",Social - Access_And_Affordability,0.1613748967647552
340,"The study showed positive results  with the potential for this combination to become a new standard of care for metastatic castration-resistant prostate cancer, subject to regulatory approval.",Social - Access_And_Affordability,0.2293121665716171
341,"Pfizer 2022 ESG Report Social eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  Innovating for Impact  2022 also brought significant launches and expansions that  provide opportunities for Pfizer to further address unmet  patient needs in categories such as rare hematology, for  example.",Social - Access_And_Affordability,0.2998757660388946
342,"Pfizer completed the acquisition of Global Blood  Therapeutics, Inc., a biopharmaceutical company dedicated  to the discovery, development, and delivery of life-changing  treatments for underserved patient communities, starting  with sickle cell disease.",Social - Access_And_Affordability,0.9430705904960632
343,"A core pillar of our product innovation work is our effort to  help slow the spread of antimicrobial resistance (AMR)—  one of the biggest threats to global health as it can make  infections harder to treat, increasing the risk of disease  spread, severe illness, and death.",Social - Employee_Health_And_Safety,0.4167223274707794
344,As many as 10 million  people could die annually from AMR by 2050.,Environmental - Air_Quality,0.1928590983152389
345,"Pfizer's recognition in the 2022 Access to Medicine AMR  Benchmark reflects our industry-leading and multi-faceted  approach to combat AMR, which includes our own product  pipeline, active stewardship, infrastructure investments,  and comprehensive tracking.",Governance - Product_Design_And_Lifecycle_Management,0.8368659019470215
346,"Pfizer’s ATLAS surveillance  program—one of the largest in the world—provides public  access to both antifungal and antibiotic resistance data,  helping researchers and stakeholders better understand  resistance patterns.",Social - Selling_Practices_And_Product_Labeling,0.1363583505153656
347,"Equitable Access and Pricing  At Pfizer, we measure ourselves not just by the creation  of breakthrough medicines and vaccines, but by the  accessibility of those critical innovations within populations  in need.",Social - Access_And_Affordability,0.4850600361824035
348,Our vaccines and medicines are not able to benefit  patients if they cannot reach or afford them.,Social - Access_And_Affordability,0.7557687163352966
349,"To change  patients’ lives, Pfizer applies a modernized approach to  access, focused on affordability and delivery for patients  with the greatest coverage gaps and out-of-pocket  exposure.",Social - Access_And_Affordability,0.8935011625289917
350,"As aresult of these efforts, in 2022, more than 1.3 billion  patients were treated and / or vaccinated by a Pfizer  product, including COMIRNATY® (the Pfizer-BioNTech  COVID-19 vaccine) and PAXLOVID® (nirmatrelvir tablets and  ritonavir tablets).'  Affordability is along term commitment and must be  embedded in our systems, incentives, and operating  model.",Social - Access_And_Affordability,0.1970386654138565
351,"At Pfizer, this is guided by An Accord for a Healthier  World, which is focused on closing the health equity gap  that persists between wealthy nations and many lower-  income countries.",Governance - Systemic_Risk_Management,0.3706434071063995
352,"Alongside governments and multi-sector  partners, Pfizer is working to co-create scalable, sustainable  solutions to enable greater access to healthcare innovation  for 1.2 billion people living in 45 lower-income countries  around the world.",Social - Access_And_Affordability,0.800385594367981
353,"Additionally, Pfizer's broad-based core methods to reduce  the number of people who cannot afford our medicines  include:  * Advocating with payers, governments, and others in the  healthcare system on behalf of patients to identify and  relieve financial burdens  * Patient assistance and donation programs when  insurance or reimbursement systems fail to provide  affordable access to our medicines  * Innovative financing mechanisms, including differential  pricing, microfinancing, peer-to-peer lending,  subscription models, and flexible payment options,  to help reduce out-of-pocket costs for patients ona  sustained basis  * New technologies that reduce barriers to care and digital  wallets with the potential to pass rebates directly to  patients at the point of sale  We also engage in global commercial access partnerships  with organizations like Gavi, the Vaccine Alliance, where  1 Please refer to About this Report for the Emergency Use Authorization (EVA) statement for COMIRNATY® and PAXLOVID®.",Social - Access_And_Affordability,0.5349104404449463
354,2 Refer to our Performance section for additional details on these figures.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.21704962849617
355,29 Pfizer 2022 ESG Report Social we've agreed to supply up to 930 million doses of  pneumococcal conjugate vaccine (PCV) through 2027 at  its lowest access price.,Social - Access_And_Affordability,0.2516026794910431
356,"In 2022, Pfizer extended this work  through a bid with UNICEF to supply Prevenar 13 to Gavi at  its lowest access price.",Social - Supply_Chain_Management,0.7044061422348022
357,Patients Treated  (including COMIRNATY and PAXLOVIDY  Traditional Channels  1.3b  U.S.,Social - Access_And_Affordability,0.1719018071889877
358,Patient Assistance Programs  75k+  Ex-U.S.,Social - Access_And_Affordability,0.812441349029541
359,"Access and Affordability Programs  1.1m  Global Commercial Access Partnerships  38.5m  Product Donation Programs  31.2mM  eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  COVID-19 vaccines arrive in Botswana  CONTINUING OUR MISSION TO WORK TOWARDS  EQUITABLE GLOBAL ACCESS TO THE COVID-19 VACCINE  In 2022, Pfizer continued our commitment to reach vulnerable  populations where there is demand through a pledge to  make available at least 2 billion doses of the Pfizer-BioNTech  COVID-19 vaccine to low- and middle-income countries  through 2022.",Social - Access_And_Affordability,0.842049241065979
360,"As of the end of 2022, Pfizer met the demand  for the vaccine from these markets, delivering nearly 1.7  billion doses to 112 countries, including South Africa, Kenya,  Rwanda, Jordan, Ukraine, Dominican Republic, Honduras,  Indonesia, Vietnam, and Malaysia—among many others.",,0.2102043032646179
361,We also continue to work closely with COVAX and partners  like the U.S.,Governance - Business_Model_Resilience,0.2853299379348755
362,Government and European Union to supply the  vaccine to meet current global demand in low- and middle-  income countries.,Social - Access_And_Affordability,0.319165289402008
363,"Pfizer remained the top supplier to COVAX  in 2022, contributing around 30% of their total supply—  nearly 600 million doses of the Pfizer-BioNTech COVID-19  vaccine.",Social - Supply_Chain_Management,0.2383052855730056
364,Pfizer also supports bilateral donations between  governments to help ensure access.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9082382917404176
365,"We set the price of our medicines and vaccines guided by the  value our products bring to patients and society, achieving  the broadest possible access.",Social - Selling_Practices_And_Product_Labeling,0.3722522556781769
366,"Our goal is to create long term  solutions that take into consideration the environments and  health systems in which we operate, using flexible payment  models designed for differing markets.",Governance - Systemic_Risk_Management,0.2515444755554199
367,"To achieve faster and  broader access to our medicines, we have over 150 financial-  based agreements currently implemented or in development  in ex-U.S.",Social - Access_And_Affordability,0.6094056367874146
368,markets.,Governance - Competitive_Behavior,0.3689367473125458
369,"In the 2022 Access to Medicine Index, Pfizer ranked No.",Social - Access_And_Affordability,0.4046703577041626
370,"6  overall, but led in the governance of access category for  an integrated access-to-medicine strategy and board-level  responsibility and showed improvement in the Research &  Development category.",Social - Access_And_Affordability,0.6306717991828918
371,Pfizer looks to leverage digital platforms and technologies  prevalent in today’s world to introduce effective and scalable  solutions that address specific patient needs.,Governance - Product_Design_And_Lifecycle_Management,0.2502839565277099
372,"This includes  support programs that aim to improve quality of care and  convenience, as well as reduce the burden of ongoing, high-  cost care.",Social - Access_And_Affordability,0.7678313851356506
373,"In 2022, Pfizer developed IUdo, a digital solution  offering a standardized and secure platform to streamline  processes for third parties managing Pfizer support  programs, combined with a mobile app for patients.",,0.4639736711978912
374,IUdo is designed to make it easier for patients enrolled  in selected Patient Support Programs to access Pfizer  medications.,Social - Access_And_Affordability,0.7459808588027954
375,It improves both the patient and healthcare  professional experience by accelerating program enrollment;  providing seamless access to financial support plans;  increasing the scale and reach of programs to patients;  and allowing the support program journey to be managed  directly from their phones.,Social - Access_And_Affordability,0.8709291219711304
376,"To date, IUdo is available in Egypt,  Lebanon, Qatar, and Mexico with plans to expand to other  countries across Emerging Markets in fiscal 2023.",Governance - Business_Model_Resilience,0.2634846568107605
377,Healthcare Infrastructure  Pfizer embraces that healthcare is more than the  development of medicines and vaccines.,Social - Access_And_Affordability,0.336515337228775
378,"Governments, civil  society, the private health sector, and communities play  a critical role in facilitating access to health innovations  by establishing and strengthening local healthcare  infrastructure.",Social - Access_And_Affordability,0.8575135469436646
379,"Through The Pfizer Foundation*, we make investments  that seek to improve health systems and increase access to  quality healthcare for underserved populations, in the U.S.",Social - Access_And_Affordability,0.947218418121338
380,and around the world.,Governance - Product_Design_And_Lifecycle_Management,0.1693887710571289
381,We have doubled down on solutions  that are evidence based and aligned with government health  priorities.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8789811730384827
382,*The Pfizer Foundation is a separate legal entity from Pfizer Inc.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2413099855184555
383,with distinct legal restrictions.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7182366847991943
384,"30 Pfizer 2022 ESG Report Social As part of our commitment to advance health equity, The  Pfizer Foundation’s ‘Accelerating Health Equity’ Grant  Program supports efforts to reduce health disparities and  improve health outcomes in Black communities in the U.S.",Social - Employee_Health_And_Safety,0.4925493001937866
385,using a social determinants of health framework.,Social - Human_Rights_And_Community_Relations,0.3512094616889953
386,"In its  second year, the program is supporting 15 community-  based organizations to develop and lead solutions that  address leading causes of disparate health outcomes.",Social - Employee_Health_And_Safety,0.8797659873962402
387,"In  the program's first year more than 900,000 people received  healthcare services, information or support, including  efforts to empower people with health knowledge, increase  access to direct health services, and provide patients and  communities with stronger social support.",Social - Access_And_Affordability,0.8615755438804626
388,"This program  also trained more than 390 community health workers and  strengthened more than 3,600 health facilities in the U.S.",Social - Employee_Health_And_Safety,0.9507542252540588
389,"Launched in 2020, in partnership with Direct Relief, The Pfizer  Foundation provided grants to 11 U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.785866916179657
390,"safety-net community  healthcare providers, supporting innovative approaches to  infectious disease education, screening, testing, treatment,  and care among the country’s most vulnerable communities.",Social - Access_And_Affordability,0.6659068465232849
391,"Assisted by the grants, these health centers are undertaking  approaches to create greater equity, including mobile vans  and pop-up clinics, telehealth technology, and electronic  health records to standardize care.",Social - Customer_Privacy,0.2285225838422775
392,"To date, the program has  reached more than 455,000 people with improved quality  care, including pregnant women and children.",Social - Access_And_Affordability,0.6101158857345581
393,"Global health system strengthening  Through global initiatives, The Pfizer Foundation focuses its  strategy on strengthening health systems to better address  vaccine-preventable illnesses and infectious disease.",Social - Employee_Health_And_Safety,0.7981240153312683
394,"Launched in 2016, the Global Health Innovation Grants (GHIG)  program works to support innovative health delivery models  in low- and middle-income countries.",Social - Access_And_Affordability,0.7001366019248962
395,These projects help to  test and scale community-based initiatives addressing global  health challenges and allow the Foundation to make wide-  reaching impact in the prevention and treatment of infectious  disease.,Social - Access_And_Affordability,0.3763984441757202
396,"Since the program launch, The Pfizer Foundation  has supported 34 organizations in 21 countries across Asia,  eS Pfizer  — Continued  Africa, and Latin America.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2768634259700775
397,"These efforts have helped to treat These are often preventable deaths caused by gaps in access under age five, by strengthening community-level prevention,  more than six million patients, provide life-saving screening to healthcare and inappropriate care for pregnancy and diagnosis, and treatment, as well as deploying social  and education for 12.2 million patients, train more than 80,000 childbirth.",Social - Access_And_Affordability,0.6240068674087524
398,"In 2022, we increased our support in this area accountability models to demand and improve utilization of  healthcare staff and open over 1,000 new health centers.",Social - Access_And_Affordability,0.5399181842803955
399,through a new partnership with PATH in Ghana to reduce quality care.,Social - Access_And_Affordability,0.7053517699241638
400,"newborn mortality by improving diagnosis and management  In addition to our GHIG initiative, the Infectious Disease Grants — of maternal infections through integration of point-of-care  program, launched in 2019, focuses on improving child health diagnostics and community-based screening of infectious  and prevention and treatment of infectious diseases.",Social - Employee_Health_And_Safety,0.4695058763027191
401,diseases.,,0.092753067612648
402,"We recognize the disproportionate risk for neonatal deaths This year, The Pfizer Foundation expanded our partnership  and maternal mortality in low- and middle-income countries.",Social - Employee_Health_And_Safety,0.723872184753418
403,with World Vision in Uganda to reduce childhood mortality  Pfizer Inc.,Social - Access_And_Affordability,0.6989451050758362
404,"Programs Supporting Equitable Access  International Trachoma Initiative  In 1998, Pfizer and the Edna McConnell Clark Foundation co-founded the International Trachoma Initiative (ITI), a nonprofit dedicated to helping eliminate  trachoma, the leading infectious cause of blindness worldwide.",Social - Employee_Health_And_Safety,0.7505295276641846
405,"The ITI, which since 2009 has been a program of the independent nonprofit The Task Force  for Global Health, manages Pfizer's donated antibiotic and collaborates with governments and partners to implement the World Health Organization's (WHO)  recommended strategy to prevent, treat, and ultimately eliminate trachoma as a public health problem.",Social - Employee_Health_And_Safety,0.1682720333337783
406,"Our Impact:  * As of January 2023, Pfizer marked the milestone of 1 billion donated doses of antibiotic, which through the ITI and many partners has reached more than  300 million patients in more than 40 countries  * Asaresult of the WHO's recommended SAFE strategy to help prevent and treat trachoma, in 2022 four additional countries were validated by the WHO  as having eliminated trachoma, even amid other public health crises.",Social - Product_Quality_And_Safety,0.1659543663263321
407,"According to the WHO, 15 countries have eliminated trachoma as a public health  problem and the number of people at risk of the disease has decreased by 92 percent since 2002  * InJune 2022, Pfizer extended our commitment to provide antibiotic donations through 2030, aligning with the goal of global trachoma elimination  endorsed by the WHO =  Photo Credit: Sala Lewis /  International Trachoma  Initiative  Local Supply Chain Partnerships  We know that it won't just be vaccines that will bring an end to the COVID-19 pandemic, but vaccinations.",Social - Supply_Chain_Management,0.4624516665935516
408,Country readiness is critical in ensuring that  vaccinations are successful.,Social - Employee_Health_And_Safety,0.2778501808643341
409,"Based on Pfizer's experience working with Ministries of Health and multilateral organizations during this unprecedented scale up of  a vaccination campaign, we recognize countries are facing multiple issues when it comes to supply planning and delivery, including the ability to absorb vaccine  in the country, lower uptake rates due to hesitancy, limited ultra-cold-chain capacity or infrastructure to properly move or store vaccines, syringe supply, and  other downstream capacity issues like workforce constraints.",Social - Supply_Chain_Management,0.8659628629684448
410,Continued investment in readiness efforts in many low-income countries is still necessary to  ensure that vaccines shipped effectively reach populations.,Social - Access_And_Affordability,0.7831764221191406
411,"Pfizer continues to partner with the global health community, governments, and private industry to  help address these challenges.",Social - Access_And_Affordability,0.4519611001014709
412,31 Pfizer 2022 ESG Report Social eS Pfizer  — Continued Environment > Social > Governance Performance > Appendix >  Zipline  Project Last Mile  Patient Centric Design  Everything we do at Pfizer is done first and foremost with  patients in mind.,Social - Human_Rights_And_Community_Relations,0.4691013991832733
413,"To be most effective in serving patients and  understanding the patient experience, we are intentional  about engaging them, along with caregivers and advocacy  groups, in all of our processes.",Social - Access_And_Affordability,0.7346408367156982
414,"By speaking directly with  patients and advocates, we glean insights on conditions  and treatments, inform patients about clinical trials, discuss  possible side effects, and educate the wider healthcare  community about helpful tools.",Social - Selling_Practices_And_Product_Labeling,0.1754115521907806
415,"In that spirit, we hosted our second annual Patients in Focus  week, engaging more than 40,000 colleagues and more than  200 Global Patient Advocacy Partners.",Social - Access_And_Affordability,0.3993696570396423
416,"From blood drives  and volunteering campaigns to patient chats and colleague  lunch-and-learns, in-person and virtual events expanded  32 Pfizer 2022 ESG Report colleagues’ understanding of patient needs and highlighted  best-in-class patient advocacy initiatives.",Social - Access_And_Affordability,0.6154427528381348
417,"In addition to improving the broader patient experience  through community engagement, health inequities are  addressed more effectively when community experts  are intentionally engaged in developing solutions that  tackle underlying issues.",Social - Human_Rights_And_Community_Relations,0.7424977421760559
418,Pfizer continues to work with key  groups across the U.S.,,0.2272242605686187
419,to help address health disparities  among historically underserved populations through its  Multicultural Health Equity Collective (The Collective).,Social - Access_And_Affordability,0.9424540400505066
420,"Building upon trust established with partner organizations,  The Collective continues to move beyond education and  health literacy efforts, while purposefully focusing on  systemic issues that cause inequitable health outcomes.",Social - Access_And_Affordability,0.3388251066207886
421,"Social As part of a four-year partnership with Zipline, Pfizer is continuing to support an innovative pilot initiative in Ghana, focused on delivering vaccines that require  cold-chain storage to hard-to-reach areas using drones.",,0.1508529782295227
422,The initial success of the project suggests the program could be expanded to deliver doses of COVID-19  vaccines to remote regions across the world where Zipline operates.,Social - Access_And_Affordability,0.5749044418334961
423,"In 2022, over 1.7 million vaccine doses from various manufacturers were delivered by  Zipline, reaching 657 health facilities across Ghana, as well as expanding to Nigeria, reaching 90 rural health facilities in Kaduna State.",Social - Access_And_Affordability,0.5971092581748962
424,"In addition to providing  much-needed vaccines to these areas, the delivery of these 1.7 million doses by drones saved over 34,000 gallons of gasoline.",Social - Access_And_Affordability,0.4663090109825134
425,"In 2021, Pfizer signed a memorandum of understanding with the Global Environment and Technology Foundation to collaborate with Project Last Mile.",Environmental - Ecological_Impacts,0.3630022704601288
426,"The  partnership is focused on aligning the supply chain expertise and technical capabilities of Coca-Cola, a company whose supply chain is characterized as one  of the widest reaching in the world, with technical expertise from Pfizer on vaccine handling, storage and administration in order to improve the availability of  vaccines in developing countries, and, in particular, to those residing in and around the last mile of the medical supply chain in Africa.",Social - Supply_Chain_Management,0.9150099158287048
427,"In 2022, The Collective hosted its inaugural Health Equity  in Action Summit: Optimal Interventions to Systemic  Drivers of Racial Health Inequities.",Governance - Systemic_Risk_Management,0.8826497793197632
428,"Co-convened by The  Century Foundation, the National Minority Quality Forum,  Morehouse School of Medicine, and National Association  of County & City Health Officials (NACCHO), the Summit  gathered more than 100 leaders from across the healthcare  ecosystem to challenge conventional thinking, highlight  the need and opportunities to disrupt racism embedded  in health systems, and make better health possible for all.",Social - Access_And_Affordability,0.263773113489151
429,"We explored solutions to advance health equity across  key areas, including digital health, healthcare facilities and  delivery, workforce development, health research and policy,  and more.",Social - Employee_Engagement_Inclusion_And_Diversity,0.4955101907253265
430,We look forward to partnering with Summit  participants to elevate solutions that address critical gaps in  equitable healthcare and reduce barriers to quality care.,Social - Access_And_Affordability,0.7332068085670471
431,eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  Human Capital  Our ability to successfully deliver on our purpose to the benefit of patients is dependent on our people.,Social - Human_Rights_And_Community_Relations,0.6718999743461609
432,"We focus on integrating workforce, workplace,  and work output by paying special attention to the health and wellness of our colleagues, prioritizing meaningful work that contributes to our Purpose:  Breakthroughs that change patients’ lives, and fostering an amazing place to work where our people can thrive and grow.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3638924062252044
433,"We engage our colleagues through every phase of their experience, bringing a people-centric approach to everything from recruiting, benefits and compensation, to growth, inclusion,  and communication.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9697524309158324
434,"Colleague Engagement  From recruitment to retirement, Pfizer works  to cultivate a positive colleague experience  dedicated to professional and personal  success, providing equitable opportunities,  and creating breakthroughs.",Social - Employee_Engagement_Inclusion_And_Diversity,0.8636976480484009
435,"We focus  on ensuring each of our employees feels  connected to our purpose and supported  by the culture we continuously work to  maintain, which is built on our company  values of courage, excellence, equity, and  Joy.",Social - Employee_Engagement_Inclusion_And_Diversity,0.4414610266685486
436,"Managers are committed to discussing  colleague performance assessments twice  annually, with the intent to encourage  breakthrough goals and drive leadership  in Pfizer values.",Governance - Business_Model_Resilience,0.263505071401596
437,"However, we understand  that communication goes both ways.",Governance - Business_Ethics,0.2298891395330429
438,Continuously listening and responding to  colleague feedback is essential to fostering  a healthy work environment with the power  to attract and retain top talent.,Social - Employee_Engagement_Inclusion_And_Diversity,0.7696439623832703
439,"Our annual  engagement survey, Pfizer Pulse, provides a  forum for our colleagues to give structured  feedback and allows us to measure and  track priority areas and equip leaders with  33 Pfizer 2022 ESG Report actionable insights.",Governance - Business_Model_Resilience,0.565453290939331
440,"We are proud that in  2022, on average 88 percent of colleagues  reported feeling engaged, as measured by  pride in working at Pfizer, a willingness to  recommend Pfizer as a great place to work,  and intent to stay.",Social - Employee_Health_And_Safety,0.2168450653553009
441,"In addition, 93 percent  agreed their daily work contributes to our  purpose.",Social - Labor_Practices,0.4623076319694519
442,"In addition to Pfizer Pulse, we initiate  informal requests for feedback during the  year.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2746466994285583
443,"Throughout the restructuring of our  growth strategy, for example, more than  6,000 colleagues provided input, leading  to a platform with overwhelmingly positive  feedback and engagement.",Governance - Business_Model_Resilience,0.4733039438724518
444,"Along with effective listening, Pfizer  prioritizes colleague recognition to drive  engagement, motivation, and productivity.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3489489257335663
445,"In 2022, we launched Bravo, Pfizer's first  global rewards and recognition program  with peer-to-peer capabilities.",Governance - Competitive_Behavior,0.4639889299869537
446,"Colleagues  are celebrated for demonstrating Pfizer  values in a way that makes an impact on the  company, a colleague, a team or a patient.",Social - Human_Rights_And_Community_Relations,0.2867564857006073
447,"From Bravo's launch in April through  fiscal 2022, 82 percent of colleagues have been recognized and more than 414,000  recognitions have been given.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.1542779356241226
448,"Growth and Development  In 2022, Pfizer continued the shift froma  traditional, linear view of career growth  to one that is built on aspirations and  empowers individuals to boldly own their  growth journey.",Social - Employee_Engagement_Inclusion_And_Diversity,0.8145372271537781
449,"We deepened our efforts  to redefine growth as a fluid process that  promotes incremental in-role growth  or mobility along horizontal, vertical or  diagonal individualized pathways—what we  are calling “Zig-Zag” growth.",Governance - Business_Model_Resilience,0.3754855990409851
450,"From a managerial perspective, Pfizer is  adopting a collective talent mindset to  support colleague growth across the entire  organization.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9285165071487428
451,We recognize that diverse  experiences drive better outcomes.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9652191996574402
452,"In 2022,  our senior managers and above made  368 diagonal zig-zag moves across the  enterprise, a 50 percent increase over the  prior year baseline of 245.",Governance - Business_Model_Resilience,0.3003070056438446
453,We also set the expectation that managers  have growth conversations with all of their  Social direct reports by the end of the year to align  on their growth aspirations and identify  actions to help propel them forward on  their growth journey.,Governance - Business_Model_Resilience,0.8124291300773621
454,"Pfizer is also committed to providing  colleagues with opportunities to grow  through experiences, connections with  others, and learning.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3284776210784912
455,"In 2022, we launched  the Pfizer Growth Universe—a singular  source for colleagues to access growth  resources and explore new experiences.",Governance - Business_Model_Resilience,0.2718282639980316
456,"The Growth Universe connects colleagues  to roles, people, and projects with the  functionality to:  * Search for growth opportunities  including full-time roles and short-term,  project based “gigs” to build skills and  gain exposure to other parts of the  business  * Explore people connections through  colleague resource groups, networking,  and mentor matching  * Get inspired by other colleagues’ stories  and reflections  eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  In 2022, we also launched the Pfizer Learning Academy to  provide personalized learning pathways for colleagues,  which draw on Pfizer and third-party learning materials.",Social - Employee_Engagement_Inclusion_And_Diversity,0.6845104098320007
457,"Colleagues can access articles, videos, podcasts, and  toolkits that address a variety of topics, from leadership  and cultural awareness to content for specialized business  functions.",Social - Employee_Engagement_Inclusion_And_Diversity,0.7929621934890747
458,"Colleague Diversity, Equity, and Inclusion (DEI)  At Pfizer, we believe every person deserves to be seen,  heard, and cared for.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9624260067939758
459,"This belief drives our refreshed Global  DEI strategy launched in 2021, focused on building a more  inclusive colleague experience, advancing equitable health  outcomes, and transforming society through external  partnerships.",Social - Access_And_Affordability,0.6622715592384338
460,"DEI is a path we choose both mindfully  and actively, and is cultivated by listening, learning, and  connecting with our colleagues, patients, and communities.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3778817355632782
461,We focus on accountability and transparency by setting  clear goals the company aspires toward and benchmarking  our progress against 28 key workplace DEI initiatives and  outcome metrics for 2022—down from 35 in 2021 due to the  completion of some initiatives.,Governance - Business_Ethics,0.9646700620651244
462,"In addition, we surpassed  our goal of hiring 100 refugees with our Pfizer Refugee  Leadership Initiative, which aims to support economic  inclusion of refugees and other displaced people through  hiring, mentorship, and advocacy.",Social - Employee_Engagement_Inclusion_And_Diversity,0.5809995532035828
463,"With such positive results,  we announced an expanded goal to hire an additional 500  qualified refugees over the next three years.",Social - Employee_Engagement_Inclusion_And_Diversity,0.7641949653625488
464,"We also launched a Self-Identification campaign, inviting  all U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.7297705411911011
465,colleagues to disclose demographic information if  they choose.,Social - Employee_Engagement_Inclusion_And_Diversity,0.6885829567909241
466,"With aggregated self-identification data, we  can better understand the demographics of our colleague  population and ensure our recruitment, development,  and promotion strategies, along with our benefits and  policies, are inclusive for all colleagues.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9718090295791626
467,"Approximately  5,000 colleagues self-identified within the first hour of the  campaign launch.",Social - Employee_Engagement_Inclusion_And_Diversity,0.3347040116786957
468,"34 Pfizer 2022 ESG Report To build authentic connections and encourage diverse  perspectives, in 2022, we launched DEI Learner's Journey  pilots among a number of business groups.",Social - Employee_Engagement_Inclusion_And_Diversity,0.8331277966499329
469,Courses are  focused on “The Neuroscience of Smarter Teams” and a  “Conscious Inclusion Workshop” for people managers.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9576223492622375
470,The program will be rolled out to all colleagues in 2023.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7103038430213928
471,"Additionally, in response to colleague feedback and to  amplify equity and inclusion, we made the decision to make  Juneteenth a U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9532654285430908
472,company holiday in 2023.,Social - Labor_Practices,0.1373257935047149
473,"Partnerships  We hire, grow, and empower diverse talent by partnering  with organizations that provide rich engagement  opportunities with people of diverse backgrounds and  experiences.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9737858176231384
474,"In 2022, Pfizer engaged in new partnerships  with the National Association of Black Journalists, National  Association of Hispanic Journalists, and MyGWork—a  networking community for LGBTQ+ professionals.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9529045224189758
475,We  also launched a refreshed strategy to better attract top  candidates from Historically Black Colleges and Universities  (HBCUs).,Social - Employee_Engagement_Inclusion_And_Diversity,0.8831096291542053
476,"Through October, Pfizer executed 15 diversity partnership  events at the enterprise level, strengthening diversity  representation in our talent pipeline and resulting in more  than 40 new hires by the end of calendar year 2022.",Social - Employee_Engagement_Inclusion_And_Diversity,0.976195514202118
477,"Colleague resource groups  In keeping with our core value of Equity, in 2022, Pfizer  encouraged greater collaboration among our seven  Enterprise Colleague Resource Groups (ECRGs) with a sharp  focus on intersectionality and co-hosted initiatives.",Social - Human_Rights_And_Community_Relations,0.1250200122594833
478,"Key 2022  initiatives for each group, many of which were co-hosted,  include:  * Global Asian Alliance trained additional colleagues  through the group's Asian Leadership Forum and  leveraged previous program graduates to host events and  discussions on culture, allyship, and intersectionality  Social * Global Black Community hosted the “Freedom to Be  Me” Juneteenth series, which highlighted the various  cultural, ethnic, religious, and gender identities within the  community through colleague stories  * Disability CRG initiated 10 hiring pilots and 150 colleague  events since 2021, leading to an increase in local CRG  chapters, more than 60 hires with disabilities, and more  than 25 interns with disabilities in summer worker  programs  * Pfizer Women’s Resource Group held regular skills-based  learning events designed to support women in taking  ownership of their career progression, including topics  like executive presence, breaking the glass ceiling, and  the power of empathy  * Out Pfizer Employee Network established new chapters in  five countries and conducted allyship training focused on  “Training the Trainers” to prepare colleagues to facilitate  future sessions  * Pfizer Latino Community engaged in a clinical trial  translations partnership with Pfizer's Clinical Trial  Experience team  * Veterans in Pfizer hosted an inaugural Veteran Service  Week to show appreciation for veterans, including  learning sessions on mentoring transitioning service  members and valuing character  Pfizer's ECRGs are supported by regional, country, and  local CRG chapters that offer development, mentoring, and  networking opportunities to help members enhance their  skills and advance their careers, while fostering community.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9583851099014282
479,"This year, the return of in-person events reinforced a sense  of belonging, allowing for positive momentum.",Governance - Competitive_Behavior,0.2824054956436157
480,"Additionally,  Pfizer held a “Lead with Inclusion Master Class” series to  equip ECRG leaders and chapter CRG leads to be more  strategic.",Governance - Business_Model_Resilience,0.4561444222927093
481,eS Pfizer  — Continued Environment > Social > Governance Performance > Appendix >  Pay equity  Our commitment to pay equity for all colleagues is based  in our value of Equity and our intention to continue to build  a diverse and inclusive workforce.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9690552353858948
482,"In terms of base pay,  Pfizer pays our female colleagues globally at greater than 99  percent (99.4 percent) of what we pay male colleagues.",Social - Labor_Practices,0.9571179747581482
483,"When  looking at minority versus non-minority pay in the U.S.,  minorities are at dollar-for-dollar parity (100 percent) with the  pay of non-minorities.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9709736108779908
484,"For the second year, Pfizer released median pay gaps for  women globally and minorities in the U.S., measuring the  distribution of pay among colleagues without accounting  for any factors.",Social - Labor_Practices,0.9626674652099608
485,"Pfizer's pay equity study demonstrated the  median pay for women globally was 101.3 percent of the  median pay of men, and the median pay for minorities in the  U.S.",Social - Labor_Practices,0.858240008354187
486,was 83.6 percent of the median pay for non-minorities.,Social - Employee_Engagement_Inclusion_And_Diversity,0.894661545753479
487,"In the UK, Pfizer continues to lead in closing the median  gender pay gap, earning recognition from the Healthcare  Businesswomen’s Association for integrating gender equity  into the company’s DNA and an award for closing the pay gap  from the Employer’s Network for Equity and Inclusion.",Social - Labor_Practices,0.8481680750846863
488,"In 2022, Pfizer’s efforts with pay equity secured an‘A’ grade  on the Arjuna Capital / Proxy Impact Racial and Gender Pay  Equity Scorecard.",Social - Labor_Practices,0.7665259838104248
489,We intend to continue to measure pay  equity on an annual basis and to publicly release results.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5291240215301514
490,"Opportunity parity  Our 2025 Opportunity Parity Goals  By 2025, we aspire to achieve global workforce parity of 47  percent for women at the VP level and above.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9560827612876892
491,"By 2025, we aspire to achieve workforce parity of 32 percent  for U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.7306363582611084
492,"minorities at the VP level and above, and double the  underrepresented population of African Americans / Blacks and  Hispanics / Latinos.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9746963381767272
493,"2022 Progress’  At the end of 2021, we reported that our representation for  women at the VP level and above was 41.5 percent.",Social - Employee_Engagement_Inclusion_And_Diversity,0.7595232129096985
494,"By December  2022, we have increased 1.6 percentage points to 43.1 percent.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4344297051429748
495,"At the end of 2021, we reported that our representation for  U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.2079163640737533
496,minorities at the VP level and above was 25 percent.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9662335515022278
497,"By  December 2022, we have increased 3.1 percentage points to 28.1  percent.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.444542795419693
498,These aspirational goals are not quotas and Pfizer continues to make  employment decisions based on quolifications.,Social - Employee_Engagement_Inclusion_And_Diversity,0.4309965670108795
499,"Recognition  Creating a working environment that is exciting, innovative,  inspiring, and safe is one of our greatest motivations.",Social - Employee_Health_And_Safety,0.6732179522514343
500,Our  efforts to build this culture with diverse perspectives at  the center has earned Pfizer industry recognition.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9533593654632568
501,"In 2022,  we remained a Best Place to Work by Disability:IN and the  Human Rights Campaign based on our top scores earned  in their equality and inclusion index reports.",Social - Employee_Engagement_Inclusion_And_Diversity,0.6212767362594604
502,"Additionally,  Pfizer was included on Forbes’ America’s Best Employers  for Diversity and Veterans 2022 Lists, and earned a five-  star rating in procurement and governance on the Hispanic  Association on Corporate Responsibility Inclusion Index™.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9715928435325624
503,"Health, Safety, and Well-being  At Pfizer, protecting the health, safety, and well-being of  colleagues and contingent workers, all of whom are essential  to driving our business forward, is an integral part of how  we operate.",Social - Employee_Health_And_Safety,0.9815085530281068
504,"Our Global Environment, Health & Safety (EHS) Policy and  supporting standards outline our approach to assessment,  evaluation, elimination, and mitigation of EHS risks  across our operations globally.",Social - Employee_Health_And_Safety,0.7992603182792664
505,"In addition, they facilitate  colleague engagement in EHS thereby enabling continuous  improvement.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3374603390693664
506,"Each Pfizer colleague and contingent worker  plays a crucial role in facilitating a culture of EHS excellence  where improvements, ideas, suggestions, and opportunities  are welcomed.",Social - Employee_Health_And_Safety,0.4574204981327057
507,Fostering this culture of interdependence  with everyone looking out for each other enables Pfizer  to meet its commitment to our patients.,Social - Human_Rights_And_Community_Relations,0.2146711200475692
508,"In 2022, to  complement our longstanding efforts to reduce workplace  injuries, we launched a focused program on Serious Injury  and Fatality Prevention designed to increase hazard  awareness and drive a more proactive approach to injury  prevention.",Social - Employee_Health_And_Safety,0.9843331575393676
509,"With the continued engagement and support of  our colleagues, we plan to deploy this program across our  manufacturing sites in 2023.",Governance - Product_Design_And_Lifecycle_Management,0.2413434237241745
510,Through our annual EHS recognition program we recognize  and celebrate actions taken by colleagues to implement  or replicate innovative solutions that achieve measurable  improvements in attaining an injury-free Pfizer.,Social - Employee_Health_And_Safety,0.8687960505485535
511,"Examples  of health and safety initiatives recognized in the past year  include:  * Perth Healthy Minds Workshop / WeCare program  designed to educate and apply management strategies to  support mental health well-being  * India Driver Safety program focused on reducing the risk  associated with driving in the region  * Solvent transfer enhancement at our Ringaskiddy, Ireland  site to reduce the risk of incidents and injuries  1 Colleagues who select “Do Not Disclose” or have not filled in their profile are not included in the denominator or numerator for gender or racial / ethnic representation.",Social - Employee_Engagement_Inclusion_And_Diversity,0.5474160313606262
512,Gender representation is calculated globally.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9592640995979308
513,Puerto Rico is excluded within racial /  ethnic representation but included in the Global Gender Representation.,Social - Employee_Engagement_Inclusion_And_Diversity,0.974271833896637
514,"35 Pfizer 2022 ESG Report Social eS Pfizer  — Continued  Colleague wellness throughout the pandemic  In 2022, we continued to carry out our pandemic  preparedness and response procedures to help ensure on-  site workers at all of our locations globally remained safe  and healthy.",Social - Employee_Health_And_Safety,0.6908005475997925
515,These precautions have been instrumental in  protecting our workforce and helping ensure a continued  supply of medicines and vaccines to patients.,Social - Access_And_Affordability,0.5475828051567078
516,"During 2022,  we:  * Continued to provide vaccinations for COVID-19  and other diseases to colleagues in countries where  employer vaccination programs are permitted  * Broadened the reach of our partnership with Thrive  Global, a wellness and organizational change initiative  with a primary focus on colleague mental health and  wellness  * Provided 45 educational webinars and information  sessions on mental health and well-being, nutrition,  and work-life balance through our employee assistance  program (EAP) provider, including targeted support for  our colleagues in Russia and Ukraine  * Shared wellness tips twice-monthly through the global  Pfizer World platform  In addition, as public health recommendations supported  the return of colleagues to office locations on a more regular  basis, Pfizer ensured benefits and processes were in place  to reinforce personal wellness and work-life balance.",Social - Employee_Health_And_Safety,0.6471702456474304
517,"For  example, beginning in 2023 we are implementing a new,  flexible working model that enables work to be regularly  conducted from home while maintaining regular on-site  collaboration to provide greater flexibility for many of  our colleagues.",Social - Employee_Engagement_Inclusion_And_Diversity,0.1541277915239334
518,36 | Pfizer 2022 ESG Report Social eS Pfizer  Ethical decision-making guides us as we work to achieve our purpose of delivering breakthroughs that change patients’ lives.,Social - Access_And_Affordability,0.1897159814834594
519,"Through proactive,  business-led risk management, Pfizer prioritizes integrity, safety, and quality in every aspect of our business.",Governance - Business_Ethics,0.6714828014373779
520,"Our Board of Directors is actively  engaged in the governance and oversight of our ESG strategy, which is embedded within our enterprise strategy.",Governance - Business_Model_Resilience,0.3824023902416229
521,"Ethics, Transparency, Quality 38 How our approach mtg Good Health and Well-Being  Ethical Decision Making to governance issues iy We aspire to ensure health and well-being  Laws and Regulations Compliance supports the SDGs for all through equitable access to medicines  Open Door Culture and Investigations and vaccines.",Governance - Business_Ethics,0.9712992906570436
522,"Transparency coos Gender Equality  Safety and Quality S We aim to end discrimination against women,  Counterfeit Medicines ensure equal opportunities for leadership, and  access to reproductive health.",Governance - Business_Ethics,0.651451587677002
523,"Supply Chain Transparenc  PPly P y 16 cus Peace, Justice and Strong Institutions  ‘AND STRONG Intellectual Property mst 7 , ; y We operate to uphold justice, promote the  Clinical Trials aie rule of law, and develop ethical, transparent,  Data Privacy and Protection and representative decision-making.",Governance - Competitive_Behavior,0.2501688301563263
524,Human Rights and the Right to Health  Political Contributions and Lobbying Activities  14} More information on the SDGs here.,Social - Human_Rights_And_Community_Relations,0.91793954372406
525,"Accountability 46  Right Incentives  Board of Directors and Board Committees  Board Leadership Structure  Governance of ESG  Board Diversity and Independence   Ethics, Transparency, Quality  At Pfizer, we have established values and clear expectations regarding how we achieve our purpose.",Governance - Business_Ethics,0.9613327383995056
526,We are committed to living our values and to  acting with integrity.,Social - Human_Rights_And_Community_Relations,0.2668312191963196
527,"Our values help guide us in making decisions ethically, thoughtfully, and responsibly to help support our business in delivering on  our purpose with quality and integrity for our patients and society.",Governance - Business_Ethics,0.6578435897827148
528,"The Regulatory and Compliance Committee of the Board of Directors oversees our quality and compliance governance framework, including the business-led Quality & Compliance  Committees across our core functions, which drive proactive risk management and accountability.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.8796467781066895
529,"This Committee’s oversight of healthcare quality and compliance includes business ethics;  quality and integrity in the discovery, development, manufacturing, and delivery of vaccines and medicines; responsible product marketing; third-party risk management; and compliance  with anti-bribery / anti-corruption, transparency, product promotion, and other applicable laws and regulations, in pursuit of advancing integrity and Pfizer's purpose.",Governance - Business_Ethics,0.9757088422775269
530,Our leaders set the  tone for our strong culture of acting with integrity in all we do and support a speak-up culture in which colleagues can raise concerns without fear of retaliation.,Governance - Business_Ethics,0.9230221509933472
531,Our patient-centric purpose  and established culture of quality and safety are of paramount importance as we innovate and continue to deliver breakthroughs.,Social - Product_Quality_And_Safety,0.8187877535820007
532,"Ethical Decision Making  Values-based decision making promotes accountability  and helps ensure that integrity, quality, safety, and ethics  are foundational to all we do.",Governance - Business_Ethics,0.9582374691963196
533,"Our Code of Conduct (the  Blue Book) and related policies, procedures, and training  are designed to support these values, including courage,  excellence, equity, and joy.",Governance - Business_Ethics,0.2935410737991333
534,"Policies governing colleague  interactions with healthcare organizations, physicians,  patients, and other stakeholders are contained in the White  Guide for U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3039619028568268
535,headquarters-based colleagues and the  Orange Guide for U.S.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2754753232002258
536,field-based colleagues.,Social - Supply_Chain_Management,0.1692418456077575
537,Pfizer also  maintains a Global Policy on Interactions with Healthcare  Professionals.,Social - Access_And_Affordability,0.279514878988266
538,"We incorporate ethics and business integrity  into internal performance evaluations, which are designed  to enhance colleague accountability, including leadership  performance with integrity.",Governance - Business_Ethics,0.9641584753990172
539,"Laws and Regulations Compliance  Our ethics and compliance program is structured around  eight fundamental elements, which form the framework for  effective compliance and risk management.",Governance - Business_Ethics,0.8958931565284729
540,"Quality, integrity,  and proactive risk management drive our efforts to enable  38 Pfizer 2022 ESG Report innovation for patients and global health.",Governance - Business_Ethics,0.6015715599060059
541,Pfizer's ethics and  compliance expectations represent a shared undertaking  and drive accountability on the part of all colleagues.,Governance - Business_Ethics,0.9691327810287476
542,"Pfizer  is committed to conducting business responsibly, and  acting ethically, in accordance with all applicable laws and  regulations.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.8821136355400085
543,"We expect the same commitment to acting  ethically and with integrity from suppliers, as well as from  consultants, agents, representatives, and other companies  and individuals acting on our behalf, as well as those acting  on their behalf (e.g., subcontractors), in connection with work  for Pfizer.",Governance - Business_Ethics,0.7853113412857056
544,"Pfizer's ethics and compliance organization is led by our Chief  Quality, Compliance & Risk Officer who reports directly to the  CEO and is a member of the Executive Leadership Team.",Governance - Business_Ethics,0.9635546803474426
545,"This  structure is designed to ensure direct access to leadership  and sufficient resourcing, and to support execution of  responsibilities independently.",Governance - Business_Model_Resilience,0.6106031537055969
546,"Pfizer’s ethics and compliance  program is overseen by a dedicated Regulatory and  Compliance Committee of the Board, which helps support  impartiality and independence of the program.",Governance - Business_Ethics,0.9545313119888306
547,"We regularly  engage independent third parties to assess our ethics and  compliance program against standards established by  governments, rating agencies, and industry best practices.",Governance - Business_Ethics,0.966899037361145
548,"Governance In 2022, we conducted an independent compliance  program review to assess program effectiveness and seek  opportunities for continuous learning and enhancement.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9214738607406616
549,"Our internal audit function has a systematic and regular  audit process and, in coordination with the Legal Division  and Compliance Division, works with key stakeholders across  the company to conduct our Enterprise Risk Management  process that assesses on an annual basis our operations  and risk management priorities, including, among others,  those related to quality, compliance and ethical standards,  responsible marketing, and anti-bribery / anti-corruption.",Governance - Business_Ethics,0.9767555594444276
550,"Our culture and our purpose embody our proactive, robust,  enterprise-wide commitment to bringing integrity and quality  to everything we do, as we deliver breakthroughs that change  patients’ lives.",Social - Employee_Engagement_Inclusion_And_Diversity,0.1684149950742721
551,"Our quality and compliance governance  framework is driven by a global, cross-functional approach  built around the elements of effective quality, compliance,  and risk management, including, for example:  ¢ Culture: Leaders are committed to and accountable for  fostering a culture consistent with our values, including  psychological safety to support colleagues in speaking  up or raising concerns without fear of retaliation and  eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  39 promoting continuous improvement.",Governance - Business_Ethics,0.6817330121994019
552,We also incorporate  ethics and business integrity expectations into  performance management frameworks and assessments.,Governance - Business_Ethics,0.9724950194358826
553,"Policies: Clear, easy-to-understand policies and  procedures provide guidance, including our principles-  based Code of Conduct and our whistleblower policy to  protect colleagues who raise concerns, outlined in our  Code of Conduct.",Governance - Business_Ethics,0.9563337564468384
554,Our international anti-bribery and  anti-corruption policies and procedures are designed  to ensure full compliance with the U.S.,Governance - Business_Ethics,0.9742465019226074
555,Foreign Corrupt  Practices Act (FCPA) and applicable international anti-  bribery laws.,Governance - Business_Ethics,0.9716414213180542
556,"Pfizer policy prohibits all forms of bribery  and corruption, whether by colleagues or our business  partners.",Governance - Business_Ethics,0.9736565351486206
557,"Colleagues and business partners must  never offer, promise, authorize, or provide a payment  or benefit that is intended to improperly influence a  government official, healthcare professional, or any other  person, including commercial entities and individuals, in  exercising their responsibilities.",Governance - Business_Ethics,0.9634327292442322
558,"Training: Colleagues and certain third parties receive  risk-based, role-specific training on our Code of Conduct  and other key areas, including ethical standards,  responsible marketing and advertising practices, and  anti-bribery / anti-corruption training, upon hire and  regularly thereafter (normally every one to two years),  to reinforce our policies and commitment to integrity.",Governance - Business_Ethics,0.975918471813202
559,"Our ethics and compliance training programs use  multi-modal components to address different learning  styles, maximize engagement, and reinforce training  content.",Governance - Business_Ethics,0.8109590411186218
560,Our training program encompasses role-based  scope of topics and depth of knowledge to drive training  effectiveness.,Social - Access_And_Affordability,0.3615827560424804
561,"Communications: Messaging about ethics and integrity,  including communications from leadership, culture  campaigns, and creative use of various media, reinforces  our focus on always doing things the right way and  speaking up with any questions or concerns.",Governance - Business_Ethics,0.9546051621437072
562,"Risk Assessment & Mitigation: Enterprise-level and  tailored quality and compliance risk assessments,  including in the area of anti-bribery / anti-corruption,  Pfizer 2022 ESG Report conducted regularly throughout the year (on a market-  by-market basis and within and across our three core  functions) and feeding into our annual Enterprise  Risk Management process.",Governance - Business_Ethics,0.9748266935348512
563,"This risk management  framework is aimed at identifying, assessing, prioritizing,  and mitigating potential risks and enables enhanced  oversight and resourcing to proactively manage risks.",Governance - Systemic_Risk_Management,0.9168518781661988
564,"¢ Monitoring: Live, continuous monitoring across key risk  areas is designed to detect and remediate any potential  non-compliance and seek opportunities for enhancement  of our ethics and compliance program.",Governance - Business_Ethics,0.9567260146141052
565,"¢ Third Party Compliance: Robust controls and processes  are designed to evaluate and mitigate risk related to  third parties we work with, including a formal global  anti-bribery / anti-corruption diligence process that  includes screening, auditing, training, confirmation of  policies (including bribery / corruption prohibitions) and  monitoring of third-party agents and intermediaries,  and other risk-based compliance controls designed to  ensure ethical business practices and compliance with  applicable laws and regulations, including anti-bribery /  anti-corruption laws.",Governance - Business_Ethics,0.976428747177124
566,"Quality and compliance committees for each of our core  functional areas, as well as our Executive Compliance  Committee (the highest-level internal compliance oversight  body, composed of Pfizer’s executive leadership and chaired  by the CEO) provide an innovative framework to advance  business-led proactive risk management and drive clear  accountabilities for leaders and colleagues to act with integrity  in all that they do.",Governance - Business_Ethics,0.952261209487915
567,"The remit of the Executive Compliance  Committee includes oversight of healthcare quality and  compliance; business ethics; quality and integrity in the  discovery, development, manufacturing, and delivery of  vaccines and medicines; responsible product marketing; third  party risk management; EHS; and compliance with anti-bribery  / anti-corruption, transparency, product promotion, and other  applicable laws and regulations.",Governance - Business_Ethics,0.9755091667175292
568,"Governance Open Door Culture and Investigations  Leaders and management are dedicated to fostering a  culture in which all colleagues can ask questions, raise  concerns, and report potential misconduct without fear of  retaliation.",Governance - Business_Ethics,0.9605331420898438
569,"We measure colleague comfort and awareness  about raising concerns, including awareness of our  whistleblower policy, through the confidential Pfizer Pulse  Engagement Survey sent to all colleagues annually.",Governance - Business_Ethics,0.920076072216034
570,"The  results are used to focus our leadership communications,  training, and other proactive efforts to drive our ethical  culture.",Governance - Business_Ethics,0.3924262821674347
571,"Many channels exist for raising questions and reporting  concerns, including the Compliance Helpline (third-party  public hotline available by phone or web, with anonymous  reporting where allowed under local law), the Compliance  Division (through email, phone, fax, mail, and colleagues),  management, and our Open Door Policy (whistleblower  policy), which encourages colleagues to present ideas, ask  questions, and raise concerns.",Governance - Business_Ethics,0.8903012275695801
572,"Retaliation against anyone  who seeks advice, raises a concern, reports misconduct, or  provides information in an investigation is strictly prohibited  by our policy that protects whistleblowers.",Governance - Business_Ethics,0.966115415096283
573,"In addition, our  Office of the Ombuds is a resource to support colleagues  with information and guidance to help them resolve work-  related issues.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.939716935157776
574,Pfizer takes reports of known or suspected violations of  company policies and applicable law seriously; our goal is to  respond promptly to all questions and reported concerns.,Governance - Business_Ethics,0.7259986996650696
575,"We aim to identify and address any potential inappropriate  conduct as early as possible, prevent future recurrences, and  inform continuous improvement.",Governance - Business_Ethics,0.9017100930213928
576,"We investigate all referable compliance issues (RCIs)—  significant potential, suspected, or actual violations of law or  policy.",Governance - Business_Ethics,0.8003957271575928
577,"For RCIs where there is a substantiated violation, we  institute individual discipline where appropriate, including  measures such as coaching, warnings, and termination.",Governance - Business_Ethics,0.9256805777549744
578,Our  compliance investigations process also includes analysis of  the root cause of substantiated RCIs.,Governance - Business_Ethics,0.745226263999939
579,"After investigation, we  work with accountable stakeholders to implement corrective  eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  and preventive actions.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6261622309684753
580,"Pfizer has a process to escalate  certain significant matters to the Executive Compliance  Committee, the Regulatory and Compliance Committee, and  the Audit Committee of the Board.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.94485342502594
581,"Transparency  Pfizer is committed to the principle of transparency, disclosing  our efforts that relate to issues of public interest.",Governance - Business_Ethics,0.9690258502960204
582,"We uphold  high ethical, scientific, and medical standards in all our  research and development activities and are committed to  disclosing financial and other interests and relationships  that may create apparent or perceived conflicts of interest.",Governance - Business_Ethics,0.8427658677101135
583,"These include areas such as funding for educational activities,  the status of our U.S.",Social - Access_And_Affordability,0.7531170845031738
584,"pharmaceutical post-marketing  commitments, our pipeline of experimental medicines, the  registration and reporting of results of clinical trials, corporate  political contributions in the U.",Governance - Competitive_Behavior,0.2189474254846573
585,"S., federal and state lobbying  activities, and disclosures of medical grants.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9007145762443542
586,Pfizer also reports to the Centers for Medicare and Medicaid  Services (CMS) payments and other transfers of value made to  U.S.-licensed physicians and U.S.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5329451560974121
587,teaching hospitals.,Social - Access_And_Affordability,0.2701674699783325
588,"In 2022,  our continuing commitment to transparency also included:  * Adhering to the “plain language results summary”  initiative intended to make our clinical trial results and  descriptions more understandable and accessible to a  general audience  * Posting all Pfizer clinical trial results to the U.S.",Governance - Competitive_Behavior,0.3169630169868469
589,"National  Library of Medicine's clinicaltrials.gov website accessible  to the public  * Sharing our positions on issues important to Pfizer and  our industry; please see Report on Incongruencies  * Communicating more transparently around product  quality and safety standards and KPI progress  Our efforts to combat COVID-19, including those to provide  equitable and affordable access to COVID-19 vaccines  and therapeutics for all, also demonstrate our continued  commitment to transparency.",Social - Product_Quality_And_Safety,0.859373152256012
590,"¢ We maintained a dedicated COVID-19 information site  40 Pfizer 2022 ESG Report on Pfizer.com to directly provide the public with ongoing  COVID-19 news and information, including how Pfizer is  responding to new variants  Safety and Quality  Patient health and safety are foundational to everything we do.",Social - Product_Quality_And_Safety,0.656918466091156
591,"We achieve our high standards in product quality and safety  through proactive and transparent systems and processes, and  clear communications to our patients, providers, and other  stakeholders about the benefits and risks of our products.",Social - Product_Quality_And_Safety,0.9145755767822266
592,These principles are codified in Pfizer's integrated Quality  Management System (QMS).,Social - Product_Quality_And_Safety,0.4183818101882934
593,Patient centric focus  Patient health and safety comes first in our work from early-  stage R&D through the full product lifecycle.,Social - Product_Quality_And_Safety,0.5648332238197327
594,Our patient-centric approach to R&D begins in the lab with data  modeling to determine potential therapies.,Social - Access_And_Affordability,0.3877237737178802
595,Our clinical trials  (page 44) are designed around patient safety with equitable and  inclusive participation.,Social - Access_And_Affordability,0.1937007457017898
596,"Our global supply network manufactures  and delivers products pursuant to quality policies and  procedures designed to ensure safety and quality in accordance  with Pfizer's Global Quality Standards and relevant regulations,  including Good Manufacturing Practices (GMP).",Social - Product_Quality_And_Safety,0.9102750420570374
597,Our policies and procedures are based on industry best  practices and relevant regulatory requirements.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9694809913635254
598,"Each of our  internal manufacturing, supply, and distribution operations,  as well as our external vendors, hold relevant manufacturing  licenses and GMP certificates.",Social - Supply_Chain_Management,0.8865215182304382
599,Our quality performance is  actively monitored through an integrated management system  to identify and mitigate risks.,Governance - Systemic_Risk_Management,0.8848169445991516
600,"Throughout each product's lifecycle, we continuously monitor  and evaluate all relevant safety and quality information,  including complaints and adverse events.",Social - Product_Quality_And_Safety,0.9210508465766908
601,"This awareness  enables effective communications and proactive, data-  driven actions related to patients, consumers, healthcare  professionals (HCPs), investigators, institutional review boards  / independent ethics committees (IRBs / IECs), Data Monitoring  Governance Committees (DMCs), and health authorities and regulators.",Governance - Business_Ethics,0.6620782017707825
602,Pfizer communicates and actions relevant safety information in  a timely manner in accordance with both internal and external  standards.,Social - Product_Quality_And_Safety,0.7871928215026855
603,"Quality Management System (QMS)  Pfizer's QMS, as defined in our Corporate Quality Policy,  provides an integrated framework through which Pfizer  achieves its quality and safety standards.",Social - Product_Quality_And_Safety,0.8661843538284302
604,"This framework is  based on industry-recognized quality management principles  and is designed and built to adhere to applicable standards  and requirements of health authorities and global regulators,  such as: International Organization for Standardization (ISO)  13485; Good Practices (GxP) such as Good Laboratory Practices  (GLP), Good Clinical Practices (GCP), Good Manufacturing  Practices (GMP), Good Distribution Practices (GDP) and  Good Pharmacovigilance Practices (GPvP); and International  Council for Harmonisation of Technical Requirements for  Pharmaceuticals for Human Use (ICH) guidelines.",Social - Product_Quality_And_Safety,0.5032686591148376
605,"The QMS  covers pharmaceuticals, vaccines, medical devices, and in-vitro  diagnostic products, in addition to focusing on:  * Research and development of products  * Clinical trial design and execution  * Regulatory submissions  * Manufacturing, packaging, and supply of products,  including raw materials procurement  * Pharmacovigilance and post-market surveillance  * Commercial and medical affairs activities  This framework embeds quality management as an end-to-  end organizational competency, supported by a governance  structure with clear policies, communications, and escalation  pathways.",Governance - Product_Design_And_Lifecycle_Management,0.4567357897758484
606,"Our QMS is continuously monitored to drive  innovation and agility, while helping to ensure the timely  identification of quality, safety, and compliance issues.",Social - Product_Quality_And_Safety,0.8058274984359741
607,eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  Quality g  Integrity  Culture  zs.,Social - Human_Rights_And_Community_Relations,0.2784376740455627
608,Elements ¢%  330 of the ae  s PfizerQMS 3  Training &  Qualificatio™  Quality & Integrity Culture  Quality & Integrity Culture initiatives are developed and  implemented by colleagues at all levels throughout the year  to continuously reinforce the importance of product quality  and safety and drive a culture of integrity.,Social - Product_Quality_And_Safety,0.8743414878845215
609,"Examples of these  initiatives include Quality & Integrity Day, Quality & Integrity  Awards, and learning case studies.",Governance - Business_Ethics,0.9317564368247986
610,"Training and qualification  Our comprehensive global training and qualification policies  and procedures are designed to ensure compliance with our  scientific, ethical, legal, and regulatory obligations, as well as  our own high standards.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4644924998283386
611,"Requirements are in place to ensure  all individuals (based on role and responsibility) who perform  work for or on behalf of Pfizer have the appropriate education,  training, and resources to work in compliance with applicable  laws, regulations, and Pfizer policies.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9221668839454652
612,Training compliance is  actively monitored and formally documented.,Governance - Business_Ethics,0.7059685587882996
613,"41 Pfizer 2022 ESG Report Risk management  Pfizer's Risk Management Framework is a systematic,  continuous, end-to-end process for identifying and mitigating  quality and compliance risks.",Governance - Systemic_Risk_Management,0.9038832783699036
614,"It provides criteria to conduct risk  assessments grounded in defined thresholds for escalation,  which are routinely tracked and monitored.",Governance - Systemic_Risk_Management,0.9179882407188416
615,"The framework  provides timely notification to management of critical issues  and significant trends, and implementation of corrective and  preventative actions.",Social - Critical_Incident_Risk_Management,0.4110892415046692
616,Third party management  Pfizer’s global QMS framework is designed to ensure that our  manufacturing sites and contract manufacturers meet or  exceed our product quality standards.,Social - Product_Quality_And_Safety,0.5311382412910461
617,"Pfizer has procedures  in place designed to ensure third party partner materials  and services meet our exacting standards, spanning the  full product life-cycle including R&D, clinical research,  manufacturing, and distribution.",Governance - Product_Design_And_Lifecycle_Management,0.7601004838943481
618,"We select companies that  are responsible, ethical, and reliable partners.",Governance - Business_Ethics,0.8246750831604004
619,"After suppliers  are selected and onboarded, they are expected to comply  with Pfizer’s Responsible Sourcing guidelines and Supplier  Conduct Principles, which are aligned to the Pharmaceutical  Supply Chain Initiative.",Social - Supply_Chain_Management,0.9498538970947266
620,"We have similarly high standards for  all materials used by third parties in clinical and commercial  manufacturing, including initial supplier qualification prior to  use in manufacturing and incoming inspection on a routine  basis.",Social - Supply_Chain_Management,0.5855005383491516
621,Pfizer monitors the performance of and regularly audits our  direct suppliers.,Social - Supply_Chain_Management,0.9123563170433044
622,Audit outcomes are used to drive continuous  improvement in both performance and compliance.,Governance - Business_Ethics,0.5967594385147095
623,"Due to the strategic importance of Contract Manufacturing  Organizations (CMOs) and Contract Research Organizations  (CROs), Pfizer has dedicated teams to maintain the necessary  policies and effectively identify and mitigate risks.",Governance - Systemic_Risk_Management,0.7842174768447876
624,"Audits and inspections  As part of our independent audit program, we regularly  assess the effectiveness of our QMS.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4522989094257355
625,"Pfizer's internal audit  processes are conducted in accordance with all applicable  Governance regulatory requirements, standards, guidelines (e.g., ISO &  ICH) and governing GxPs, to ensure patient safety, product  quality, and applicable licenses and certifications are  maintained.",Social - Product_Quality_And_Safety,0.916923761367798
626,"The audit program spans preclinical, clinical,  pharmacovigilance, regulatory, medical, manufacturing and  logistics, suppliers, and post-launch activities.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.41492560505867
627,The program  also covers regulated processes and information technology  controls.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8816981911659241
628,Our audits are designed to provide assurance that  we are compliant with regulatory requirements worldwide  and that we proactively identify and remediate risks to  compliance.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.939407765865326
629,"We also routinely undergo GMP, GCP, and  pharmacovigilance (PV) inspections from regulatory agencies  worldwide.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.8496149778366089
630,"Continuous Improvement (CI)  At Pfizer we pursue innovation and continuous improvement  in our work, and Cl initiatives are a cornerstone of Pfizer’s  business divisions across the enterprise.",Governance - Business_Model_Resilience,0.373479813337326
631,"Recent examples of  Cl initiatives include:  * Enhanced management of Pfizer's quality, safety, and  audit data  * Increased efficiency and effectiveness of Pfizer's quality  lab practices and safety systems  * Increased use of advanced analytics in Pfizer's  Manufacturing and Supply Chain networks  Pfizer's Integrated Manufacturing Excellence (IMEx) program  drives continuous improvement across the entire supply  network, standardizing a ‘one best way’ of working focused  on consistent work and increased effectiveness.",Social - Employee_Health_And_Safety,0.6585193276405334
632,"Under this  program, all colleagues have a voice and receive required  support when needed.",Social - Access_And_Affordability,0.3667357563972473
633,"eS Pfizer  — Continued  Safety and Quality KPIs 2022  # Internal Audits across GCP / PV / GMP"" 91  # Third Party Audits across GCP / PV / GMP?",Social - Product_Quality_And_Safety,0.753095269203186
634,875  # GCP / GMP / PV FDA Inspections?,Governance - Management_Of_Legal_And_Regulatory_Framework,0.475260853767395
635,46  # GCP / GMP / PV Inspections from All Other Health Authorities?,Social - Product_Quality_And_Safety,0.1890584975481033
636,137  # Unique Health Authorities Completing Inspections 63  # FDA inspections of Pfizer facilities that resulted in an enforcement action‘ 0  # GMP Inspections resulting in VAI status 18  # GMP Inspections resulting in OAI status 15  # GCP Inspections resulting in VAI status 0  # GCP Inspections resulting in OAI status 0  # PV Inspections resulting in VAI Status 0  # PV Inspections resulting in OAI Status 0  # FDA Recalls® 7  % of batches distributed with no recalls (U.S.,Social - Product_Quality_And_Safety,0.3653398752212524
637,"Market) 99.8%  # Class I Recalls 37  # Class II Recalls 4  # Class III Recalls 0  GCP Good Clinical Practices  VAI Voluntary Action Indicated (US FDA)  OAI Official Action Indicated (US FDA)  Count of internal audits includes all Pfizer audits performed of a Pfizer clinical / GMP / PV facility and / or process  Count of third party audits includes all Pfizer audits performed of an external clinical / GMP / PV vendor, clinical site, or contract manufacturing organization (CMO)  Count of inspections includes all GCP / GMP / PV inspections of Pfizer listed below:  * GCP: Investigator sites, sponsor, vendors / CROs  * GMP: Pfizer Global Supply (PGS) sites, PharmSci sites, Pfizer Country Offices (PCOs), Distribution / Logistics Centers (LC), SLS (Labs), Quality Centers  * PV: Sponsor, vendors  Data includes both regulatory warning letter as well as enforcement actions (e.g., seizure, injunction, criminal prosecution and / or criminal fines)  In January 2023, this facility was reclassified as Voluntary Action Indicated (VAI)  Definition of Recall Classifications  Data includes one recall that was initiated in 2022 and classified as Class I in January 2023 won  MN OD uw Bw  42 Pfizer 2022 ESG Report Governance  — Continued Environment > Social > Governance > Performance > Appendix >  Counterfeit Medicines  Counterfeit medicines pose a significant risk to patient health  and safety.",Governance - Business_Ethics,0.4754102826118469
638,"To protect our patients, we take a proactive  approach to product safety by investing in an enterprise-wide,  global strategy to combat counterfeit threats through patient  education, legislative advocacy, surveillance, and interdiction’.",Social - Product_Quality_And_Safety,0.8843930959701538
639,"Additionally, we are building a coalition with healthcare  providers and associations, policy leaders, regulatory  agencies, distributors, insurers, pharmacies, patient advocacy  groups, and other pharmaceutical companies to combat the  risk counterfeits pose to the health of our communities.",Governance - Business_Ethics,0.4766319394111633
640,Pfizer routinely provides training to policy makers and law  enforcement to better identify counterfeit medicines and  discourage counterfeiting.,Governance - Business_Ethics,0.7737334966659546
641,"In 2022, we launched the No  Fakes for Health Sake education and awareness campaign,  which aims to raise greater awareness about the dangers  of counterfeits among patients, healthcare providers,  pharmacists, policy leaders, and government agencies.",Governance - Business_Ethics,0.45416060090065
642,Our  Counterfeit Medicines: A Serious Threat to Patient Safety toolkit  provides robust resources for U.S.,Social - Product_Quality_And_Safety,0.8049824833869934
643,Attorneys General and  lawmakers ready to engage and to join the fight against  counterfeits.,Governance - Business_Ethics,0.3005708456039428
644,"For additional resources on how to safely buy  online, please visit Pfizer.com/Counterfeits.",Governance - Business_Ethics,0.3596566319465637
645,"In addition to our traditional anti-counterfeit efforts, Pfizer  addresses illicit online prescription drug offers through  advanced internet monitoring and disruption programs.",Governance - Business_Ethics,0.476970225572586
646,We search and systematically disrupt online pharmacy and  social media groups dispensing counterfeit versions of Pfizer  medicines and vaccines with enhanced digital tools that  keep pace with the sophisticated and rapidly evolving tactics  employed by counterfeiters to target patients.,Governance - Business_Ethics,0.4871793091297149
647,"If a counterfeit product is identified in the legitimate supply  chain, a formal process is in place to alert the appropriate  authorities and relevant trading partners.",Social - Product_Quality_And_Safety,0.342176228761673
648,"Additionally, we  collaborate with distributors and repackagers to monitor  distribution channels and improve surveillance.",Governance - Competitive_Behavior,0.2396276593208313
649,"Pfizer evaluates and invests in the latest packaging and  information technologies to align with global serialization  regulations and challenges associated with counterfeiting,  theft, and diversion.",Governance - Business_Ethics,0.6865970492362976
650,"The unique Product Identifiers  developed for serialization will enable the tracking and  tracing of product movement through the supply chain, from  the manufacturing site to patient dispensation (including  Government Systems and Trading Partners) and allows  authorized trading partners today to verify the authenticity of  our medicines with a simple scan.",Social - Selling_Practices_And_Product_Labeling,0.4416247010231018
651,Supply Chain Transparency  We set high standards for our internal and external partners  guided by robust governance processes to help ensure  responsible supply chain management.,Social - Supply_Chain_Management,0.7460837364196777
652,This helps ensure the  safety and quality of everything we produce and aligns with  our core value of equity.,Social - Product_Quality_And_Safety,0.5528973340988159
653,We see compliance with regulatory  standards as the foundation of risk mitigation and a crucial  component of providing the world with a reliable supply of  safe and effective medicines and vaccines.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.61874920129776
654,"Our regular evaluation of these stakeholders extends to  assessing environmental, health, safety, and sustainability  performance, including labor and human rights reviews.",Social - Human_Rights_And_Community_Relations,0.4059092402458191
655,"Our  collaborations with our suppliers are focused on improving  sustainability, compliance with laws, and alignment to our  Supplier Conduct Principles and the Pharmaceutical Supply  Chain Initiative (PSCI) Principles for Responsible Supply Chain  Management.",Social - Supply_Chain_Management,0.949164867401123
656,We act on these engagements and reviews  by working together to improve operational efficiency and  impact reductions.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4409126341342926
657,These reviews are also conducted through a human rights  lens.,Social - Human_Rights_And_Community_Relations,0.8878414034843445
658,Pfizer maintains a focused Modern Slavery program as  described in our Modern Slavery Statement which outlines  our management approach in our supply chain and our  operations.,Social - Supply_Chain_Management,0.9491678476333618
659,"Pfizer is currently focusing on targeted high-risk  areas as identified by the Global Slavery Index and is taking  steps to address these risks as described in our Statement,  including implementation of our corporate labor and human  1 In this context, “interdiction” refers to the seizure, raids, and arrests to prevent counterfeits from reaching their targeted audience.",Governance - Business_Ethics,0.6139958500862122
660,43 Pfizer 2022 ESG Report Governance rights standard.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4958052933216095
661,"If we identify these higher risk areas, our  process outlines additional due diligence processes to be  implemented to help avoid being complicit in supporting  modern slavery.",Governance - Systemic_Risk_Management,0.7517539262771606
662,"Through a combination of remote and on-site audits we  assessed EHS performance for 116 supplier facilities in 2022,  resulting in 921 observations.",Social - Supply_Chain_Management,0.9384185671806335
663,"Of the suppliers audited, 2  were identified as not meeting Pfizer's expectations for EHS  performance, resulting in Pfizer not pursuing business with  those suppliers.",Social - Supply_Chain_Management,0.938912570476532
664,"We require our suppliers to develop action  plans in response to our audits and implement improved  controls, as needed.",Social - Supply_Chain_Management,0.8910791277885437
665,eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  Intellectual Property  Pfizer's ability to drive science forward and deliver  breakthroughs that change patients’ lives is fueled by the  protections provided by the intellectual property system.,Governance - Competitive_Behavior,0.4217237830162048
666,These protections are the incentive that turns ideas into reality  and contributes to a thriving society and global economic  development.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.718355119228363
667,"We are committed to the responsible use of  our intellectual property, as reflected in the “IP Principles for  Advancing Cures and Therapies” (IP PACT).",Social - Customer_Privacy,0.2283317297697067
668,"We recognize the unique socioeconomic challenges facing  Least Developed Countries, as defined by the United Nations  Committee for Development Policy, and have a policy of patent  nonenforcement in those countries.",Governance - Business_Model_Resilience,0.3791175186634063
669,"With regards to Pfizer's  efforts to expand access to our oral COVID-19 treatment, our  voluntary licensing agreement with the Medicines Patent Pool  (MPP), a United Nations-backed public health organization, is  intended to help facilitate the production and supply of generic  versions of our oral COVID-19 treatment to the most vulnerable  populations.",Social - Access_And_Affordability,0.4477831423282623
670,"We believe that accessible patent information promotes  scientific progress and helps improve the procurement of  medicines; in line with this belief, we are a member of the  Patent Information Initiative for Medicines (Pat-INFORMED),  an initiative hosted by the World Intellectual Property  Organization (WIPO) that facilitates access to medicine patent  information.",Governance - Competitive_Behavior,0.7302887439727783
671,"As a founding member of the WIPO Re:Search public-  private partnership, we're proud of the impact this 11-year  collaboration, which came to a close at the end of 2022,  has had in the fight against neglected tropical diseases.",Social - Access_And_Affordability,0.2502036094665527
672,"Additionally, the 2022 Access to Medicine Index recognized  Pfizer as performing “above average” in terms of sharing IP  assets with third-party researchers.",,0.335320770740509
673,"We are also a sponsor  of the Inventor Assistance Program, a WIPO initiative in  cooperation with the World Economic Forum that matches  developing country inventors and small businesses of limited  financial means with patent attorneys that provide pro bono  legal assistance to secure patent protection.",Governance - Competitive_Behavior,0.8686789870262146
674,44 Pfizer 2022 ESG Report Clinical Trials  Our work in clinical trials is fundamental to achieving our  purpose of delivering breakthroughs that change patients’  lives.,Governance - Business_Model_Resilience,0.1608353853225708
675,"Patient health and safety is at the heart of this—  including how we design, run, and communicate our clinical  trial research.",Social - Product_Quality_And_Safety,0.7202966809272766
676,"Our conduct is guided with the help and  oversight of a variety of groups, including patient groups,  institutional review boards, regulatory authorities, data and  safety monitoring boards, medical and industry association  guidelines governing ethical clinical trial conduct and research  integrity, and our own Bioethics Advisory Council.",Social - Product_Quality_And_Safety,0.4192333221435547
677,* The Declaration of Helsinki  * The United States Belmont report  More information on Pfizer policies related to clinical trials can  be found on our research integrity and transparency page at  Pfizer.com  You can learn more about our clinical trial work at Pfizer.com/  ClinicalTrials and by searching Pfizer on ClinicalTrials.gov.,Governance - Business_Ethics,0.9472573399543762
678,"In keeping with our core value of equity, our teams continue to  find new ways to remove barriers to trial participation, such as  identifying clinical trial sites that offer mobile site options and  implementing protocols that permit at-home follow-ups, where  possible.",Governance - Competitive_Behavior,0.5375434756278992
679,"By meeting potential participants where they are,  we're able to offer flexibility, increasing participation among  those who may have not participated otherwise and accelerate  development so we can bring more potential breakthroughs  to more patients faster.",Social - Access_And_Affordability,0.1846760958433151
680,"We have that same mindset for  increasing awareness, using the internet and social media to  share educational information about our trials.",Social - Access_And_Affordability,0.6844980120658875
681,"Recognizing  that language can also be a barrier to participation, in 2022  we launched Pfizer Estudios Clinicos, a searchable, Spanish-  language website about Pfizer clinical trials.",Social - Employee_Engagement_Inclusion_And_Diversity,0.1954292207956314
682,"DIVERSITY IN CLINICAL TRIALS  All Pfizer-sponsored interventional studies respect human  rights and patient privacy and are conducted in accordance  with our high ethical standards, applicable laws and  regulations, and principles derived from relevant international  standards, including: Pfizer has made a commitment to conducting clinical trials  with populations that reflect the racial and ethnic diversity  of the communities that we serve.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9729362726211548
683,Pfizer continues to  take decisive steps to improve diversity in our trials and  share our insights with others.,Social - Employee_Engagement_Inclusion_And_Diversity,0.959627330303192
684,"In 2022, Pfizer published  a whitepaper on the role of pharmacology in improving  diversity in clinical trials.",Governance - Competitive_Behavior,0.2985047399997711
685,We recognize that different  people may respond to our medicines and vaccines  differently and including these groups in our trials would  allow for enhanced understanding of a study medicine.,Social - Access_And_Affordability,0.3047947585582733
686,"* The Council for International Organizations of Medical  Sciences (CIOMS) International Ethical Guidelines  * The International Council for Harmonisation of Technical  Requirements for Pharmaceuticals for Human Use (ICH)  E6 guideline for Good Clinical Practice  * PhRMAs Principles on Conduct of Clinical Trials and  Communication of Clinical Trial Results  eS Pfizer Governance  — Continued  Data Privacy and Protection Human Rights and the Right to Health  We are committed to the responsible, transparent, and secure Pfizer is committed to conducting business in an ethical and  use of personal data entrusted to us by patients, customers, responsible manner.",Social - Customer_Privacy,0.6205376386642456
687,"This includes respecting internationally  employees, and others.",Governance - Business_Ethics,0.5553961396217346
688,Our privacy practices are governed by recognized human rights throughout our operations.,,0.6384380459785461
689,"Our  our Global Privacy Committee, a cross-functional governance responsibility to respect human rights extends throughout  body composed of senior-level leaders who provide oversight our operations from lab to patient, including our diverse  and guidance that informs company practices.",Social - Human_Rights_And_Community_Relations,0.8191329836845398
690,"Additionally, global supply chain of numerous local and global third-party  our Global Privacy Office maintains an enterprise-wide vendors.",Social - Supply_Chain_Management,0.9208686947822572
691,"policy and standards that guide the collection, maintenance,  and protection of personal data and consider the legal and In line with the UN Guiding Principles on Business and  regulatory requirements where we do business.",Social - Customer_Privacy,0.9603325128555298
692,"We also Human Rights, Pfizer's Human Rights Policy Statement  mandate regular employee and contractor training on global focuses on addressing risks that could have the most severe  privacy principles in accordance with our commitment to impact on people: our patients, our colleagues, the workers  respect and safeguard personal data.",,0.7207783460617065
693,"We do all of this to of our business partners, and the communities in which  help ensure that we are respecting the right to privacy of we operate.",Social - Customer_Privacy,0.7306302785873413
694,We also seek to prioritize the individuals and  individuals and responsibly collecting and managing the data groups who may be most vulnerable to impacts.,,0.2289237827062606
695,True to our  we collect.,Governance - Competitive_Behavior,0.1479099839925766
696,"efforts to continually monitor and address risks and impacts  on people, we are currently updating Pfizer's human rights  In 2022, we developed a set of Privacy Principles outlining policy statement to reflect the evolving landscape for human  our view of the appropriate uses of personal health data and rights—progressing our responsibility to address the salient  what we do to help ensure safeguards are in place to protect human rights issues for our business.",Social - Customer_Privacy,0.3269008100032806
697,what has been entrusted to us.,Governance - Business_Ethics,0.1229607537388801
698,"Throughout 2022 and looking forward, we have continued  to focus on the right to health as our most salient issue,  with availability, accessibility, and affordability as key focus  areas.",Social - Access_And_Affordability,0.6630891561508179
699,Other salient human rights are the principle of non-  discrimination; the right to privacy; freedom from slavery and  forced labor and other abuses; the right to enjoy just and  favorable working conditions; the right to a safe workplace;  and the right to a healthy environment.,Social - Labor_Practices,0.9311115145683287
700,Read more about Pfizer’s commitment to human rights at  Pfizer.com/about/responsibility/human-rights.,Social - Human_Rights_And_Community_Relations,0.9557691216468812
701,45 Pfizer 2022 ESG Report Governance Pfizer  — Continued  Political Contributions and Lobbying Activities  We understand the impact public policy has on our  ability to meet patient needs and provide value to our  shareholders.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9430944323539734
702,"As such, we actively participate in dialogue  around public policy with lawmakers to advocate and  educate, in addition to explaining our perspectives.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9023314118385316
703,"We  believe the business community has a responsibility to  transparently engage in this space, given our extensive  knowledge, research, and societal impact.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3635648488998413
704,Pfizer is a member of various industry and trade groups  that represent both the pharmaceutical industry and the  business community at large to bring about consensus  on broad policy.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8187147378921509
705,"In addition to trade group positions on  healthcare policy issues, we realize these organizations  may engage in a broad range of other issues that extend  beyond the scope of what is of primary importance to  Pfizer's business.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7174150347709656
706,"If concerns arise about a particular  issue, we convey our concerns, as appropriate.",Social - Human_Rights_And_Community_Relations,0.1628112941980362
707,"We  believe there is value in making sure our positions on  issues important to patients, Pfizer, and our industry  are communicated and understood within those  organizations.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4420314133167267
708,"In December 2021, Pfizer issued a report  outlining the public policy positions of Pfizer and five  trade associations across six areas of key public policy  and ESG significance for Pfizer.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9077285528182985
709,The report also compares  Pfizer and the trade associations’ positions and describes  the degree of alignment and areas of misalignment.,Governance - Competitive_Behavior,0.5104947090148926
710,"Pfizer  will update this report periodically, as needed.",Governance - Systemic_Risk_Management,0.1624588519334793
711,"Pfizer's corporate political contributions and lobbying  activities are focused on promoting the interests of the  patients we serve and our company, without regard to the  personal political preferences or affiliations of any of our  employees, officers, or board members.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2041951119899749
712,"The company’s  corporate political contributions and lobbying activities  are subject to robust internal procedures designed  to align these efforts with our public policy priorities,  applicable law, and patient-centric agenda.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9508593678474426
713,The company  has an extensive training and reporting program in place  designed to ensure compliance with applicable laws and  regulations as well as Pfizer's internal standards.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9349930286407472
714,46 Pfizer 2022 ESG Report Governance Accountability  Right Incentives  We aspire to drive positive social and environmental change  in our role as a responsible corporate citizen.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3758156895637512
715,This commit-  ment fundamentally informs how we fulfill our purpose:  Breakthroughs that change patients’ lives.,Social - Access_And_Affordability,0.2651280164718628
716,Our ESG strategy  is designed by leadership to leverage compensation as a key  motivator to hold ourselves accountable.,Governance - Business_Ethics,0.4616087973117828
717,"For the 2022 perfor-  mance year, the Compensation Committee of the Board lever-  aged the ESG Scorecard, which included three selected social  and environmental key performance indicators (KPIs).",Social - Human_Rights_And_Community_Relations,0.3458939790725708
718,"Those  ESG Scorecard KPIs, listed below, were factors in determining  the funding of our annual short-term incentive plan (Global  Performance Plan [GPP] program) for over 30,000 global col-  leagues and leaders.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6053656935691833
719,"The three ESG metrics selected by the Compensation Com-  mittee, in relation to the 2022 GPP program, are consistent  with key guiding principles and aligned with our strategy.",Governance - Business_Model_Resilience,0.3157391250133514
720,"Additionally, these KPIs are objectively measurable.",Governance - Competitive_Behavior,0.5249246954917908
721,"We believe  these ESG Scorecard KPIs—(i) percentage of Vice President and  higher roles held by women (globally), (ii) percentage of Vice  President and higher roles held by minorities (U.S.), and (iii)  Greenhouse Gas Emissions—are holistic drivers of our future  success as a company.",Environmental - GHG_Emissions,0.9580063223838806
722,"The goals set for 2022, as part of the  GPP program, were also based on our publicly announced  longer term goals in these areas.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3030537068843841
723,"We will continue this approach for the 2023 performance year,  as well.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2455565929412841
724,Incorporating ESG into our executive compensation  program amplifies our commitment to long term value cre-  ation and sustainability.,Governance - Business_Model_Resilience,0.3413902819156647
725,"For additional details on the GPP Program, refer to the Pfizer  2023 Proxy Statement.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7710484266281128
726,eS Pfizer  — Continued Environment > Social > Governance > Performance > Appendix >  Board of Directors and Board Committees  The Board of Directors is elected annually by the  shareholders.,Governance - Director_Removal,0.7229012846946716
727,The primary responsibility of the Board  is to represent shareholders and to enhance long term  shareholder value.,Governance - Director_Removal,0.5627694129943848
728,The Board elects the chief executive  officer and other members of the senior management team  and acts as an advisor and counselor to senior management  and ultimately monitors its performance.,Governance - Director_Removal,0.7453356981277466
729,The function of the  Board to monitor the performance of senior management  is facilitated by the presence of a majority of independent  non-employee Directors who have substantive knowledge  of the company’s business.,Governance - Director_Removal,0.7928420901298523
730,The Board has determined that  all of our current Directors (other than Dr.,Governance - Director_Removal,0.7826621532440186
731,Albert Bourla) are  independent.,Governance - Director_Removal,0.1527522504329681
732,Pfizer's Board Committees are integral to the overall  functioning of the Board.,Governance - Director_Removal,0.5928600430488586
733,"The Board has six committees:  Audit Committee  Compensation Committee  Executive Committee  Governance & Sustainability Committee  Regulatory and Compliance Committee  Science and Technology Committee  {4 Thecommittee’s charters may be viewed on our corporate  website at: Board Committee Charters  Board Leadership Structure  In December 2022, following a thorough review by the  Governance & Sustainability Committee, the independent  Directors re-evaluated the Board's leadership structure and  considered the company’s current operating environment,  peers’ Board leadership structures, best practices, as well  as investor feedback.",Governance - Director_Removal,0.5833821296691895
734,"The Committee, along with the other  independent Directors, determined that continuing to  combine the roles of Chairman and CEO would be in the best  47 Pfizer 2022 ESG Report interests of the company and its shareholders.",Governance - Director_Removal,0.763575553894043
735,"The company  can more effectively execute its strategies with a Chair  who has deep scientific and industry expertise, along with  extensive company knowledge.",Governance - Business_Model_Resilience,0.4982567727565765
736,"The combined role, coupled  with the strong Lead Independent Director, has enabled the  Board to be responsive to challenges and opportunities as  they continue to arise.",Governance - Business_Model_Resilience,0.2866649329662323
737,"Governance of ESG  Our ESG efforts underscore our commitment to achieving  our purpose—delivering breakthroughs that change  patients’ lives—and supporting the communities in which we  live and work through ethical decision-making and our core  values: courage, excellence, equity, and joy.",Social - Human_Rights_And_Community_Relations,0.9107110500335692
738,"Values-based  decision making promotes accountability and helps ensure  that integrity, quality, safety, and ethics are foundational  to all we do.",Governance - Business_Ethics,0.96450537443161
739,"Pfizer’s robust governance of ESG priorities—  aligned with our enterprise strategy—is critical to help  enable impact, innovation, and reporting.",Governance - Business_Model_Resilience,0.544841468334198
740,"The ESG function within Pfizer and its cross-functional  governing committees (at the senior management and the  executive level) have responsibility for considering and  adopting potential goals and targets, with escalation to the  Governance & Sustainability Committee (G&SC) of the Board,  based on input from experienced subject matter experts and  advisors.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2515624463558197
741,"Our cross-functional Sustainability Steering Committee,  chaired by our Chief Sustainability Officer, advises on key  issues and guides the integration and implementation  of Pfizer’s non-financial reporting related to ESG.",Governance - Business_Model_Resilience,0.593368411064148
742,"This Committee is overseen by a dedicated Executive  Sustainability Committee, chaired by the Executive  Leadership Team member leading Corporate Affairs, who  reports directly to the Chairman and CEO.",Governance - Director_Removal,0.6352977752685547
743,"Our ESG governance has as its foundation oversight by  the Board of Directors, commitment and accountability  by leadership, and engagement by colleagues across the  company.",Governance - Director_Removal,0.4710023403167724
744,Diverse perspectives from internal and external  stakeholders inform our ESG strategy and priorities.,Social - Human_Rights_And_Community_Relations,0.418494701385498
745,Governance The Board of Directors is fully engaged and supportive of  Pfizer's ESG program.,Governance - Business_Model_Resilience,0.3213435113430023
746,The G&SC of the Board is primarily  responsible for oversight of our ESG strategy and reporting.,Governance - Business_Model_Resilience,0.362133651971817
747,"In addition, the G&SC is responsible for considering risks  relating to the company’s lobbying priorities and activities  and political spending, and the company’s policies and  practices related to its human capital management, which  may include culture, diversity, equity and inclusion, pay  equity, and talent management.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9733326435089112
748,"Throughout the year, the  G&SC receives updates from company leaders regarding our  ESG priorities and progress and changes in the ESG external  environment.",Governance - Business_Model_Resilience,0.6240958571434021
749,Other Board Committees oversee elements of our  ESG program associated with their respective areas of  responsibility.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3269702792167663
750,"For example:  * The Audit Committee, which has primary responsibility  for overseeing Pfizer's Enterprise Risk Management  (ERM) program, reviews and receives briefings  concerning risks to Pfizer associated with certain  priority issues (for example, information security and  technology, cybersecurity, drug pricing, access, and  reimbursement) and company culture (compliance  related concerns, workplace behavior, and harassment  and retaliation).",Governance - Business_Ethics,0.7588701844215393
751,ERM provides a framework for risk  identification and management which includes risks  associated with ESG factors.,Governance - Systemic_Risk_Management,0.9175562858581544
752,The Audit Committee is  also monitoring potential mandatory sustainability  reporting under consideration by regulators.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8790713548660278
753,"* The Compensation Committee has responsibility  for the executive compensation program, which  includes approving the compensation of our executive  officers, overseeing executive diversity, pay equity,  inclusion, recruiting, retention, career development  and succession planning (in collaboration with the  Governance & Sustainability Committee).",Social - Employee_Engagement_Inclusion_And_Diversity,0.9708607792854308
754,"Effective  for the 2022 performance year, the Compensation  Committee adopted the ESG Scorecard to tie the  funding of our annual short-term incentive plan for over  30,000 global colleagues and leaders, in part, to select  social and environmental key performance indicators  eS Pfizer  — Continued > Social > Governance > Performance > Appendix >  (KPIs).",Social - Human_Rights_And_Community_Relations,0.3431041538715362
755,"In addition, the overarching ESG factors, including  the three metrics used in the ESG Scorecard for the short-  term annual incentive plan, may also be included in the  individual performance goals of executives throughout the  organization, which will further align their compensation  with ESG factors.",Governance - Business_Model_Resilience,0.2737183570861816
756,See Pfizer’s 2023 Proxy Statement for  further details on the executive compensation program.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3621456623077392
757,"* The Regulatory and Compliance Committee oversees the  compliance program, ethics and integrity, product quality  and safety, the compliance governance framework, and risk  management, in addition to overseeing healthcare-related  regulatory and compliance risks in connection with the  development, manufacture and marketing of products, and  risk mitigation efforts.",Governance - Business_Ethics,0.4911955893039703
758,We encourage all colleagues to contribute to achieving our ESG  goals by understanding our strategy and to apply an ESG lens  to their day-to-day activities.,Governance - Business_Model_Resilience,0.4535328447818756
759,We integrate ESG by partnering  closely with colleagues in our priority areas to establish ESG  goals and define action plans to achieve those goals.,Governance - Business_Model_Resilience,0.4583017230033874
760,"Board Diversity and Independence  Our Board is composed entirely of independent directors other  than our Chairman and CEO, Albert Bourla, and is diverse, with  diversity reflecting gender, age, race, ethnicity, background,  professional experience, and perspectives.",Social - Employee_Engagement_Inclusion_And_Diversity,0.974402666091919
761,"Each Director provides  a unique perspective, experience, and skill set, which creates an  effective and well-functioning Board.",Governance - Director_Removal,0.5873125791549683
762,"To help ensure effective refreshment and proactively manage  eventual vacancies on the Board, the Governance & Sustainability  Committee and the full Board consider a diverse pool of qualified  director candidates on an ongoing basis.",Governance - Director_Removal,0.7475428581237793
763,"This process resulted in  the election of five new independent directors over the past five  years, bringing our average Board tenure to seven years.",Governance - Director_Removal,0.7928658723831177
764,"48 Pfizer 2022 ESG Report Board Composition  Board Tenure  7 years  Average Tenure  Board Diversity  Key Skills and Experience  ie) Business Leadership and Operations  International Business  Medicine and Science  Healthcare and Pharma  nnn a  Finance and Accounting  Risk Management  Academia  RAR A  Human Capital Management  Goverment and Public Policy 3  Technology 3  Shareholders and other interested parties may communicate with any of our directors, including the Lead Independent Director and the  Audit Committee Chair, as follows:  By email: https://investors.",Governance - Director_Removal,0.721315324306488
765,"pfizer.com/Investors/Corporate-Governance/Contact-Our-Directors/default.aspx  By mail: 66 Hudson Boulevard East  New York, NY 10001-2192  Governance Pfizer  understanding the impact of our operations, driving  continuous improvement, and maintaining a transparent  dialogue with our stakeholders.",Governance - Director_Removal,0.4245101809501648
766,We are committed to improving our ESG  performance because it is crucial to our long term  success as a responsible business and is essential  to achieving our purpose.,Governance - Business_Model_Resilience,0.7929443120956421
767,The key performance  indicators we track are driven by an assessment  of issues of greatest relevance and impact to our  stakeholders and our business.,Governance - Business_Model_Resilience,0.4937939345836639
768,"Performance >  2019 2020 2021 2022 2030  (baseline) Goal  Climate change (Scopes 1 & 2)"".",Environmental - Physical_Impacts_Of_Climate_Change,0.9266507625579834
769,Carbon emissions (in million metric tons CO2e)* 1.28 1.16 1.15 1.14 .69  Renewable electricity (%) 9.5 3.9 7.7 7.8 100%  2019 2020 2021 2022 2025  (baseline) Goal  Supply chain environmental sustainability (Scope 3)?,Social - Supply_Chain_Management,0.5642975568771362
770,Suppliers of purchased goods and services by spend with science-based targets (%)° 19% 29% 64%  Business travel carbon emissions (in thousand metric tons CO2e)*® 359.5 97.9 31.8 80.2 270  Upstream transportation & distribution carbon emissions (in thousand metric tons CO2e)’ 509.0 517.6 777.3 712.3 458  1 Pfizer's organizational boundaries for environmental performance include all owned sites and leased facilities where Pfizer has operational control.,Environmental - GHG_Emissions,0.580353319644928
771,"Data are baseline adjusted, reported absolute, using reporting boundaries per the World  Resources Institute (WRI) Greenhouse Gas (GHG) Protocol.",Environmental - GHG_Emissions,0.9673753380775452
772,The 2019-2021 GHG data is independently verified to the limited assurance level.,Environmental - GHG_Emissions,0.9621606469154358
773,Verification of the 2022 GHG data will be completed in 2023.,Environmental - GHG_Emissions,0.9629075527191162
774,2 Scopes 1 and 2 as defined by the GHG Protocol Corporate Standard  .,Environmental - GHG_Emissions,0.963485062122345
775,Scope 1: Direct GHG emissions.,Environmental - GHG_Emissions,0.9661567807197572
776,"Direct GHG emissions occur from sources that are owned or controlled by the company, for example, emissions from combustion in owned or controlled boilers, furnaces, vehicles, etc.; emissions from  chemical production in owned or controlled process equipment.",Environmental - GHG_Emissions,0.9619483351707458
777,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
778,Scope 2: Electricity indirect GHG emissions.,Environmental - GHG_Emissions,0.9643344879150392
779,GHG emissions from the generation of purchased electricity consumed by the company.,Environmental - GHG_Emissions,0.9592771530151368
780,Purchased electricity is defined as electricity that is purchased or otherwise brought into the  organizational boundary of the company.,Environmental - Energy_Management,0.966887891292572
781,"3 Data presented represents information available as of 31 Jan 2023, including certain estimates and assumptions.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2738307416439056
782,Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4794793426990509
783,Updated 2022 data will be published on Pfizer's Environmental Sustainability page.,Governance - Product_Design_And_Lifecycle_Management,0.2946650087833404
784,"4 Pfizer's 2030 GHG emissions goal is to achieve a 46% reduction from the 2019 baseline, inclusive of the 100% renewable electricity target.",Environmental - GHG_Emissions,0.9665425419807434
785,There may be differences in baseline and subsequent reporting year values due to changes inthe  business that require baseline adjustments conducted in accordance with the GHG Protocol.,Environmental - GHG_Emissions,0.963281512260437
786,Estimates comprise less than 3% of Scope 1 and 2 GHG emissions.,Environmental - GHG_Emissions,0.9615749716758728
787,5 Tracking of the Scope 3 supplier engagement goal was initiated in 2021.,Social - Supply_Chain_Management,0.9287786483764648
788,"We have expanded to include companies publicly committed to setting science-based targets through the Science Based Target Initiative (SBTi), along with companies  with SBTi-approved targets.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4066333174705505
789,6 Pfizer's 2030 GHG emissions goal is to achieve a 25% reduction in business travel emissions from the 2019 baseline.,Environmental - GHG_Emissions,0.9675987362861632
790,There may be differences in baseline and subsequent reporting year values due to changes in the business that require  baseline adjustments conducted in accordance with the GHG Protocol.,Environmental - GHG_Emissions,0.963430643081665
791,7 Upstream transportation emissions are calculated from Pfizer and third-party datasets.,Environmental - GHG_Emissions,0.7261751294136047
792,We recently revised our methodology to more accurately capture source data and have applied this methodology to our 2022 calculations.,Social - Customer_Privacy,0.1623011976480484
793,Data for  previous years is in review.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3907201588153839
794,Updated data will be published on Pfizer's Environmental Sustainability page.,Governance - Product_Design_And_Lifecycle_Management,0.2701055109500885
795,50 Pfizer 2022 ESG Report Performance Pfizer  — Continued  2019 2020 2021 2022  Water and waste’?,Environmental - Waste_And_Hazardous_Materials_Management,0.8601800799369812
796,Water withdrawal (in million cubic meters) 34.8 32.4 27.5 28.8  Water discharge (in million cubic meters) 30.8 28.5 23.6 24.8  Water consumption (in million cubic meters) 4.0 3.9 3.9 4.0  Hazardous waste generated (in thousand metric tons) 86.4 83.1 73.8 75.7  Hazardous waste diverted from disposal (in thousand metric tons) 9.3 11.6 10.6 6.4  Hazardous waste disposed (in thousand metric tons) 77.0 71.5 63.2 69.3  Non-hazardous waste generated (in thousand metric tons) 37.7 36.9 39.7 37.6  Non-hazardous waste diverted from disposal (in thousand metric tons) 16.6 17.4 23.9 20.4  Non-hazardous waste disposed (in thousand metric tons) 21.2 19.5 15.8 17.2  1 Pfizer's organizational boundaries for environmental performance include all owned sites and leased facilities where Pfizer has operational control.,Environmental - Waste_And_Hazardous_Materials_Management,0.9840458631515504
797,"Data are baseline adjusted, reported absolute, using reporting boundaries per the World  Resources Institute (WRI) Greenhouse Gas (GHG) Protocol.",Environmental - GHG_Emissions,0.9673753380775452
798,The 2019-2021 GHG data is independently verified to the limited assurance level.,Environmental - GHG_Emissions,0.9621606469154358
799,Verification of the 2022 GHG data will be completed in 2023.,Environmental - GHG_Emissions,0.9629075527191162
800,"2 Data presented represents information available as of 31 Jan 2023, including certain estimates and assumptions.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2672685086727142
801,Historical estimates may periodically be subject to revision due to data source restatements and updates to methodology.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4794793426990509
802,Updated 2022 data will be published on Pfizer's Environmental Sustainability page.,Governance - Product_Design_And_Lifecycle_Management,0.2946650087833404
803,51 Pfizer 2022 ESG Report Performance Pfizer  Innovation and Global Health 2020 2021 2022  Product Innovation  Time to market (in years) (first-in-human (FIH) to approval)’ 8.4 8.1 4.8  Success rate (FIH to approval)?,Governance - Product_Design_And_Lifecycle_Management,0.903452694416046
804,21% 21% 18%  Number of drugs in portfolio?,Governance - Competitive_Behavior,0.4226152300834656
805,Product Listing >  Number of drugs in research and development?,Social - Selling_Practices_And_Product_Labeling,0.3619131743907928
806,95 89 110  Products on WHO List of Prequalified Medicinal Products and Vaccines?,Governance - Product_Design_And_Lifecycle_Management,0.3641485571861267
807,"WHO Medicinal Products and Vaccines List >  Key projects driving large-scale digital solutions in R&D, manufacturing and healthcare provider and patient engagement 28 38 38  1 Biosimilars and generics are excluded from all analyses, as are product enhancements (supplemental indications, major new formulations, etc.).",,0.3316714465618133
808,"New molecular entities (NME) are the foundation of Pfizer's, and the industry's, innovative  medicines pipelines.",,0.2540542781352997
809,NMEs originating outside of Pfizer and acquired or licensed by Pfizer after achieving FIH or more advanced development milestones are generally excluded from FIH-approval cycle time calculations where substantial  development effort occurred before Pfizer's operational control.,Governance - Business_Model_Resilience,0.3679312765598297
810,"Cycle times from FIH to approval are calculated between the FIH date for the NME in its first indication pursued, and first major regulatory approval (U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.864447832107544
811,FDA or EU European  Medicines Agency) for the NME.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8326225280761719
812,The NME approval may or may not be for the same indication by which the NME triggered its first FIH milestone.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.1544370651245117
813,Rolling cohorts are used to provide sufficient sample sizes to calculate cycle times between  major development milestones.,Governance - Business_Model_Resilience,0.1938254237174987
814,2 The FIH to approval NME success rate metric is a composite metric.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5094980001449585
815,It is a cumulative success rate derived using individual phase success rates from FIH (start of Phase 1) to approval (first regulatory approval) at an NME level.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8171011805534363
816,"Combinations  of approved NMEs, biosimilars and generics are excluded from all success rate calculations.",Governance - Competitive_Behavior,0.8228697776794434
817,"Cumulative NME success rate is calculated using three-year rolling cohorts for Phase 1 and five-year rolling cohorts for Phase 2, Phase 3 and  registration.",Social - Employee_Engagement_Inclusion_And_Diversity,0.1430898159742355
818,3.,Governance - Competitive_Behavior,0.146579697728157
819,Included on Pfizer's Product Listing:  * Co-Marketing agreements - Products that were co-marketed with other companies are included in the products listing.,Social - Selling_Practices_And_Product_Labeling,0.5271183252334595
820,"However, the third party may be taking or be responsible for a significant portion of the underlying marketing.",Social - Selling_Practices_And_Product_Labeling,0.2624107897281647
821,* U.S.,Governance - Business_Model_Resilience,0.1007309183478355
822,Products Only - The product listing shows products available to U.S.,Governance - Product_Design_And_Lifecycle_Management,0.9033114314079284
823,consumers only.,Governance - Product_Design_And_Lifecycle_Management,0.3964250981807709
824,* New Drug Application (NDA) / Abbreviated New Drug Application (ANDA) / Biologic License Application (BLA) - Products included are only shown (or removed) if they have an active application (or the application has been withdrawn).,Social - Selling_Practices_And_Product_Labeling,0.4182375371456146
825,This results in certain products being listed that are not actively marketed.,Governance - Product_Design_And_Lifecycle_Management,0.3664093315601349
826,"4 The 2022 figure is as of January 31, 2023 and represents the number of R&D programs in Phase 1 to registration, including programs for additional uses and dosage forms for in-line and in-registration products.",Governance - Product_Design_And_Lifecycle_Management,0.6601601839065552
827,"For latest information, please  see Pfizer's R&D Portfolio.",Governance - Business_Model_Resilience,0.5438495874404907
828,"5 Tosee the products prequalified, perform a database search per manufacturer name.",Governance - Product_Design_And_Lifecycle_Management,0.764549732208252
829,52 Pfizer 2022 ESG Report Performance Pfizer  — Continued  Innovation and Global Health 2021 2022  Breakthrough and Expedited Regulatory Designations’  % of Pfizer NME / BLA novel drug approvals by the U.S.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4725735187530517
830,FDA achieving breakthrough therapy designation (over a rolling 5-year period) 45% 44%  (vs.,Social - Product_Quality_And_Safety,0.1815838515758514
831,30% for industry) (vs.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2251920849084854
832,30% for industry)  % of Pfizer NME / BLA novel drug approvals by the U.S.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4925668835639953
833,FDA achieving one or more expedited review designations (over a rolling 5-year period) 91% 100%  (vs.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6907757520675659
834,66% for industry) (vs.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2272022068500518
835,67% for industry)  1 Breakthrough and other expedited U.S.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3217586576938629
836,Food and Drug Administration (FDA) regulatory designations are cited as a proxy measure of innovation among Pfizer and biopharmaceutical industry novel drug approvals.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8059298396110535
837,"As with success rate and  time-to-market metrics, the metrics exclude biosimilars, generics and product enhancements.",Governance - Product_Design_And_Lifecycle_Management,0.4770512282848358
838,"Our criteria for FDA expedited designations includes breakthrough therapy, fast track, priority review and accelerated approval.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3894205689430237
839,These four  designations are well-defined and established in FDA reporting and suitable for tracking over time.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.742874264717102
840,"The metrics cover a rolling 5-year period (e.g., 2021 values represent 2017-2021; 2022 values represent 2018-2022).",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5868581533432007
841,and references Pfizer  internal medicines portfolio data and data provided by the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).,Social - Selling_Practices_And_Product_Labeling,0.1802458316087722
842,"The scope of these metrics is limited to new molecular entities (NME),  novel biologics license applications (BLA) and novel vaccine approvals.",Governance - Competitive_Behavior,0.3215968012809753
843,Pfizer novel drug approval counts include co-developed or acquired assets which may not be listed as distinctly Pfizer assets among FDA data.,Governance - Competitive_Behavior,0.4108438193798065
844,Industry novel drug  approval counts exclude Pfizer approvals.,Governance - Competitive_Behavior,0.5142921805381775
845,53 Pfizer 2022 ESG Report Performance Pfizer  — Continued  Innovation and Global Health 2020 2021 2022  Equitable Access and Pricing  Description of actions and initiatives to promote access 2020 ESG Report - 2021 ESG Report — 2022 ESG Report - Tackling the  Social Narrative Social Narrative Health Equity Gap Together  2022 ESG Report - Equitable  Access and Pricing  Patients treated’ 399 million 383 million 372 million  (excluding COMIRNATY® and PAXLOVID®) (excluding COMIRNATY® and PAXLOVID®)  1.4 billion 1.3 billion  (including COMIRNATY® and PAXLOVID®) (including COMIRNATY® and PAXLOVID®)  Access to Medicine Index (ATMI) Ranking?,Social - Access_And_Affordability,0.7609536647796631
846,Ath Ath 6th  Antimicrobial Resistance (AMR) Benchmark Position?,,0.2170621007680893
847,69% / 2nd 81% / Joint Leader 81% / Joint Leader  Percent change in average net price for U.S.,Governance - Competitive_Behavior,0.3549012839794159
848,portfolio* 1% 5% 6%  Patient-centric design  54 Position in Global PatientView Survey® Ath 2nd 2nd  The Patients Treated metric is calculated from Pfizer and third-party datasets.,Social - Access_And_Affordability,0.387302964925766
849,"Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage).",,0.2312667071819305
850,"Numbers are estimates and in  some cases use global volume, daily dosage and number of treatment days to facilitate calculations.",Environmental - Energy_Management,0.4350352883338928
851,Methodologies to calculate estimates may vary by product type given the nature of the product and available data.,Governance - Product_Design_And_Lifecycle_Management,0.8981063365936279
852,Patients taking multiple  Pfizer products may be counted as multiple patients towards total.,,0.4142107367515564
853,Numbers include estimated patient counts from U.S.,Social - Access_And_Affordability,0.2931924164295196
854,"Patient Assistance Programs, ex-U.S.",Social - Access_And_Affordability,0.7070438265800476
855,"access & affordability programs, product donations and Global Commercial Access  Partnerships (this does not include An Accord for a Healthier World).",Social - Access_And_Affordability,0.7452213764190674
856,Historical estimates may periodically be subject to revision due to restatements in the underlying data source.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5484902262687683
857,Note: 2021 Patients Treated estimate of 383 million is a  revision from the figure included in the 2021 ESG Report due to data source restatements and updates to methodology.,Social - Access_And_Affordability,0.6909881830215454
858,"The 2022 Access to Medicine Index assesses the top 20 largest research-based pharmaceutical companies on their actions to improve access to medicines in 108 low- and middle-income countries for 83 diseases, conditions and pathogens.",Social - Access_And_Affordability,0.6525928378105164
859,"As  the ATMI is published every 2 years, the 2021 disclosure is the same as the 2020 disclosure.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.798882782459259
860,ATMI 2022 Ranking  The 2021 AMR Benchmark evaluates companies active in the development and deployment of antibacterials and antifungals.,,0.2803660631179809
861,"Among the eight R&D-based multinational companies assessed, Pfizer achieved a 81% total score and was  designated “joint leader”.",Social - Supply_Chain_Management,0.2829760909080505
862,"As the AMR Benchmark is published every 2 years, the 2022 disclosure is the same as the 2021 disclosure.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4712512195110321
863,AMR Benchmark  The U.S.,Governance - Systemic_Risk_Management,0.5108930468559265
864,portfolio includes all pharmaceutical products marketed by the company.,Social - Selling_Practices_And_Product_Labeling,0.4376734495162964
865,The product sales utilized in the analysis represent ~88% of the total U.S.,Governance - Product_Design_And_Lifecycle_Management,0.9022006988525392
866,portfolio in 2022 and exclude our alliance products and contract manufacturing  operations.,Governance - Product_Design_And_Lifecycle_Management,0.9623703360557556
867,"Excluding COMIRNATY® and PAXLOVID®, the percentage change in average net price for the U.S.",Governance - Competitive_Behavior,0.3388729095458984
868,"portfolio for 2021 and 2022 is -4% and -2%, respectively.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4176562428474426
869,"Year-over-year comparisons of net price may be impacted by changes to  our portfolio, including, but not limited to, new formulations, strengths, and product delivery formats.",Governance - Product_Design_And_Lifecycle_Management,0.8827219009399414
870,Ranked #1 among the largest Pharma companies in the 2021 PatientView Global Survey.,Governance - Systemic_Risk_Management,0.1956469863653183
871,"The survey was conducted from November 2021 to February 2022 across 2,150 respondent patient groups from 89 countries, covering 234 medical  specialties.",Social - Access_And_Affordability,0.6410529017448425
872,Forty-seven companies were assessed for performance on 10 patient related key-indicators of reputation.,Governance - Systemic_Risk_Management,0.5836190581321716
873,PatientView website.,Social - Access_And_Affordability,0.4212032854557037
874,"Pfizer 2022 ESG Report Performance Pfizer  — Continued  Human Capital  Colleague Diversity, Equity and Inclusion* 2020 2021 2022  Gender representation (global) Female Male Female Male Female Male  Vice President and above 38.1% 61.9% 41.5% 58.5% 43.1% 56.9%  Senior Director 42.4% 57.6% 46.4% 53.6% 48.4% 51.6%  Director 49.7% 50.3% 50.9% 49.1% 52.9% 47.1%  Manager / Senior Manager 50.7% 49.3% 52.0% 48.0% 53.6% 46.4%  Analyst and below 47.3% 52.7% 47.7% 52.3% 49.6% 50.4%  2022 Racial / Ethnic Group Representation (U.S.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9734562039375304
875,only)* Asian Black or African Hispanic or White Two or More Other  American Latino Races  Vice President and above 14.4% 7.4% 5.4% 71.9% 0.9%  Senior Director 16.7% 3.7% 5.3% 72.5% 1.8%  Director 20.0% 5.0% 5.3% 67.7% 2.0%  Manager / Senior Manager 20.9% 6.1% 6.4% 64.5% 2.1%  Analyst and below 9.2% 21.2% 7.7% 58.4% 3.5%  * Colleagues who select “Do Not Disclose” or have not filled in their profile are not included in the denominator or numerator for gender or racial / ethnic representation.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9701758623123168
876,Gender representation is calculated globally.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9592640995979308
877,Puerto Rico is excluded  within racial / ethnic representation but included in the Global Gender Representation.,Social - Employee_Engagement_Inclusion_And_Diversity,0.974271833896637
878,"55 Pfizer 2022 ESG Report Performance =] Pfizer  Human Capital 2020 2021 2022  Description of talent and recruitment efforts 2020 ESG Report - 2021 ESG Report - 2022 ESG Report -  Social Narrative Social Narrative Social Narrative  Pay equity 2020 ESG Report - 2021 ESG Report - 2022 ESG Report -  Social Narrative Social Narrative Social Narrative  Employee Engagement and Purpose  Employee Engagement (composite score, favorable %)' 91% 90% 88%  Employee Purpose (favorable %)?",Social - Employee_Engagement_Inclusion_And_Diversity,0.8932174444198608
879,93% 92% 93%  Employee Turnover?,Social - Labor_Practices,0.7648686766624451
880,"Voluntary Employee Turnover 5.3% 7.2% 7.3%  Involuntary Employee Turnover 3.9% 5.3% 7.0%  1 Composite score across four questions: 1.1 am proud to work for Pfizer, 2.",Social - Labor_Practices,0.4419765472412109
881,"1 would recommend Pfizer as a great place to work, 3.",Governance - Product_Design_And_Lifecycle_Management,0.4276852309703827
882,"I would like to be working at Pfizer one year from now, 4.",,0.1471613496541977
883,"If lwere offered a comparable position with similar pay  and benefits at another company, I would stay with Pfizer.",Social - Labor_Practices,0.870673656463623
884,2 Scored from question: “My work contributes to our purpose - Breakthroughs that change patients’ lives”.,Social - Access_And_Affordability,0.4175659716129303
885,3.,Governance - Competitive_Behavior,0.146579697728157
886,Average Monthly Headcount = (Total of Headcounts for January 2022 through December 2022) / 12.,Governance - Systemic_Risk_Management,0.3928081393241882
887,"The number of employees at Pfizer who are actively working and are paid directly by the company, or those on leave for 6 months or less and  eligible for benefits available to Pfizer employees in the country of their employment or hired without an actual expected termination date.",Social - Labor_Practices,0.904600203037262
888,"56 Pfizer 2022 ESG Report Performance Pfizer  — Continued  Colleague Health & Safety’ 2020 2021 2022  Total Injury Rate (TIR)* 0.27 0.30 0,29  Lost Time Injury Rate (LTIR)?",Social - Employee_Health_And_Safety,0.983991265296936
889,"0.13 0.14 0.12  Fatalities* 0 0 0  1 To facilitate consistent reporting practices, Pfizer applies the U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5472636818885803
890,Occupational Safety and Health Administration Recordkeeping Requirements as its global reporting standard.,Social - Employee_Health_And_Safety,0.9795976281166076
891,2.,Governance - Competitive_Behavior,0.1579564213752746
892,Injuries or illnesses per 100 colleagues.,Social - Employee_Health_And_Safety,0.97907155752182
893,3.,Governance - Competitive_Behavior,0.146579697728157
894,Injuries or illnesses resulting in time away from work per 100 colleagues.,Social - Employee_Health_And_Safety,0.980782389640808
895,4 Work-related injuries or illnesses that led to loss of life.,Social - Employee_Health_And_Safety,0.9821604490280152
896,"57 Pfizer 2022 ESG Report Performance  2020 2021 2022  Ethics, Transparency, Quality  Ensuring quality and patient safety during clinical trials  Products listed on FDA’s MedWatch List  Fatalities as reported in FDA Adverse Event Reporting System  Code of ethics governing the promotion of off-label use of products  Code of ethics governing interactions with healthcare providers  Alerts of risks associated with counterfeit products  Counterfeit drug process for maintaining traceability 2020 ESG Report -  Governance Narrative  FDA’s MedWatch List  FDA AE Reporting System 2021 ESG Report -  Governance Narrative 2022 ESG Report -  Governance Narrative  — | al  2020 ESG Report -  Governance Narrative  2020 ESG Report -  Governance Narrative  2020 ESG Report -  Governance Narrative  2020 ESG Report -  Governance Narrative 2021 ESG Report -  Governance Narrative  2021 ESG Report -  Governance Narrative  2021 ESG Report -  Governance Narrative  2021 ESG Report -  Governance Narrative — | al  2022 ESG Report -  Governance Narrative  2022 ESG Report -  Governance Narrative  2022 ESG Report -  Governance Narrative  2022 ESG Report -  Governance Narrative  Accountability  Proportion of women on Board of Directors’  1 Pfizer's Board of Directors  58 Pfizer 2022 ESG Report 4 out of 12  Performance 4 out of 12 4 out of 12  eS Pfizer  Allocation of the Net Proceeds from the 2020 Sustainability Bond  In March 2020, Pfizer issued the biopharmaceutical industry's first Sustainability Bond, which raised a total of $1.25 billion notional, resulting in approximately $1.24 billion of net proceeds.",Governance - Business_Ethics,0.8481953740119934
897,"In  accordance with the Use of Proceeds defined on pages S-6 and S-7 of the Prospectus Supplement dated March 25, 2020, the proceeds were allocated to new projects and projects that had received  funding in the three years prior to the issuance of the March 2020 Sustainability Bond as follows: (1) to help manage our environmental impact by supporting more environmentally efficient design  and the construction of new office and manufacturing facilities, (2) to support increased patient access to Pfizer's medicines and vaccines, especially among underserved populations, and (3) to  help strengthen healthcare systems.",Social - Access_And_Affordability,0.9379042387008668
898,"As of December 31, 2022, the net proceeds of approximately $1.24 billion from the March 2020 Sustainability Bond were fully allocated, funding a portion of the  aggregate spend of $1.275 billion.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7639016509056091
899,A breakdown of the specific allocation of funds can be found in the table below.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7136656641960144
900,"2017 2018 2019 2020 2021 2022 Spend Through 2022  $in Millions Full Year Actual Full Year Actual Full Year Actual Full Year Actual Full Year Actual Full Year Actual  API Manufacturing, Tuas Singapore 0 0 2 26 208 354 591  NYHQ Transformation - 66 Hudson 0 1 4 10 150 190 355  Sayana Press filling line 6 10 7 12 4 2 41  Pfizer Foundation 200 0 10 10 50 10 280  AMR Fund 0 0 0 0 1 8 9  Total 206 11 23 59 413 564 1,275  1 Some figures may not add due to rounding  For additional details, see About This Report  59 Pfizer 2022 ESG Report Performance Pfizer  — Continued  API Manufacturing, Tuas Singapore:  Through the application of proceeds from the 2020 Sustainability Bond, Pfizer is nearing completion of a new multi-product API manufacturing facility in Tuas, Singapore.",Governance - Product_Design_And_Lifecycle_Management,0.505996584892273
901,Design priorities included  integration of systems and technologies to increase energy efficiency and enable effective energy demand management.,Environmental - Energy_Management,0.979735255241394
902,The design was informed through identification of the largest energy  consuming systems and processes enabling evaluation of opportunities for reduction of electrical and thermal loads.,Environmental - Energy_Management,0.9771325588226318
903,"This analysis included use of benchmarking studies to identify good practices,  including incorporation of a comprehensive metering infrastructure facilitating early investigation and action of energy demand changes.",Environmental - Energy_Management,0.8871077299118042
904,The project was issued a Green Mark Gold Certificate by the  Singapore Building and Construction Authority in December 2022 and is on track for completion in 2023.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.1845525056123733
905,"NYHQ Transformation - 66 Hudson:  Proceeds were also used to advance sustainable design principles in Pfizer’s new corporate headquarters in Hudson Yards, New York City.",Governance - Product_Design_And_Lifecycle_Management,0.8348820805549622
906,This new Pfizer facility was designed to meet or exceed the  Gold level of two independent certification standards including the US Green Building Counsel (USGBC) Leadership in Energy and Environmental Design (LEEDv4) standard and the International WELL  Building Institute (IWBI) WELLv2 Pilot Standard and is currently undergoing certification review.,Social - Product_Quality_And_Safety,0.3462075591087341
907,"The design includes maximizing the use of natural lighting, reducing lighting power demand 30% below  the LEEDv4 baseline, water use management through incorporation of low flow plumbing fixtures, and enabling effective energy management through installation of advanced energy metering and  energy performance modeling.",Environmental - Energy_Management,0.97713303565979
908,"Based on this energy performance modeling, we are forecasting a greenhouse gas emissions reduction of around 70% compared with emissions levels in 2019 at our  previous headquarters location.",Environmental - GHG_Emissions,0.9636703729629515
909,This forecast is based on design efficiencies in space utilization and energy reduction strategies.,Environmental - Energy_Management,0.9785544276237488
910,Colleagues began working from the new Hudson Yards facility at the  end of 2022.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.1115802749991417
911,Sayana Press Filing Line:  An estimated 190 million women of reproductive age worldwide would like to delay or prevent pregnancy but are not using any method of contraception.,Social - Access_And_Affordability,0.2763980031013489
912,Pfizer Inc.,,0.2082080990076065
913,"and a consortium of partners are  part of a public-private collaboration to broaden access to Sayana® Press, Pfizer's long-acting, injectable, and reversible contraceptive.",Social - Access_And_Affordability,0.3139534294605255
914,"In total, Pfizer allocated $41 million from our Sustainability Bond  proceeds to fund the capital expense of establishing a new automated filling line for the Uniject™ injection system, which delivers the contraceptive.",Social - Access_And_Affordability,0.5039764046669006
915,"Once operational, this new filling line will allow for  capacity to scale from 23 million units per year, to up to 30 million units per year.",Environmental - Energy_Management,0.8533645272254944
916,"In 2023, the new automated filling line will undergo process validation and EU regulatory review and is expected to  enter into commercial production.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9586828351020812
917,"Pfizer Foundation:  Proceeds from the March 2020 Sustainability Bond are being used to support the company’s work to increase access to Pfizer's medicines and vaccines, especially among underserved communities,  and strengthen healthcare systems.",Social - Access_And_Affordability,0.9457501173019408
918,"Pfizer has allocated $280 million of the Sustainability Bond proceeds to The Pfizer Foundation, a charitable organization established by Pfizer Inc., that works to  help address the challenges of a complex and evolving global health landscape.",Social - Access_And_Affordability,0.1967693865299224
919,The Pfizer Foundation is a separate legal entity from Pfizer Inc.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3442288935184479
920,with distinct legal restrictions.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7182366847991943
921,The Pfizer Foundation is  focused on accelerating innovative solutions and improving health systems to help improve the health of communities around the world.,Social - Employee_Health_And_Safety,0.6109672784805298
922,"Through its programs, The Foundation aims to help reduce  the impact of infectious disease and improve access to healthcare for underserved patients around the world.",Social - Access_And_Affordability,0.9469877481460572
923,"AMR Fund:  In 2020, Pfizer pledged $100 million to support the AMR Action Fund, a collaboration of more than 20 biopharmaceutical companies that aims to bring two to four new antibiotics to patients by 2030.",,0.2455774992704391
924,Pfizer plans to use proceeds from the Sustainability Bond to invest $20 million over 5 years.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3773158490657806
925,The Fund has begun investing in clinical-stage biotechs developing antibiotics and other anti-infectives  that target WHO and Centers for Disease Control and Prevention (CDC) priority drug-resistant pathogens.,Governance - Systemic_Risk_Management,0.115407571196556
926,"These investments are expected to help bring novel antibiotics to market and, importantly,  re-establish an innovation ecosystem to support long term antibiotic development.",,0.2496000975370407
927,"In 2022, Pfizer contributed $7 million of the Fund's $54 million investment to three early stage drug development  companies aligned with this focus: Ventorex Pharmaceuticals Inc., Adaptive Phage Therapeutics, Inc., and BioVersys AG.",,0.2139143645763397
928,"60 Pfizer 2022 ESG Report Performance Pfizer  We are aligning our efforts and reporting to recognized ESG  standards: The Sustainability Accounting Standards Board  (SASB), Global Reporting Initiative (GRI) and Task Force on  Climate-Related Financial Disclosures (TCFD), as well as the UN  Sustainable Development Goals (SDGs), where appropriate.",Governance - Business_Model_Resilience,0.2797560691833496
929,> Governance > Performance > Appendix >   to the GRI standards.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7279798984527588
930,"Pfizer continues to evaluate our approach to reporting, including reference to several existing, globally recognized external frameworks—for  GRI Table  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  GRI 2: Universal Disclosures  2-1 Organizational Details  2-2 Entities included in the organization's  sustainability reporting  2-3 Reporting period, frequency and contact point  2-4 Restatements of information  2-5 External Assurance  2-6 Activities, value chain and other business  relationships  2-7 Employees  2-8 Workers who are not employees  62 Pfizer 2022 ESG Report Direct Response: Pfizer Inc.",Social - Labor_Practices,0.2756897509098053
931,"is a publicly owned incorporated entity headquartered in New York, NY, USA.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6841415762901306
932,"Our global operations are detailed on our Global Manufacturing, Supply, and Distribution webpage.",Social - Supply_Chain_Management,0.9159035086631776
933,About This Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4167661368846893
934,"81  Direct Response: This report covers all of Pfizer's global operations included within the 2022 financial  statements, unless otherwise stated.",Governance - Business_Model_Resilience,0.571376383304596
935,About This Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4167661368846893
936,81  Direct Response: Pfizer restates information as appropriate and when needed.,Social - Customer_Privacy,0.236061081290245
937,Please refer to the Key  Performance Indicator tables in the Performance section of the report for any restated information included  during this reporting period.,Governance - Systemic_Risk_Management,0.3649649322032928
938,Direct Response: There is no third party assurance on the information provided in the GRI standards.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8113722205162048
939,Information about assurance we have obtained can be found in About This Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6131839752197266
940,81.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2210268527269363
941,Letter from our Chairman & CEO; pg.,Governance - Director_Removal,0.1727710515260696
942,4-5  Our Approach to ESG; pg.,Governance - Business_Model_Resilience,0.3615998327732086
943,"&  Connecting our Purpose, Strategy, and ESG; pg.",Governance - Business_Model_Resilience,0.736276388168335
944,9  Priority ESG Issues; pg.,Governance - Systemic_Risk_Management,0.2273589074611663
945,10  Tackling the Health Equity Gap Together; pg.,Governance - Systemic_Risk_Management,0.6073887348175049
946,16 - 17  Keeping Patients at the Center of Everything We Do; pg.,Social - Access_And_Affordability,0.421942263841629
947,18 - 20  Climate Change; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.9357685446739196
948,23  Innovation and Global Health; pg.,Governance - Business_Model_Resilience,0.3433759808540344
949,"31  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9700881242752076
950,"41, 43  Pfizer Annual Report on Form 10-K for the year ended December 31, 2022; pg.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5704828500747681
951,3- 14  Direct Response: There were no significant changes within the organizational value chain during the  reporting period.,Governance - Business_Model_Resilience,0.3747863471508026
952,Human Capital; pg.,Governance - Competitive_Behavior,0.4667259454727173
953,33-35  Direct Response - Omission Statement: The organization considers the data confidential and thus cites  ‘confidentiality constraints’ as our reason for omission.,,0.5671406984329224
954,Reason for Omission: Confidentiality Constraints  Direct Response - Omission Statement: The organization considers the data confidential and thus cites  ‘confidentiality constraints’ as our reason for omission.,,0.481292188167572
955,Reason for Omission: Confidentiality Constraints  Appendix =] Pfizer  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  2-9 Governance structure and composition  2-10 Nomination and selection of the highest  governance body  2-11 Chair of the highest governance body  2-12 Role of the highest governance body in overseeing the  management of impacts  2-13 Delegation of responsibility for managing impacts  2-14 Role of the highest governance body in sustainability  reporting  2-15 Conflicts of interest  2-16 Communication of critical concerns  2-17 Collective knowledge of the highest governance  body  2-18 Evaluation of the performance of the highest  governance body  2-19 Remuneration policies  2-20 Process to determine remuneration  63 Pfizer 2022 ESG Report Accountability; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.341100126504898
956,47 - 48  Board of Directors  Board of Committees and Charters  Accountability; pg.,Governance - Director_Removal,0.6648154854774475
957,47 - 48  Accountability; pg.,Governance - Business_Ethics,0.4338025450706482
958,"47 - 48  Connecting our Purpose, Strategy, and ESG; pg.",Governance - Business_Model_Resilience,0.7774013876914978
959,9  Priority ESG Issues; pg.,Governance - Systemic_Risk_Management,0.2273589074611663
960,"10  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9708698987960817
961,38 - 41  Accountability; pg.,Governance - Business_Ethics,0.4415633678436279
962,"47 - 48  Board Committees and Charters  Connecting our Purpose, Strategy, and ESG; pq.",Governance - Director_Removal,0.4392264187335968
963,9  Accountability; pg.,Governance - Business_Ethics,0.5329978466033936
964,47 - 48  Accountability; pg.,Governance - Business_Ethics,0.4338025450706482
965,47 - 48  About This Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5367439985275269
966,"81  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9705765843391418
967,"39 - 40  Code of Business Conduct and Ethics for Members of the Board  Ethics, Transaparency, Quality; pg.",Governance - Business_Ethics,0.9689624309539796
968,38 - 40  Direct Response - Omission Statement: Pfizer does not publicly  disclose the number of critical concerns communicated during the  reporting period.,Social - Critical_Incident_Risk_Management,0.2709579467773437
969,Pfizer considers the data confidential and thus cites  ‘confidentiality constraints’ as our reason for omission.,,0.5397698879241943
970,Reason for Omission: Confidentiality Constraints  Accountability; pg.,Governance - Business_Ethics,0.9074912667274476
971,47 - 48  Accountability; pg.,Governance - Business_Ethics,0.4338025450706482
972,47 - 48  About this Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5367439985275269
973,"81  2023 Proxy Statement  Board Compensation Committee Charter  2023 Proxy Statement  Appendix Goal 5: Gender Equality  Goal 16: Peace, Justice, and  Strong Institutes  Goal 5: Gender Equality  Goal 16: Peace, Justice, and  Strong Institutes  Goal 16: Peace, Justice, and  Strong Institutes  Goal 16: Peace, Justice, and  Strong Institutes  Goal 16: Peace, Justice, and  Strong Institutes  Goal 16: Peace, Justice, and  Strong Institutes  Goal 16: Peace, Justice, and  Strong Institutes GENDER  EQUALITY  g  16 sino  INSTITUTIONS.",Social - Employee_Engagement_Inclusion_And_Diversity,0.773249626159668
974,=] Pfizer  — Continued  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  Governance  16 sino  INSTITUTIONS.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4299100935459137
975,2-22 Statement on sustainable development CEO and Chairman Letter; pg.,Governance - Business_Model_Resilience,0.2200280278921127
976,"4-5 »%,  strategy Message from the Lead Independent Director; pq.",Governance - Director_Removal,0.3886818885803222
977,6  2-23 Policy commitments Our Approach to ESG; pg.,Governance - Business_Model_Resilience,0.362033486366272
978,"8 Goal 16: Peace, Justice,  Connecting our Purpose, Strategy, and ESG; pg.",Social - Human_Rights_And_Community_Relations,0.7860510349273682
979,"9 and Strong Institutes  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.972971498966217
980,"38 - 39, 44 - 45  Accountability; pg.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4274767637252807
981,46  Human Rights Policy Statement  Our Values and Culture  Corporate Compliance  2023 Proxy Statement  Direct Response: Pfizer may apply the precautionary principle in order  to manage and report on risks and impacts.,Social - Human_Rights_And_Community_Relations,0.8675429224967957
982,"2-24 Embedding policy commitments Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.97388756275177
983,"40  2023 Proxy Statement  Commitment to Quality: Everyone's Job  Pfizer Training  2-26 Mechanisms for seeking advice and raising Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.975628137588501
984,"38 - 41 Goal 16: Peace, Justice,  concerns SASB Index; pg.",Social - Human_Rights_And_Community_Relations,0.6323173642158508
985,"72-73 and Strong Institutes  Corporate Compliance  2-27 Compliance with laws and regulations Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.972700297832489
986,"38 - 39  Direct Response: Omission Statement: Pfizer does not publicly disclose  the number, nature, or monetary value of fines imposed for significant  instances of non-compliance.",Governance - Business_Ethics,0.8627055287361145
987,Pfizer considers the data confidential and  thus cites ‘confidentiality constraints’ as our reason for omission.,,0.5397698879241943
988,"Reason for Omission: Confidentiality Constraints  2-28 Membership of associations Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.968566119670868
989,"46  Political Partnerships  2-29 Approach to stakeholder engagement Connecting our Purpose, Strategy, and ESG; pg.",Social - Human_Rights_And_Community_Relations,0.4518000185489654
990,9  Priority ESG Issues; pg.,Governance - Systemic_Risk_Management,0.2273589074611663
991,10 - 12  Our Stakeholders; pg.,Social - Human_Rights_And_Community_Relations,0.4678542613983154
992,13 - 14  Accountability; pg.,Governance - Business_Ethics,0.6945419907569885
993,46 - 48  64 Pfizer 2022 ESG Report Appendix =] Pfizer  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  GRI 3: Material Topics  3-1  3-2  3-3 Process to determine material topics  List of material topics  Management of material topics  GRI 200: Economic Disclosure Our Approach to ESG; pg.,Governance - Business_Model_Resilience,0.2300769090652465
994,"&  Connecting our Purpose, Strategy, and ESG; pg.",Governance - Business_Model_Resilience,0.736276388168335
995,9  Priority ESG Issues; pg 10 - 12  About This Report; pg.,Governance - Systemic_Risk_Management,0.2446251958608627
996,81  2022 Annual Review: About This Review; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6877502202987671
997,54  Priority ESG Issues; pg.,Governance - Systemic_Risk_Management,0.2796325385570526
998,11  Our Approach to ESG; pq.,Governance - Business_Model_Resilience,0.5526057481765747
999,"8  Connecting our Purpose, Strategy, and ESG; pg.",Governance - Business_Model_Resilience,0.7403777241706848
1000,9  Priority ESG Issues; pg.,Governance - Systemic_Risk_Management,0.2273589074611663
1001,10 - 12  Economic Performance  3-3 Management of material topics  201-1 Direct economic value generated and  distributed  65 Pfizer 2022 ESG Report Annual Review: Performance Review; pg.,Governance - Systemic_Risk_Management,0.3745282888412475
1002,51 - 52  Annual Review: Performance Review; pg.,Governance - Competitive_Behavior,0.2388316690921783
1003,51 - 52  Appendix =] Pfizer  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  Indirect Economic Impacts  3-3 Management of material topics  203-1 Infrastructure investments and services  supported  203-2 Significant indirect economic impacts Priority ESG Issues; pg.,Governance - Business_Model_Resilience,0.5276895761489868
1004,10 - 11  Innovation and Global Health; pg.,Governance - Business_Model_Resilience,0.5009852051734924
1005,27 - 32  Corporate Compliance  Priority ESG Issues; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5337371230125427
1006,10 - 11  Tackling the Health Equity Gap Together; pg.,Governance - Systemic_Risk_Management,0.606887936592102
1007,16 - 17  Keeping Patients at the Center of Everything We Do; pg.,Social - Access_And_Affordability,0.421942263841629
1008,18 - 19  Improving Health Literacy for All Patients; pg.,Social - Access_And_Affordability,0.838267982006073
1009,20  Innovation and Global Health; pg.,Governance - Business_Model_Resilience,0.3690008521080017
1010,27 - 32  Corporate Compliance  Priority ESG Issues; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5337371230125427
1011,10 - 11  Tackling the Health Equity Gap Together; pg.,Governance - Systemic_Risk_Management,0.606887936592102
1012,16 - 17  Keeping Patients at the Center of Everything We Do; pg.,Social - Access_And_Affordability,0.421942263841629
1013,18 - 20  Innovation and Global Health; pg.,Governance - Business_Model_Resilience,0.4964179694652557
1014,"29 - 30 Goal5  Goal 9  Goal 17  Goal 1  Goal 3  Goal 8 Gender Equality  Industry, Innovation and Infrastructure  Partnerships for the Goals GENDER  EQUALITY  VATER  6 pape  No Poverty  Good Health and Well-being 8 icc  Decent Work and Economic Growth  Anti-Corruption  3-3 Management of material topics  205-1 Operations assessed for risks related to  corruption  GRI 300: Environmental Disclosures Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9730927348136902
1015,"41 - 43  Anti-Bribery and Anti-Corruption Policy  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9760743975639344
1016,41 - 43  Anti-Bribery and Anti-Corruption Policy  Direct Response: Omission Statement - Confidentiality Constraint:  Pfizer does not publicly disclose critical concerns communicated during  the reporting period.,Governance - Business_Ethics,0.9758422374725342
1017,Pfizer considers the data confidential and thus  cites ‘confidentiality constraints’ as our reason for omission.,,0.5397698879241943
1018,Goal 16 INSTITUTIONS.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6668301224708557
1019,"y  PARTNERSHIPS Peace, Justice and Strong Institutions FoR THE cous &  Water  3-3 Management of material topics  303-2 Water withdrawal Climate Change; pg.",Environmental - Water_And_Wastewater_Management,0.9692953824996948
1020,23  Sustainable Medicines; pg.,,0.2916171848773956
1021,25  Climate Change; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.9412801861763
1022,23  Sustainable Medicines; pg.,,0.2916171848773956
1023,25  Performance Data; pg.,Governance - Systemic_Risk_Management,0.2119459956884384
1024,51 Goal 6 Clean Water and Sanitation  Emissions  3-3 Management of material topics  66 Pfizer 2022 ESG Report Climate Change; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.714616596698761
1025,23  Performance Data; pg.,Governance - Systemic_Risk_Management,0.2394691407680511
1026,50  TCFD Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5292405486106873
1027,79 - 81  Appendix =] Pfizer  GRI Indicator Description Reference United Nations (UN) Sustainable Relevant SDGs  Development Goals (SDGs)  Emissions  305-1 Direct (Scope 1) GHG emissions 2022 Progress and Highlights; pg.,Environmental - GHG_Emissions,0.9668568968772888
1028,7 Goal 3 Good Health and Well-being  Climate Change; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.9408242106437684
1029,22 - 23 Goal12 Responsible Consumption and Production  Performance Data; pg.,Environmental - Energy_Management,0.911432147026062
1030,50 Goal 13 Climate Action  TCFD Report; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.8513549566268921
1031,79 - 81 Goal 14 Life Below Water  Goal 15 Life on Land 12 mest  305-2 Energy indirect (Scope 2) GHG emission 2022 Progress and Highlights; pq.,Environmental - GHG_Emissions,0.9672158360481262
1032,7 Goal 3 Good Health and Well-being GO  Climate Change; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.9424432516098022
1033,22 - 23 Goal12 Responsible Consumption and Production 1B  Performance Data; pg.,Environmental - Energy_Management,0.927297830581665
1034,50 Goal 13 Climate Action ~  TCFD Report; pg.,Environmental - Physical_Impacts_Of_Climate_Change,0.8442627191543579
1035,79 - 81 Goal 14 Life Below Water G>  Goal 15 Life on Land  305-5 Reduction of GHG emissions Climate Change; pq.,Environmental - GHG_Emissions,0.9631306529045104
1036,22 - 23  Performance Data; pg.,Governance - Systemic_Risk_Management,0.209358349442482
1037,50  TCFD Report; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5292405486106873
1038,79 - 81  Waste  3-3 Management of material topics Sustainable Medicines; pg.,Environmental - Waste_And_Hazardous_Materials_Management,0.8828659057617188
1039,24  306-1 Waste generation and significant waste-related Sustainable Medicines; pg.,Environmental - Waste_And_Hazardous_Materials_Management,0.983512818813324
1040,24 Goal 3 Good Health and Well-being  impacts Goal 6 Clean Water and Sanitation  Goal12 Responsible Consumption and Production  Goal 14 Life Below Water  Goal 15 Life on Land  306-2 Management of significant waste-related Sustainable Medicines; pg.,Social - Employee_Health_And_Safety,0.7825118899345398
1041,24 - 25 Goal 3 Good Health and Well-being  impacts Goal 6 Clean Water and Sanitation  Goal12 Responsible Consumption and Production  306-3 Waste generated Performance Data; pg.,Social - Employee_Health_And_Safety,0.8828116655349731
1042,51 Goal 6 Clean Water and Sanitation  Goal12 Responsible Consumption and Production  Goal 14 Life Below Water  Goal 15 Life on Land  67 Pfizer 2022 ESG Report Appendix =] Pfizer  — Continued  GRI Indicator Description Reference United Nations (UN) Sustainable Relevant SDGs  Development Goals (SDGs)  Waste  306-4 Waste diverted from disposal Performance Data; pg.,Environmental - Waste_And_Hazardous_Materials_Management,0.976569414138794
1043,51 Goal 6 Clean Water and Sanitation  Goal12 Responsible Consumption and Production coat  Goal 14 Life Below Water pet  Goal 15 Life on Land Sg  306-5 Waste directed to disposal Performance Data; pg.,Environmental - Water_And_Wastewater_Management,0.498353511095047
1044,51 Goal 6 Clean Water and Sanitation  Goal12 Responsible Consumption and Production  Goal 14 Life Below Water con woausn  Goal 15 Life on Land  GRI 400: Social Disclosures  Employment  3-3 Management of material topics Human Capital; pg.,Environmental - Water_And_Wastewater_Management,0.9721657037734984
1045,33-35  401-1 New employee hires and employee turnover Performance Data; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.5684086680412292
1046,55 - 56 Goal 5 Gender Equality  Goal 8 Decent Work and Economic Growth  Goal 10 Reduced Inequality  Occupational Health and Safety  3-3 Management of material topics Human Capital; pg.,Social - Employee_Health_And_Safety,0.9377420544624328
1047,"35 - 36  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.971889317035675
1048,40 - 42  EHS Governance  EHS Policy Statement  Prioritizing Health and Safety  403-1 Occupational health and safety management Human Capital; pg.,Social - Employee_Health_And_Safety,0.9839968085289
1049,"35 - 36 Goal 3 Good Health and Well-being  system Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9744163155555724
1050,40 - 42  Performance Data; pg.,Governance - Systemic_Risk_Management,0.2951510548591614
1051,"57  EHS Management Systems  Direct Response: To facilitate consistent reporting practices,  Pfizer applies the U.S.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3299208581447601
1052,Occupational Safety and Health  Administration Recordkeeping Requirements as its global  reporting standard.,Social - Employee_Health_And_Safety,0.9795976281166076
1053,"403-2 Hazard identification, risk assessment, and Human Capital; pg.",Social - Critical_Incident_Risk_Management,0.4639549553394317
1054,"35 Goal Decent Work and Economic Growth  incident investigation Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9746279120445251
1055,40 - 42  EHS Governance  EHS Policy Statement  68 Pfizer 2022 ESG Report Appendix =] Pfizer  — Continued  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  Occupational Health and Safety  403-3 Occupational health services Human Capital; pg.,Social - Employee_Health_And_Safety,0.9822923541069032
1056,"35 - 36 Goal 3 Good Health and Well-being  Goal 8 Decent Work and Economic Growth coat  403-4 Worker participation, consultation and Human Capital; pg.",Social - Employee_Health_And_Safety,0.8749194741249084
1057,"35 - 36 Goal 8 Decent Work and Economic Growth g  communication on occupational health and Goal 16 Peace, Justice and Strong Institutions wc aD  safety Ww,  al  403-5 Worker training on occupational health and Blue Book - Code of Conduct; pg.",Social - Employee_Health_And_Safety,0.9840615391731262
1058,10- 12 Goal 8 Decent Work and Economic Growth 16 eee  safety EHS Governance ery  Prioritizing Health and Safety »¥  403-6 Promotion of worker health Human Capital; pg.,Social - Employee_Health_And_Safety,0.9846512079238892
1059,"35 - 36 Goal 3 Good Health and Well-being  Prioritizing Health and Safety  403-7 Prevention and mitigation of occupational Ethics, Transparency, Quality; pg.",Social - Employee_Health_And_Safety,0.9795275330543518
1060,"40 - 41 Goal 8 Decent Work and Economic Growth  health and safety impacts directly linked by Prioritizing Health and Safety Goal 16 Peace, Justice and Strong Institutions  business relationships  403-9 Work-related injuries Performance Data; pg.",Social - Employee_Health_And_Safety,0.9842242002487184
1061,"57 Goal 3 Good Health and Well-being  Goal 16 Peace, Justice and Strong Institutions  Training and Education  3-3 Management of material topics Human Capital; pg.",Social - Access_And_Affordability,0.4536604881286621
1062,33 - 34  404-2 Programs for upgrading employee skills and Human Capital: pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.7906247973442078
1063,33 - 34 Goal 8 Decent Work and Economic Growth  transition assistance programs  Diversity and Equal Opportunity  3-3 Management of material topics Human Capital; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9692858457565308
1064,35  Accountability; pg.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3389426469802856
1065,47 - 48  405-1 Diversity of governance bodies and employees Human Capital; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.9671815037727356
1066,35 Goal 5 Gender Equality  Accountability; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.6886784434318542
1067,47 - 48 Goal 8 Decent Work and Economic Growth  Performance Data; pg.,Social - Labor_Practices,0.9300910234451294
1068,55  69 Pfizer 2022 ESG Report Appendix =] Pfizer  GRI Indicator Description Reference United Nations (UN) Sustainable  Development Goals (SDGs) Relevant SDGs  Diversity and Equal Opportunity  GENDER  EQUALITY  405-2 Ratio of basic salary and remuneration of Human Capital; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.970141053199768
1069,35 Goal 5 Gender Equality  women to men Performance Data; pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.7561392188072205
1070,55 Goal 8 Decent Work and Economic Growth saz e0  Goal 10 Reduced Inequality wi  au  Human Rights Assessment  3-3 Management of material topics Human Capital; pg.,Social - Human_Rights_And_Community_Relations,0.9519198536872864
1071,"35  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9707724452018738
1072,38 - 40 16 eee  Human Rights Statement ery  Human Rights Policy Statement »y  2021 Modern Slavery Statement  Supplier Conduct Principles  412-1 Operations that have been subject to human Human Capital; pg.,Social - Human_Rights_And_Community_Relations,0.9097086191177368
1073,"35 Goal 8 Decent Work and Economic Growth  rights reviews or impact assessments Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9727340936660768
1074,"38 - 40  Human Rights Statement  Human Rights Policy Statement  2021 Modern Slavery Statement  Supplier Conduct Principles  412-2 Employee training on human rights policies or Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9331933856010436
1075,39  procedures Human Rights Policy Statement  2021 Modern Slavery Statement  Local Communities  3-3 Management of material topics Innovation and Global Health; pg.,Social - Human_Rights_And_Community_Relations,0.9636911749839784
1076,"29 - 32  Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9712462425231934
1077,"44 - 45  413-1 Operations with local community engagement, Innovation and Global Health; pg.",Social - Human_Rights_And_Community_Relations,0.932951271533966
1078,"29 - 32 Goal 8 Decent Work and Economic Growth  impact assessments and development Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9724015593528748
1079,"44 - 45  programs  Public Policy  3-3 Management of material topics Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9746691584587096
1080,"46  Political Partnerships  State Lobbying Activities  415-1 Political contributions Ethics, Transparency, Quality; pg.",Governance - Business_Ethics,0.9619398713111876
1081,"46 Goal 16 Peace, Justice and Strong Institutions  Political Partnerships  State Lobbying Activities  70 Pfizer 2022 ESG Report Appendix Pfizer  Pfizer has chosen to use the voluntary Sustainability Accounting Standards Board (SASB) framework for our industry—biotechnology and pharmaceuticals—as well as the professional and  communication services and healthcare drug retailer sectors for human capital metrics that fit our priority issues.",Governance - Systemic_Risk_Management,0.3258525729179382
1082,We are continually improving our data collection and coordination across Pfizer's operations in support of our commitment to strengthen our reporting processes and disclosures in the  coming years.,Social - Customer_Privacy,0.1140350103378295
1083,"SASB Table  SASB Code Metric Description Disclosure Location  Safety of Clinical Trial Participants  HC-BP-210a.1 Discussion, by world region, of the management process for ensuring quality and patient safety during clinical trials pg.",Social - Product_Quality_And_Safety,0.8186107277870178
1084,"40; 44: Ethics, Transparency, Quality  HC-BP-210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary pg.",Governance - Business_Ethics,0.9662142992019652
1085,"42: Ethics, Transparency, Quality  Action Indicated (VAI) and (2) Official Action Indicated (OAI)  HC-BP-210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries Pfizer is not reporting against this metric at this time.",Governance - Business_Ethics,0.962559938430786
1086,Access to Medicines  HC-BP-240a.1 Description of actions and initiatives to promote access of the management process to healthcare products.,Governance - Product_Design_And_Lifecycle_Management,0.2275506407022476
1087,pg.,Social - Labor_Practices,0.1017670258879661
1088,16: Tackling the Health Equity Gap Together  pg.,Governance - Systemic_Risk_Management,0.5703771114349365
1089,"29: Innovation and Global Health  HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) WHO Medicinal Products  WHO Prequalified Vaccines  Direct Response: To see the products pre-qualified,  perform a database search per manufacturer name.",Governance - Product_Design_And_Lifecycle_Management,0.3419796824455261
1090,Affordability & Pricing  HC-BP-240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and / or provisions to Pfizer is not reporting against this metric at this time.,Governance - Competitive_Behavior,0.7936659455299377
1091,delay bringing an authorized generic product to market for a defined time period  HC-BP-240b.2 Percentage change in: (1) average list price and (2) average net price across U.S.,,0.2583077549934387
1092,product portfolio compared to previous year pg.,Governance - Product_Design_And_Lifecycle_Management,0.7933894991874695
1093,54: Performance Data  HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year Pfizer is not reporting against this metric at this time.,Governance - Product_Design_And_Lifecycle_Management,0.3991530239582062
1094,71 Pfizer 2022 ESG Report Appendix Pfizer  — Continued  SASB Code Metric Description Disclosure Location  Drug Safety  HC-BP-250a.1 List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database FDA MedWatch Safety Alerts for Human Medical Products database  HC-BP-250a.2 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System EDA Adverse Event Reporting System  HC-BP-250a.3 Number of recalls issued; total units recalled pq.,Social - Product_Quality_And_Safety,0.866272509098053
1095,"42: Ethics, Transparency, Quality  HC-BP-250a.4 Total amount of product accepted for takeback, reuse or disposal Pfizer is not reporting against this metric at this time.",Governance - Product_Design_And_Lifecycle_Management,0.6938669085502625
1096,"HC-BP-250a.5 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (CGMP), by type Pfizer is not reporting against this metric at this time.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5740675330162048
1097,Counterfeit Drugs  HC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and pg.,Governance - Product_Design_And_Lifecycle_Management,0.1416722983121872
1098,"43: Ethics, Transparency, Quality  prevent counterfeiting  HC-BP-260a.2 Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit pg.",Governance - Business_Ethics,0.9089719653129578
1099,"43: Ethics, Transparency, Quality  products  HC-BP-260a.3 Number of actions that led to raids, seizure, arrests, and / or filing of criminal charges related to counterfeit products Pfizer is not reporting against this metric at this time.",Governance - Business_Ethics,0.90349018573761
1100,Ethical Marketing  HC-BP-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims Pfizer is not reporting against this metric at this time.,Governance - Business_Ethics,0.6065636277198792
1101,HC-BP-270a.2 Description of code of ethics governing promotion of off-label use of products pg.,Social - Selling_Practices_And_Product_Labeling,0.6769315600395203
1102,"38: Ethics, Transparency, Quality  Direct Response: Our Global Policy covers information on  ethical marketing and off-label promotion.",Governance - Business_Ethics,0.9333703517913818
1103,"Furthermore, we  disclose several policies and information that address ethical  marketing and promotion of off-label use of products.",Social - Selling_Practices_And_Product_Labeling,0.7784144282341003
1104,"Employee Recruitment, Development, and Retention  HC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and development personnel pg.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9676017761230468
1105,"33 -35: Human Capital  HC-BP-330a.2 (1) Voluntary and (2) involuntary turnover rate for: (a) executives / senior managers, (b) midlevel managers, (c) pq.",Social - Labor_Practices,0.3398397862911224
1106,"56: Performance Data  professionals, and (d) all others  72 Pfizer 2022 ESG Report Appendix Pfizer  SASB Code Metric Description Disclosure Location  Supply Chain Management  HC-BP-430a.1 Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Pfizer is not reporting against this metric at this time.",Social - Supply_Chain_Management,0.9466969966888428
1107,Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients  Business Ethics  HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery Pfizer is not reporting against this metric at this time.,Governance - Business_Ethics,0.9750746488571168
1108,HC-BP-510a.2 Description of code of ethics governing interactions with healthcare professionals pq.,Governance - Business_Ethics,0.966602087020874
1109,"38: Ethics, Transparency, Quality  Activity Metrics  HC-BP-000.A Number of patients treated pg.",Governance - Business_Ethics,0.966754138469696
1110,29: Innovation and Global Health  pg.,Governance - Business_Model_Resilience,0.3469119071960449
1111,54: Performance Data  HC-BP-000.B Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) pg.,Social - Selling_Practices_And_Product_Labeling,0.3568335771560669
1112,"27: Innovation and Global Health  Other Relevant Industry Standards (not currently reported under SASB, but included in ESG report) pg.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2116210758686065
1113,52: Performance Data  Healthcare: Drug Retailers - Drug Supply Chain Integrity  HC-DR-250a.1.,Social - Supply_Chain_Management,0.9497461318969728
1114,Description of efforts to reduce the occurrence of compromised drugs within the supply chain pq.,Social - Supply_Chain_Management,0.8540312051773071
1115,"43: Ethics, Transparency, Quality  Services: Professional & Commercial Services - Workforce Diversity & Engagement  SV-PS-330a.1.",Social - Employee_Engagement_Inclusion_And_Diversity,0.9341458082199096
1116,Percentage of gender and racial / ethnic group representation for (1) executive management and (2) all other pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.974911332130432
1117,35: Human Capital  employees pg.,Governance - Competitive_Behavior,0.3311018049716949
1118,54; Performance Data  SV-PS-330a.3.,Environmental - Energy_Management,0.3058226704597473
1119,Employee engagement as a percentage pg.,Social - Employee_Engagement_Inclusion_And_Diversity,0.926000475883484
1120,33: Human Capital  pg.,Governance - Competitive_Behavior,0.679620623588562
1121,"56: Performance Data  73 Pfizer 2022 ESG Report Appendix =] Pfizer  Pfizer recognizes the significant risks posed by climate  change, including potential adverse impacts on human  health, increasing frequency of severe weather events  impacting communities, personnel and operations, and  the potential disruption of value chains critical to providing  medicines and vaccines to patients.",Environmental - Physical_Impacts_Of_Climate_Change,0.9480866193771362
1122,That's why we have  made long-standing commitments to climate action through  resource conservation and greenhouse gas (GHG) emission  reductions.,Environmental - GHG_Emissions,0.9697769284248352
1123,"Over the period 2001 - 2021 we reduced  our Scope 1 & 2 greenhouse gas emissions by 64%, fully  delivering three generations of GHG goals.",Environmental - GHG_Emissions,0.96984201669693
1124,"In 2015, we were  one of the first companies to have our then GHG emissions  reduction goal approved by the Science Based Targets  Initiative (SBTi), and we remain committed to developing  and implementing a science-based climate action strategy.",Environmental - GHG_Emissions,0.9646853804588318
1125,"In June 2022 we announced our ambition to achieve the  voluntary Net-Zero standard by 2040, 10 years ahead of the  timeline outlined in the standard.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7758233547210693
1126,"In addition, as described in  our Climate Change Position Statement, we aim to conduct  robust risk assessments to safeguard resiliency of our  research, manufacturing, and commercial activities and to  transparently report on our progress, risks, and opportunities  aligned with Task Force on Climate-related Financial  Disclosure (TCFD) recommendations.",Environmental - Physical_Impacts_Of_Climate_Change,0.9003581404685974
1127,"Governance  Pfizer has embedded Environmental, Social & Governance  (ESG) principles into the company's strategy and has  identified climate change as one of six priorities in Pfizer's  ESG strategy.",Environmental - Physical_Impacts_Of_Climate_Change,0.9439877867698668
1128,"Our climate change strategy is championed by  the Executive Vice President, Chief Global Supply Officer, who  reports to the CEO.",Environmental - Physical_Impacts_Of_Climate_Change,0.9321630597114564
1129,"Implementation of the strategy is led and  managed by the Global Environment, Health and Safety (EHS)  team in partnership with Legal with active engagement of a  cross-disciplinary team of leaders representing Engineering,  Facilities, Sourcing, Scientific and Manufacturing lines, and  is integrated into Pfizer’s operational and risk management  processes as described below.",Social - Employee_Health_And_Safety,0.8775194883346558
1130,"74 Pfizer 2022 ESG Report Risk & Operational Governance:  The Governance & Sustainability Committee of the Board of  Directors, composed solely of independent directors, provides  oversight of Pfizer's ESG strategy and reporting and corporate  citizenship matters.",Governance - Director_Removal,0.3254226744174957
1131,The committee is regularly updated by  management on Pfizer's climate action program and progress  toward goals.,Environmental - Physical_Impacts_Of_Climate_Change,0.9126328229904176
1132,"Pfizer's Global Supply (PGS) Quality & Compliance Committee  (PGS QCC) reports key risks, including those related to  climate change, to the Executive Compliance Committee of  Pfizer's Executive Leadership Team, including the CEO, and  to the Regulatory and Compliance Committee of the Board  of Directors.",Environmental - Physical_Impacts_Of_Climate_Change,0.9418651461601256
1133,The PGS QCC risk management process also  informs Pfizer’s Enterprise Risk Management (ERM) program.,Governance - Systemic_Risk_Management,0.7923739552497864
1134,"Pfizer's ERM program provides a framework for risk  identification and management of significant risks,  including risks related to climate change and the long-  term sustainability of the business.",Environmental - Physical_Impacts_Of_Climate_Change,0.9469703435897828
1135,"Each risk is assigned to  a member or members, as appropriate, of the Executive  Leadership Team.",Governance - Director_Removal,0.6353094577789307
1136,"The Audit Committee of the Board of  Directors, composed solely of independent directors, has  primary responsibility for overseeing Pfizer's ERM program.",Governance - Director_Removal,0.7536923289299011
1137,"Periodically, the Regulatory and Compliance Committee  and the Audit Committee hold joint sessions to discuss risks  relevant to both committees’ areas of risk oversight, including  an annual discussion of the ERM program.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7372552156448364
1138,The board is kept  informed of its committees’ risk oversight and other activities  through reports by the committee chairs to the full board.,Governance - Director_Removal,0.4505142569541931
1139,Pfizer’s integration of climate change into divisional and  enterprise risk management processes includes reviewing  risks that could be material to the company to support U.S.,Environmental - Physical_Impacts_Of_Climate_Change,0.9566631317138672
1140,Securities and Exchange Commission (SEC) 10-K reporting.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8267625570297241
1141,More information on the risk assessment process for climate  change is provided in the risk assessment section below.,Environmental - Physical_Impacts_Of_Climate_Change,0.9555337429046632
1142,"Manufacturing at our internal network of sites, managed  by PGS, accounts for over 70% of the company's energy  consumption and GHG emissions.",Environmental - GHG_Emissions,0.9315237402915956
1143,"The Executive Vice  Appendix President, Chief Global Supply Officer leads Pfizer's  manufacturing and supply chain, serves as the executive  sponsor of climate change risk management and has  operational control over PGS operations and strategy,  including operating expenses (OPEX) and capital expense  (CAPEX) investment in GHG emission reduction projects.",Environmental - GHG_Emissions,0.7761921286582947
1144,Environmental sustainability has been integrated into Pfizer's  business strategy and GHG emissions reduction is monitored  as a key performance indicator.,Environmental - GHG_Emissions,0.967253804206848
1145,"In 2022, an ESG modifier that  includes a climate performance KPI was added to Pfizer’s  annual performance-based variable bonus program to  support Pfizer’s commitment to reducing GHG emissions.",Environmental - GHG_Emissions,0.967909574508667
1146,"ESG Governance:  The ESG function within Pfizer and its cross-functional  governing committees (at the senior management and  the executive level) have responsibility for considering and  adopting potential goals and targets, with escalation to the  Governance & Sustainability Committee (G&SC) of the Board,  based on input from experienced subject matter experts and  advisors.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2869468927383423
1147,"Our cross-functional Sustainability Steering Committee,  chaired by our Chief Sustainability Officer, advises on key  issues and guides the integration and implementation  of Pfizer's non-financial reporting related to ESG.",Governance - Business_Model_Resilience,0.5986403822898865
1148,"This  Committee is overseen by a chartered Executive Sustainability  Committee, chaired by the Executive Leadership Team  member leading Corporate Affairs, who reports directly to the  Chairman and CEO.",Governance - Director_Removal,0.6546140909194946
1149,"Strategy  Our Scenario Analysis Process  To improve the understanding of Pfizer's resilience to the  impacts of climate change, we conducted an in-depth  assessment of our exposure to physical and transition risks  and opportunities using scenario analysis; informed by data  modelling insights from a global sustainability consultancy.",Governance - Business_Model_Resilience,0.4711890518665313
1150,"eS Pfizer  — Continued > Appendix >  Table 1  Aligned with TCFD guidance, we assessed risks and  opportunities on a short- (2030) and long-term (2050) basis, } } .",Governance - Systemic_Risk_Management,0.7304369211196899
1151,}  while also considering transition risks and opportunities on a Type Scenario 2100 Warming Description Key Parameters & Assumptions  medium-term basis (2040).,Governance - Systemic_Risk_Management,0.504008412361145
1152,"This is aligned with our strategic  2040 Net-Zero planning, international and national climate Physical IPCC +1.8°C This scenario is aligned to the * Global Net-Zero reached  policy milestones, and the expected lifetime of our assets.",Environmental - Physical_Impacts_Of_Climate_Change,0.305666983127594
1153,SSP1-2.6 current commitments under in 2050  the Paris Agreement.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6624996066093445
1154,"The , Renewables account for  ; ; ; ; ; world shifts towards a more more than half of the  The scenario analysis began with the identification of sustainable path, emphasizing energy supply by 2050  relevant physical and transition risks and opportunities that more inclusive development, + Few challenges to  could have a potential impact on our business.",Environmental - Energy_Management,0.5474900603294373
1155,Each risk driven by an Peeing crimate mitigation and  and opportunity was qualitatively assessed using impact evelopment goals eying adaptation  and uncertainty ratings and validated with a wide range of  stakeholders representing different Pfizer functions and  divisions.,Governance - Systemic_Risk_Management,0.5414503216743469
1156,"Impact ratings were assigned using the same IPCC +4.4°C This is a high emissions * Energy demand triples  categorizations applied in our enterprise risk management SSP5-8.5 scenario with no additional by 2100, dominated by climate policy (business-as- fossil fuels  framework.",Environmental - Physical_Impacts_Of_Climate_Change,0.8158225417137146
1157,usual).,Governance - Systemic_Risk_Management,0.1187617257237434
1158,"The push for economic ° Current atmospheric CO,  and social development is levels double by 2050  As climate scenarios are inherently uncertain, the scenario couple wit ine exploration of , Many challenges to  analysis considered the full range of potential impacts and the adoption of tecourea.",Environmental - Physical_Impacts_Of_Climate_Change,0.7674490809440613
1159,with few challenges to  from all scenarios without considering the likelihood and energy intensive lifestyles adaptation  of each scenario developing.,Environmental - Energy_Management,0.9318251609802246
1160,The top 20 potential risks around the world.,Governance - Systemic_Risk_Management,0.9184783697128296
1161,"and opportunities were prioritized based on the impact-  ay ng ier a eeeper dive using specific ‘bed in Transition NGFS Current +3°C This scenario assumes that * — Emissions peak in 2080  ata, USINg physical an transition scenarios described In Policies (CP) only currently implemented , IPCC's SSP2 ‘Middle of  Table 1.",Environmental - GHG_Emissions,0.580024003982544
1162,"policies are preserved, with an the Road’ socioeconomic  expected temperature outcome assumptions adjusted for  .",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3818100392818451
1163,eae .,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2305118590593338
1164,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
1165,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
1166,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
1167,.,Governance - Product_Design_And_Lifecycle_Management,0.0769689232110977
1168,"~3° - i 1 For each prioritized item, a scenario indicator was assigned, of ~3°C.",Environmental - GHG_Emissions,0.2968237400054931
1169,COVID-19 impact  acting as a proxy to explore how it may develop in each  scenario.,Governance - Business_Model_Resilience,0.4438747465610504
1170,"These were combined with exposure ratings, NGFS Net- +1.5°C This is an ambitious scenario * Ambitious climate  derived from the assigned impact rating, to give an overall Zero 2050 that limits global warming policy is introduced  risk / opportunity rating at each timeframe.",Environmental - Physical_Impacts_Of_Climate_Change,0.7693083882331848
1171,Items rated a (NZ 2050) to 1.5 °C through stringent immediately  high risk / opportunity at any timeframe are described in  Table 2.,Governance - Systemic_Risk_Management,0.8176905512809753
1172,1 NGFS Climate Scenarios for central banks and supervisors.,Environmental - Physical_Impacts_Of_Climate_Change,0.8285894989967346
1173,"Network for Greening the Financial System, June 2021, p.",Governance - Systemic_Risk_Management,0.3036741316318512
1174,21.,Governance - Competitive_Behavior,0.1996401846408844
1175,"75 Pfizer 2022 ESG Report Appendix climate policies and innovation,  reaching Net-Zero CO2  emissions around 2050.",Environmental - GHG_Emissions,0.5790852308273315
1176,° Global Net-Zero reached  in 2050  .,Environmental - Energy_Management,0.2216191589832306
1177,"IPCC's SSP2 ‘Middle of  the Road’ socioeconomic  assumptions adjusted for  COVID-19 impact’  =] Pfizer  Table 2  Risk or opportunity  Transition Risk -  Carbon pricing  mechanisms  Transition Risk -  Stakeholder  pressure to  decarbonize capital  assets  Transition Risk -  Increasing  energy price  volatility  Transition Risk -  Increasing demand  for low-carbon  products  76 Pfizer 2022 ESG Report TCFD Category  Policy & Legal  Technology  Resource  Efficiency  Market Description  As policymakers implement carbon pricing mechanisms in  more geographies, as well as increase the weight and scope  of these mechanisms, Pfizer is increasingly exposed to the  cost of carbon in our operations and could be exposed to  pass-through costs in the supply chain.",Social - Supply_Chain_Management,0.3809302747249603
1178,"Carbon prices are  expected to increase dramatically in a Net-Zero scenario,  reaching upwards of $200 / mtCO,e.",Governance - Competitive_Behavior,0.2297454625368118
1179,A growing need to decarbonize and reach Net-Zero to meet  both internal Net-Zero targets and external stakeholder  pressure will require large investment to decarbonize capital  assets.,Governance - Systemic_Risk_Management,0.4132986068725586
1180,"This could include replacing production equipment  with equipment that is newer and more efficient, runs on  renewables or alternative fuel sources, or is electrically  powered.",Environmental - Energy_Management,0.9388591647148132
1181,"In the NZ2050 scenario, emissions in the chemicals  sector decrease significantly, from almost 3,000M mtco,  in 2020 to less than 500M mtCO, in 2040.",Environmental - GHG_Emissions,0.8849086165428162
1182,Achieving  this emissions reduction will require significant capital  investment.,Environmental - GHG_Emissions,0.5802068710327148
1183,Atransition away from fossil fuels may result in volatile  energy and fuel prices.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5019970536231995
1184,"Rapid shifts away from fossil fuel  supplies without adequate low-carbon energy infrastructure  in place could lead to supply constraints, which may be  exacerbated in a disorderly scenario.",Social - Supply_Chain_Management,0.6779106259346008
1185,"Gas price increases  sharply in the NZ2050 scenario reaching almost $30 /  gigajoule (GJ) in 2050, more than double the gas price in the  CP scenario ($12.5 / GJ).",Environmental - GHG_Emissions,0.8337798118591309
1186,"An increasing number of national healthcare systems and  countries have announced targets to become Net-Zero by  future dates, e.g., NHS England 2050 Net-Zero target which  may impose additional requirements of their suppliers and  a preference for low-carbon goods.",Social - Supply_Chain_Management,0.6743236184120178
1187,There may be increasing  pressure to decarbonize products across their whole life  cycle including Scope 3 emissions.,Governance - Product_Design_And_Lifecycle_Management,0.956333339214325
1188,"As ~80% of Pfizer's  emissions are Scope 3, there is additional complexity in  producing low-carbon products as it relies on suppliers  decarbonizing their operations.",Governance - Product_Design_And_Lifecycle_Management,0.882983386516571
1189,"Competitor products with  lower emissions intensity / lower energy demand than  Pfizer products may lead to substitution of Pfizer products,  resulting in reduced revenues.",Governance - Product_Design_And_Lifecycle_Management,0.9533241391181946
1190,"Appendix Scenario & Risk / Opportunity Rating  2030:  2040:  2050:  2030:  2040:  2050:  2030:  2040:  2050:  2030:  2040:  2050: High risk  High risk  High risk  Medium risk  High risk  High risk  Medium risk  High risk  High risk  Medium risk  High risk  High risk Potential Financial Impact  Increased direct costs and increased  indirect (operating) costs  Increased capital expenditures, decreased  asset value or asset useful life leading to  write-offs, and asset impairment or early  retirement of existing assets  Increased direct costs  Decreased revenues due to reduced  demand for products and services  =] Pfizer  Table 2 - continued  Risk or opportunity  Transition  Opportunity -  Increased resilience  to energy and fuel  price volatility  Transition  Opportunity -  Increasing demand  for low-carbon  products  Physical Risk - Water  scarcity and drought  impact on operations  77 Pfizer 2022 ESG Report TCFD Category  Resource  Efficiency  Market  Chronic physical Description  Through replacing our capital assets to become more  efficient and use alternative fuel sources, Pfizer could  increase resilience to volatile fuel and energy prices  resulting from the low-carbon transition and increase  returns on investment in low-emissions technology.",Governance - Business_Model_Resilience,0.5309378504753113
1191,"Gas  price increases sharply in the NZ2050 scenario reaching  almost $30 / GJ in 2050, more than double the gas price  in the CP scenario ($12.5 / GJ).",Environmental - GHG_Emissions,0.8251544237136841
1192,"Transitioning from gas to  alternative sources of heating therefore is a cost savings,  reducing Pfizer's exposure to increasing gas prices.",Environmental - Energy_Management,0.6105631589889526
1193,Fuel  prices would be expected to follow a similar trajectory.,Environmental - Energy_Management,0.3960635662078857
1194,"An increasing number of national healthcare systems and  countries have announced targets to become Net-Zero  by future dates, e.g., 2050 including in their supply chain  i.e., the suppliers and pharmaceutical products used by  healthcare providers.",Social - Supply_Chain_Management,0.9013786911964417
1195,Healthcare systems may therefore  prefer or require suppliers to provide low-carbon products.,Governance - Product_Design_And_Lifecycle_Management,0.9343273043632508
1196,"If Pfizer's products are demonstrably lower in carbon  than competitors, this may lead to increased demand for  products and increase revenue.",Governance - Product_Design_And_Lifecycle_Management,0.8763706088066101
1197,"Higher temperatures and more extreme, less predictable,  weather conditions under climate change are expected to  affect water availability by altering the distribution of  rainfall, snowmelt, river flows and groundwater.",Environmental - Water_And_Wastewater_Management,0.9104949235916138
1198,"A lower  availability of water may heighten potential financial risk for  Pfizer by increasing water costs, and / or reducing revenue  due to production shutdowns.",Environmental - Water_And_Wastewater_Management,0.9762743711471558
1199,"By 2030, under a high emissions scenario, almost half of  the 40 manufacturing and research and development sites  assessed during the scenario analysis are shown to be ata  high risk of water scarcity and drought.",Environmental - Water_And_Wastewater_Management,0.966510772705078
1200,"Appendix Scenario & Risk / Opportunity Rating  2030: High opportunity  2040: High opportunity  2050: High opportunity  2030: Medium opportunity  2040: High opportunity  2050: High opportunity  2030: High risk  2050: High risk Potential Financial Impact  Decreased direct costs and increased  demand for products and services  Increased revenues resulting  from increased demand for  products and services  Increased direct (operating) costs and  decreased revenues due to reduced  production capacity  =] Pfizer  Table 2 - continued  Risk or opportunity  Physical Risk - River  and extreme rainfall  flooding impact  on operations and  supply chain Acute physical  Physical Risk -  Extreme heat impact  on operations and  supply chain Acute physical  78 Pfizer 2022 ESG Report TCFD Category Description  Extreme weather events, including high levels of  precipitation and extreme rainfall, are projected to increase  due to climate change.",Environmental - Physical_Impacts_Of_Climate_Change,0.6628758311271667
1201,"This is likely to heighten both the  frequency and intensity of flooding, increasing the risk of  physical damage to infrastructure, and / or supply chain  disruption.",Social - Supply_Chain_Management,0.610058069229126
1202,"By 2030, under a high emissions scenario, 7 of the 36  manufacturing sites assessed during the scenario analysis  are shown to be at a high risk of flooding.",Environmental - Water_And_Wastewater_Management,0.2929801344871521
1203,Maximum temperatures and the frequency of extreme  heat events are anticipated to rise globally due to climate  change.,Environmental - Physical_Impacts_Of_Climate_Change,0.8940748572349548
1204,"A higher prevalence of this hazard may increase  potential financial risk for Pfizer by increasing operating  costs associated with running air conditioning, or backup  generators if electricity supply is interrupted, and/or  reducing revenue due to production shutdowns.",Environmental - Energy_Management,0.7087370157241821
1205,"By 2050, under a high emissions scenario, eight of the  40 manufacturing and research and development sites  assessed during the scenario analysis are shown to be ata  high risk of extreme heat.",Environmental - GHG_Emissions,0.6884300112724304
1206,"Appendix Scenario & Risk / Opportunity Rating  2030: High risk  2050: High risk  2030: Low risk  2050: High risk Potential Financial Impact  Increased capital expenditures, increased  direct (operating) costs, decreased asset  value or asset useful life leading to write-  offs, and decreased revenues due to  reduced production capacity  Increased direct costs and decreased  revenues due to reduced production  capacity.",Governance - Systemic_Risk_Management,0.2698629796504974
1207,"=] Pfizer  — Continued  Strategic Resilience Under Climate Scenarios  Following the findings from the scenario analysis, we consider  our current business model and strategy to be resilient under  the assessed scenarios.",Governance - Business_Model_Resilience,0.9220701456069946
1208,A number of risks and opportunities were found to have  potential impact on financial performance and financial  position for which mitigation measures have been identified.,Governance - Systemic_Risk_Management,0.924375593662262
1209,"To further understand the financial impact of these risks,  Pfizer has begun a pilot to quantify the financial impact of  selected potentially significant items.",Governance - Systemic_Risk_Management,0.9351358413696288
1210,"We will evaluate the  findings from the pilot, refine the methodologies and data  sources, and expand quantification to other items in the  next year.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2662561535835266
1211,"Physical climate risks are currently managed through our  Loss Prevention and Business Resilience programs, described  in further detail under Risk Management.",Governance - Business_Model_Resilience,0.8586233258247375
1212,We continue to  review these programs considering the scenario analysis to  assess whether further measures could be required.,Environmental - Physical_Impacts_Of_Climate_Change,0.4153026640415191
1213,"By achieving our Net-Zero goal we can mitigate many  transition risks and maximize transition opportunities  identified in the scenario analysis (e.g., meeting an increased  demand for low-carbon products and minimizing our  exposure to volatile energy prices).",Governance - Product_Design_And_Lifecycle_Management,0.8236975073814392
1214,We plan to publish a  transition plan summarizing the strategies and actions we are  taking to achieve our goal.,Governance - Business_Model_Resilience,0.7339339256286621
1215,It should be noted that there are key uncertainties associated  with using global climate models to project the effects  of physical risks on our business strategy.,Environmental - Physical_Impacts_Of_Climate_Change,0.8689782023429871
1216,These include  uncertainties in how:  * Future emissions could lead to changes in the global  climate system;  * Changes in this larger system may evolve for us  locally; and * Climate hazards could manifest due to natural variability  which is not fully captured by the models.,Environmental - Physical_Impacts_Of_Climate_Change,0.773061215877533
1217,Trends in some physical climate hazards are also more  difficult to project than others.,Environmental - Physical_Impacts_Of_Climate_Change,0.886137843132019
1218,"For example, hazards driven  by rainfall variables (e.g., flooding, water stress and drought)  are more uncertain than those related to temperature  variables (e.g., extreme heat) as they depend on the response  of regional atmospheric circulations to global warming.”  Key uncertainties that could influence our resilience to  transition risks and opportunities include:  * How quickly our suppliers can decarbonize; given that  80% of our emissions are in the value chain rather than  in our direct operations;  * How quickly technology will become commercially  available to decarbonize our company hard to abate  processes; and  * How healthcare systems and services will implement  Net-Zero requirements in the supply chain.",Social - Supply_Chain_Management,0.9152703285217284
1219,"Impact of Climate-related Risks and Opportunities on our  Businesses, Strategy, and Financial Planning  Climate-related risks and opportunities have influenced  Pfizer's business strategy and are incorporated into  financial planning.",Environmental - Physical_Impacts_Of_Climate_Change,0.9471194744110109
1220,"* In 2020, Pfizer completed a $1.25 billion ten-year  sustainability bond, a first for a biopharmaceutical  company.",Governance - Business_Model_Resilience,0.3228873610496521
1221,"Proceeds from the bond are being used to  help manage our environmental impact and support  increased patient access to Pfizer's medicines and  vaccines, especially among underserved populations,  and strengthen healthcare systems.",Social - Access_And_Affordability,0.947789192199707
1222,"As of December 31,  2022, the net proceeds of approximately $1.24 billion  from the March 2020 Sustainability Bond were fully allocated, funding a portion of the aggregate spend  of $1.275 billion.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7639016509056091
1223,Certain of these funds have been  allocated to more environmentally efficient design and  construction of a new office and manufacturing facility  (a breakdown of the specific allocation of funds can be  found on page 59).,Environmental - Energy_Management,0.4360606968402862
1224,Pfizer responds to numerous requests for environmental  performance information from current customers  and as part of tenders.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4026699960231781
1225,"While the level of influence  that our environmental performance has on customer  purchasing decisions has not been fully quantified, the  number of customer and tender inquiries has been  observed to increase each year.",Governance - Business_Model_Resilience,0.3502916693687439
1226,Annual targets are established for energy conservation  project savings.,Environmental - Energy_Management,0.9679604768753052
1227,Our medium and large sites are required  to maintain master plans that identify opportunities  for emission reductions.,Environmental - Air_Quality,0.938684105873108
1228,These projects are reviewed  through our capital project appropriation process.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8081722259521484
1229,The costs to implement these projects as well as the  expected cost savings are included in the site’s operating  budgets and / or capital plans as appropriate.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5993798971176147
1230,Our Loss Prevention and Business Resilience programs  assess and manage potential impacts of acute and  chronic physical risks on our operations.,Governance - Business_Model_Resilience,0.9192566871643066
1231,Assessments  are refreshed annually.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2815359532833099
1232,Costs to maintain Pfizer's risk  engineering provider is estimated at $0.3M annually.,Governance - Systemic_Risk_Management,0.8979913592338562
1233,"Costs relating to property protection and supply chain  management are annualized, expected to be incurred  annually and are incorporated into existing budgets.",Social - Supply_Chain_Management,0.9482476115226746
1234,Site protection systems improvements and maintenance  costs are estimated at $0.1M annually.,Environmental - Ecological_Impacts,0.8375320434570312
1235,Direct staff costs  related to managing this risk is estimated at $2.0M  annually.,Governance - Systemic_Risk_Management,0.2285365313291549
1236,2 Multiple sources are used to consider these uncertainties and variables.,Governance - Systemic_Risk_Management,0.4019331932067871
1237,"IPCC AR6 is one of the primary sources, but also includes sources for specific hazards such as flooding and water stress and drought, including WRI Aqueduct and  Fathom-Global 2.0.",Environmental - Water_And_Wastewater_Management,0.970255970954895
1238,79 Pfizer 2022 ESG Report Appendix eS Pfizer  — Continued  Risk Management  Pfizer's strategy for managing climate-related risks and  opportunities includes our ambitious 2040 Net-Zero target  covering our operations and entire value chain.,Environmental - Physical_Impacts_Of_Climate_Change,0.64323490858078
1239,"Measures we  take to mitigate climate-related risks include:  * Operational emissions reductions - To achieve our  public goals for GHG emission reductions, Pfizer has  implemented numerous efficiency improvements to  our operations.",Environmental - GHG_Emissions,0.9570372104644777
1240,"We look for opportunities to design  environmental sustainability attributes into new facility  or renovation projects, replace equipment at end of life  with energy-efficient alternates, and invest in no / low  carbon technologies at our sites and in programs that  enable sourcing of clean energy from renewable sources  (for example, our North American solar virtual power  purchase agreement is described on page 23 of our ESG  report).",Environmental - Energy_Management,0.9777573943138124
1241,We are a member of Renewable Energy 100  (RE100) and we have a goal to achieve 80% renewable  electricity by 2025 and 100% by 2030.,Environmental - Energy_Management,0.9689449667930604
1242,We are currently  working to develop site-specific emissions reduction  plans to achieve our near-term (2030) and Net Zero  (2040) targets.,Environmental - GHG_Emissions,0.5170850157737732
1243,* Research and innovation in green chemistry - Pfizer has  a long history of using the concepts of green chemistry  and promoting them across our industry.,Governance - Product_Design_And_Lifecycle_Management,0.7616726160049438
1244,Through  scientific innovation we aim to design more efficient  processes that can reduce the environmental impact  of our medicines throughout the product life cycle.,Governance - Product_Design_And_Lifecycle_Management,0.9632705450057985
1245,"To  support environmental footprint reduction efforts, Pfizer  is conducting representative life cycle assessments  (LCAs) for small molecules, large molecules, vaccines,  and devices.",Governance - Product_Design_And_Lifecycle_Management,0.3234739899635315
1246,"Guided by these assessments, we are  working to define environmental sustainability criteria  across the product lifecycle.",Governance - Product_Design_And_Lifecycle_Management,0.9619107246398926
1247,* Loss Prevention and Business Continuity programs -  Pfizer's primary controls for the management of acute  and chronic physical risks are our infrastructure and  systems.,Governance - Systemic_Risk_Management,0.718449056148529
1248,Many of our facilities are located in areas  with limited exposure to physical risks and we have  robust processes in place to identify and mitigate  80 Pfizer 2022 ESG Report potential vulnerabilities.,Governance - Systemic_Risk_Management,0.885391116142273
1249,"Through our Loss Prevention  and Business Continuity programs we maintain plans  to minimize business disruption, including alternative  sourcing options and buffer inventory (depending on  product).",Governance - Product_Design_And_Lifecycle_Management,0.7720333337783813
1250,Pfizer maintains resources for assessing and  establishing business continuity arrangements such as  the activation of alternative supply chains.,Social - Supply_Chain_Management,0.9555982947349548
1251,"Supply chain  and business continuity professionals are retained as  staff and consultants to ensure these plans are updated  at least annually, exercised at least annually, and key  colleagues on site are trained on their content and  implementation.",Social - Supply_Chain_Management,0.941035807132721
1252,* Working and engaging our suppliers - As part of our  Net-Zero goal we aim to use our influence to catalyze  ambitious GHG emissions reductions across our value  chain.,Environmental - GHG_Emissions,0.9646111726760864
1253,"We are implementing a multipronged approach,  including embedding environmental sustainability  criteria in our vendor selection processes, strengthening  expectations within contracts, and engaging with key  suppliers of goods and services to drive at least 64% by  spend to adopt science based GHG emission reduction  goals (SBT goals) by 2025.",Environmental - GHG_Emissions,0.9605175256729126
1254,"Pfizer is part of Energize,  a collaboration between 10 global pharmaceutical  companies that provides pharmaceutical suppliers, some  of which may not otherwise have the internal resources  or expertise available, the opportunity to participate  in the market for power purchase agreements.",Social - Supply_Chain_Management,0.6176016926765442
1255,"We are  also members of Activate, a collective action initiative  supporting the decarbonization of active pharmaceutical  ingredient supply chains.",Social - Supply_Chain_Management,0.8044347763061523
1256,Metrics & Targets  Pfizer calculates Scope 1 and 2 emissions in accordance with  the GHG Protocol (revised edition).,Environmental - GHG_Emissions,0.9681784510612488
1257,Our 2019-2021 GHG data  (including Scope 3 categories 1-8 and 15) was independently  assured pursuant to ISAE 3000 (revised) by ERM-CVS and  verification of 2022 data is underway.,Environmental - GHG_Emissions,0.9601980447769164
1258,"Emissions are reported  annually in our CDP response and are broken down by type,  country, and business division.",Environmental - GHG_Emissions,0.8471500873565674
1259,"We also track metrics relative  to our business continuity and disaster recovery programs  (e.g., number of supplier assessments completed; sites  Appendix with fully implemented plans for the management of risk  associated with natural perils such as flooding and severe  weather, noting it is not possible to state with certainty  whether individual weather events are a result of climate  change).",Environmental - Physical_Impacts_Of_Climate_Change,0.9268447756767272
1260,"Pfizer discloses our Scope 1, Scope 2 and Scope 3 emissions  annually through our CDP submittal and publishes our Scope  1 + 2 emissions in our ESG Report (formerly in our Annual  Review) and on our website.",Environmental - GHG_Emissions,0.8028127551078796
1261,"We have achieved three consecutive GHG reduction goals  (2000-2007, 2007-2012, and 2012-2020) and have reduced our  GHG emissions over 60% since 2000.",Environmental - GHG_Emissions,0.967702567577362
1262,We remain committed  to ambitious long-term actions and have announced our  ambition to achieve the Science Based Target initiative's  voluntary Net-Zero standard by 2040.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5153349041938782
1263,"As part of the  commitment, Pfizer aims to decrease our GHG emissions by  95% and value chain emissions by 90% from 2019 levels by  2040 through accelerating the transition away from fossil  fuels and engaging suppliers to catalyze equivalent action.",Environmental - GHG_Emissions,0.966361165046692
1264,"In 2020, after achieving our third generation GHG emission  reduction goal, Pfizer set a new goal to reduce Scope 1 & 2  GHG emissions 46% by 2030 from a 2019 baseline and, by  2025, advancing goals to reduce emissions in three Scope  3 categories.",Environmental - GHG_Emissions,0.9597565531730652
1265,This includes catalyzing 64% of suppliers of  goods and services by spend to set science-based emission  reduction goals and reducing emissions related to upstream  logistics by 10% and business travel by 25% by 2025 from a  2019 baseline.,Environmental - GHG_Emissions,0.4957374334335327
1266,Pfizer continues to make progress towards  these near-term targets while advancing our long-term Net-  Zero by 2040 goal.,Governance - Business_Model_Resilience,0.7058193683624268
1267,"Recognizing that Scope 3 emissions are the most challenging  to quantify due to complex global value chains, inconsistent  methodologies, and lack of transparent disclosure, we  have launched initiatives to improve our measurement  and reporting capabilities and are collaborating with our  pharmaceutical peers to align on Scope 3 data collection and  emissions calculation methodologies.",Environmental - Air_Quality,0.544808030128479
1268,"eS Pfizer  This ESG Report details our performance on Environmental, Social, and Governance topics and contains non-financial disclosures covering the period of  January 1, 2022, through December 31, 2022, unless otherwise stated.",Governance - Business_Model_Resilience,0.5243245363235474
1269,Our financial disclosures can be found in our 2022 Annual Review and our 2022  Annual Report on Form 10-K.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3258020877838135
1270,We plan to report our ESG performance on an annual basis as a supplement to our Annual Review.,Governance - Systemic_Risk_Management,0.2718624174594879
1271,"This report covers all of Pfizer's global operations included within the 2022  financial statements, unless otherwise stated.",Governance - Business_Model_Resilience,0.4737529456615448
1272,Our priority assessment has  validated issues that traditionally have been viewed as meaningful to our  business and our external stakeholders.,Governance - Business_Model_Resilience,0.3562736809253692
1273,"In addition, we intend to continually evaluate our performance reporting  and enhance our related data collection processes and controls.",Social - Customer_Privacy,0.5555841326713562
1274,"Some of  our disclosures in this report are estimates or based on assumptions, due to  the inherent measurement uncertainties.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3144309520721435
1275,"As an example, because of patient  privacy laws, data constraints, and contractual obligations, we have used  shipping data, financial performance, and third-party reports to determine  patient counts in support of our KPI measuring the number of patients treated.",Social - Customer_Privacy,0.4526707828044891
1276,"Although we believe such estimates and assumptions are reasonable, actual  results will vary.",Governance - Competitive_Behavior,0.3982438147068023
1277,"Except as indicated on this page, the information in this report has not been  audited, verified, or attested to by any third party.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.7368060946464539
1278,We have obtained limited  assurance verification by ERM-CVS of certain greenhouse gas emissions data  that we submit to CDP.,Environmental - GHG_Emissions,0.9651666879653932
1279,"We have obtained reasonable assurance over our  Management Assertion from KPMG LLP, see Independent Accountants’ Report.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5849411487579346
1280,The term “material” as used in context of this report and in our GRI Index are  different from such terms as used in the context of filings with the Securities  and Exchange Commission (SEC).,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7486873865127563
1281,Issues deemed material for the purposes of  this report should not necessarily be considered material for SEC reporting  purposes.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8532012104988098
1282,"This report has been reviewed by our head of Corporate Affairs, our Chairman  and CEO, members of our cross-functional Sustainability Steering Committee,  and the Governance & Sustainability Committee of our Board of Directors.",Governance - Director_Removal,0.3789351880550384
1283,Note: All trademarks mentioned are the property of their owners.,Social - Customer_Privacy,0.2839707434177398
1284,Global Reporting Frameworks  This report's content is grounded in our ESG priority assessment and has been  informed by several globally recognized external frameworks.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5058615207672119
1285,"These include  the Global Reporting Initiative (GRI), Sustainability Accounting Standards  Board (SASB), and Task Force on Climate-Related Financial Disclosure (TCFD).",Environmental - Physical_Impacts_Of_Climate_Change,0.8667774200439453
1286,We relied to some extent on each framework to develop this report while  formally adhering to none in their entirety.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8557021021842957
1287,"Pfizer also considers elements of other ESG indices and sustainability  indicators—in particular, the Access to Medicine Index (ATMI) and the United  Nations (UN) Sustainable Development Goals (also known as the Global Goals).",Governance - Business_Model_Resilience,0.2551118731498718
1288,"As a signatory to the UN Global Compact, we submit an annual communication  to the UN on our progress made toward achieving the Global Goals.",Social - Human_Rights_And_Community_Relations,0.4230213463306427
1289,"81 Pfizer 2022 ESG Report Management Assertion  As of December 31, 2022, Pfizer has fully allocated approximately $1.24 billion  in net proceeds from the issuance of its March 2020 Sustainability Bond to  eligible projects identified on page 59 of this report in accordance with the Use  of Proceeds defined on pages S-6 and S-7 of the Prospectus Supplement dated  March 25, 2020.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4280681312084198
1290,"Pfizer is responsible for its assertion and the completeness, accuracy and  validity of the information and metrics presented in this ESG Report.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.673935055732727
1291,Third Party Websites and Links  This ESG Report may contain references or links to other websites maintained  by third parties over whom Pfizer has no control.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5752863883972168
1292,Such links are provided  merely as a convenience.,Social - Customer_Privacy,0.4546495974063873
1293,"Pfizer makes no warranties or representations of  any kind as to the accuracy, currency, or completeness of any information  contained in such third party websites, including any third party social  media or mobile app platform.",Social - Customer_Privacy,0.6034256219863892
1294,"The information contained on our website,  our Facebook, YouTube, and LinkedIn pages or our Twitter accounts is not  incorporated by reference into this ESG Report.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.1592136323451995
1295,Inclusion of any third party  link in this ESG Report does not imply an endorsement or recommendation  by Pfizer and a link to this ESG Report from another website does not imply  arelationship between Pfizer and any third party.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.5775730609893799
1296,Your use of any such third  party site or platform is at your own risk and will be governed by such third  party’s terms and policies (including its privacy policy).,,0.5735586881637573
1297,"Emergency Use Authorization (EUA) Statement  As used in this Pfizer 2022 ESG Report, “PAXLOVID®” refers to an oral COVID-19  treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), and  “COMIRNATY®” refers to, as applicable, and as authorized or approved, the  Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine,  Bivalent (Original and Omicron BA.4 / BA.5), the COMIRNATY® Original /  Omicron BA.1 Vaccine, and COMIRNATY® Original / Omicron BA.4/BA.5  Vaccine”.",Social - Selling_Practices_And_Product_Labeling,0.3618694543838501
1298,"PAXLOVID® and emergency uses of the Pfizer-BioNTech COVID-19  Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and  Omicron BA.4/ BA.5), have not been approved or licensed by the FDA.",Social - Selling_Practices_And_Product_Labeling,0.2506974935531616
1299,"PAXLOVID® has been authorized for emergency use by the FDA under an EVA,  for the treatment of adults and pediatric patients (12 years of age and older  weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19  and who are at high risk for progression to severe COVID-19, including  hospitalization or death.",Social - Employee_Health_And_Safety,0.8465907573699951
1300,"Emergency uses of the Pfizer-BioNTech COVID-19  Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent have been  authorized by the FDA under an EVA to prevent COVID-19 in individuals aged  6 months and older.",Social - Access_And_Affordability,0.4049673080444336
1301,"The emergency uses are only authorized for the duration  of the declaration that circumstances exist justifying the authorization  Appendix of emergency use of the medical product during the COVID-19 pandemic  under Section 564(b)(1) of the FFDCA, unless the declaration is terminated  or authorization revoked sooner.",Social - Critical_Incident_Risk_Management,0.9738272428512572
1302,Please see the EUA Fact Sheets at www.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.8430641293525696
1303,covid19oralrx.com and www.cvdvaccine-us.com.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.1540442556142807
1304,"Forward Looking Statements  This ESG Report includes forward-looking statements about, among other  things, our performance on Environmental, Social, and Governance topics,  our ESG strategy, targets, and goals, company strategies, product pipeline,  in-line products, product candidates, and growth potential, and our efforts to  respond to COVID-19, including COMIRNATY® (the Pfizer-BioNTech COVID-19  vaccine) and our oral COVID-19 treatment (PAXLOVID® (nirmatrelvir tablets  and ritonavir tablets)) that are subject to substantial risks and uncertainties.",Governance - Business_Model_Resilience,0.426811158657074
1305,We cannot guarantee that any forward-looking statement will be realized.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4540791809558868
1306,"Should known or unknown risks or uncertainties materialize or should  underlying assumptions prove inaccurate, actual results could vary materially  from past results and those anticipated, estimated or projected.",Governance - Systemic_Risk_Management,0.7869938015937805
1307,"Please refer  to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2022,  and Pfizer's subsequent reports on Form 10-Q, including the sections thereof  captioned “Risk Factors” and “Forward-Looking Information and Factors That  May Affect Future Results,” as well as Pfizer's subsequent reports on Form  8-K for a description of the substantial risks and uncertainties related to the  forward-looking statements included in this ESG Report.",Governance - Systemic_Risk_Management,0.8928106427192688
1308,These reports are  available on our website at www.pfizer.com and on the U.S.,,0.2307580709457397
1309,Securities and  Exchange Commission's (SEC) website at www.sec.gov.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.9035471677780152
1310,"The forward-looking  statements in this ESG Report speak only as of the original date of this ESG  Report, and we undertake no obligation to update or revise any of these  statements, as the result of new information or future events or developments  or otherwise.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.3246883749961853
1311,"Note on Non-Financial Reporting  Non-financial information is subject to measurement uncertainties resulting  from limitations inherent in the nature of, and the methods used for  determining, such data.",Governance - Systemic_Risk_Management,0.5753620266914368
1312,Some of our disclosures in this report are based on  assumptions due to the inherent measurement uncertainties.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.2744614779949188
1313,The selection  of different but acceptable measurement techniques can result in materially  different measurements.,Governance - Competitive_Behavior,0.4301865994930267
1314,The precision of different measurement techniques  may also vary.,Governance - Competitive_Behavior,0.3057568669319153
1315,"For questions or feedback, contact our ESG Office:  ESG.Office@pfizer.com  eS Pfizer  Report  Pfizer Inc.",Governance - Business_Model_Resilience,0.2906996011734009
1316,"Management:  We have examined management of Pfizer Inc.'s (“Pfizer”) assertion  set forth on page 81 of the Pfizer 2022 Environmental, Social  & Governance Report that as of December 31, 2022, Pfizer has  fully allocated approximately $1.24 billion in net proceeds from  the issuance of its March 2020 Sustainability Bond to the eligible  projects identified on page 59 of Pfizer’s 2022 Environmental,  Social & Governance Report (the “Allocations”), in accordance  with the Use of Proceeds as defined on pages S-6 and S-7 of the  Prospectus Supplement dated March 25, 2020 (the “Prospectus  Supplement”).",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4320524632930755
1317,Pfizer’s management is responsible for its assertion.,Social - Supply_Chain_Management,0.2260093688964843
1318,Our responsibility is to express an opinion on management's  assertion based on our examination.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.4623309075832367
1319,Our examination was conducted in accordance with attestation  standards established by the American Institute of Certified Public  Accountants.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.7268288731575012
1320,"Those standards require that we plan and perform  the examination to obtain reasonable assurance about whether  management's assertion is fairly stated, in all material respects.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.6235747933387756
1321,An  examination involves performing procedures to obtain evidence  about management's assertion.,Governance - Business_Ethics,0.5315554738044739
1322,"The nature, timing, and extent of  the procedures selected depend on our judgment, including an  assessment of the risks of material misstatement of management's  assertion, whether due to fraud or error.",Governance - Business_Ethics,0.9744604825973512
1323,We believe that the  evidence we obtained is sufficient and appropriate to provide a  reasonable basis for our opinion.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.6651623845100403
1324,We are required to be independent and to meet our other ethical  responsibilities in accordance with relevant ethical requirements  relating to the examination engagement.,Governance - Business_Ethics,0.922006905078888
1325,"82 Pfizer 2022 ESG Report Our examination was not conducted for the purpose of evaluating  Pfizer’s 2022 Environmental, Social & Governance Report or any  of the metrics contained herein.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.2811594605445862
1326,"Thus, we did not examine the  sufficiency, completeness, appropriateness or accuracy of such  metrics, reporting criteria, or other information.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.5433138608932495
1327,"Accordingly, we  do not express an opinion or any other form of assurance other  than on management's assertion.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.4596329927444458
1328,"In our opinion, management's assertion that the Allocations were  allocated in accordance with the Use of Proceeds as defined in the  Prospectus Supplement, is fairly stated in all material respects.",Governance - Management_Of_Legal_And_Regulatory_Framework,0.9319849014282228
1329,"KPWGs LLP  New York, New York  March 16, 2023  Appendix  The product information provided in this  site is intended only for residents of the  United States.",Social - Selling_Practices_And_Product_Labeling,0.6424593925476074
1330,The products discussed  herein may have different product labeling  in different countries.,Social - Selling_Practices_And_Product_Labeling,0.8209571242332458
1331,Copyright © 2022-2023 Pfizer Inc.,Governance - Management_Of_Legal_And_Regulatory_Framework,0.3234778046607971
1332,"All rights reserved  66 Hudson Boulevard East  New York, NY 10001-2192  (212) 733-2323  www.pfizer.com",Social - Customer_Privacy,0.1201788112521171
